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Abstract 
Background  
Smoking cessation interventions are underprovided in primary care. This thesis examines the 
impact of financial incentives on the provision of smoking cessation interventions, and 
inequalities in provision, in primary care. 
Methods 
• Systematic review of financial incentives for smoking cessation in healthcare.  
• Cross sectional study using general practice data from Wandsworth, London, using 
logistic regression to examine associations between ethnicity and disease group with 
ascertainment of smoking status and provision of cessation advice following the 
introduction of the UK’s Quality and Outcomes Framework (QOF).      
• Before-and-after studies using general practice data from Hammersmith & Fulham, 
London, looking at the impact of a local financial incentive scheme (QOF+) on 
smoking outcomes for patients without smoking-related diseases (primary 
prevention), and antenatal patients, using logistic regression to examine inequalities.  
Results 
Introduction of financial incentives was associated with increased recording of smoking 
status and advice to smokers, most evident for patients with smoking-related diseases 
compared with patients without smoking-related diseases, for whom there were much smaller 
incentives for recording smoking status and none for offering stop smoking advice. However, 
12 
 
when specific incentives were provided for primary prevention large improvements in 
smoking outcomes were seen.  
The youngest and oldest groups of patients were less likely to be asked about smoking. White 
British patients were more likely to smoke than other ethnic groups, except Black Caribbean 
men with depression, 62% of whom smoked. Smoking advice was provided relatively 
equitably, but Black Caribbean men with depression were less likely to receive advice than 
White British men with depression (59% vs 81%). Disparities in smoking outcomes with 
respect to age and ethnicity persisted after the financial incentives were introduced. 
Conclusions 
Introduction of financial incentives was associated with increases in recording smoking status 
and largely equitable provision of cessation advice, but variations in smoking outcomes 
between groups persisted. Extending financial incentives to include recording of ethnicity 
and rewarding quit rates may further improve smoking outcomes in primary care.
13 
 
Chapter 1: Smoking 
Introduction 
 
Currently 20% of people in the United Kingdom (UK) smoke,1 markedly reduced from 
around 70% for men and around 40% of women in the 1960s.2 Globally, approximately one 
billion people smoke cigarettes or other tobacco products, 80% of whom live in low or 
middle income countries.3 
 
In the UK in 2010/11, amongst people aged 35 years and over, there were approximately 1.5 
million hospital admissions with a primary diagnosis of a disease that can be caused by 
smoking, and 460,000 admissions directly attributable to smoking,1 representing around 5% 
of all admissions to hospital. For the same age group there were 79,100 deaths attributable to 
smoking, around 6% of all deaths.1 These figures give a strong indication of the impact of 
smoking both on individuals and on the NHS. Smoking is also a major cause of health 
inequalities, since people from more deprived circumstances are more likely to smoke than 
those who are affluent,4 and find it more difficult to stop smoking.5 6 
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Brief history of tobacco  
 
Discovery of tobacco 
The cultivated species of tobacco plants are Nicotiana tabacum and Nicotiana rusticus, of 
which tabacum is more commonly smoked. Both are native to North and South America and 
are from the same Nicotiana genus as potato, peppers and deadly nightshade. It is believed 
that tobacco may have grown in the Americas since around 5,000 BC but its earliest use is 
estimated to be around 1 BC by American Indians who smoked it in pipes for religious 
ceremonies and as a pain-relieving medicine.7  
In 1492 the explorer Christopher Columbus landed in San Salvador and was given dried 
tobacco leaves by American Indians. He is credited with first bringing tobacco back to 
Europe but it wasn’t until the mid-16th Century that it started to become popular due to its 
supposed medicinal properties. In 1560 Sir Frances Drake introduced Sir Walter Raleigh to 
pipe smoking and he in turn brought the habit to England in 1600. In 1604 King James I was 
the first to impose taxes on tobacco use in England and wrote a scathing criticism of tobacco 
and its users in a pamphlet entitled A Counterblaste to Tobacco, cited in Gately.7 
Nevertheless, by the beginning of the 17th century tobacco was being regularly imported into 
the UK 
 
Key milestones in the UK smoking epidemic 
By the mid-1800s cigars and cigarettes were introduced as a more convenient way of using 
tobacco than smoking a pipe, snorting it nasally (snuff) or chewing it. Industrialisation meant 
that cigarettes were easily and cheaply manufactured, and cigarettes became popular amongst 
soldiers during the First World War.8 Between the wars competition between cigarette 
manufacturers increased and advertising was used to target women. During the Second World 
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War cigarettes were provided free to soldiers and smoking was heavily promoted in films as a 
desirable and glamorous habit, with a consequent surge in popularity with women. Smoking 
rates peaked in the USA and Europe between the end of the Second World War and the mid-
1960s and prevalence started to decline with the emergence of links between smoking and 
lung cancer.9 Since then, tobacco use, including passive smoking, has now been established 
as the foremost preventable health risk in the developed world, and an important cause of 
premature death worldwide.10  
 
Health risks of smoking 
 
Morbidity 
 
Epidemiological studies from the 1700s described an association of tobacco with nasal cancer 
among snuff workers, and oral cancers among pipe smokers, but the strongest evidence 
linking tobacco use with lung cancer came from 20th century epidemiologic studies.11 In 1940 
a case-control study by Müller in Germany concluded, ‘the extraordinary rise in tobacco use 
was the single most important cause of the rising incidence of lung cancer.’8 By 1944, the 
American Cancer Society began to warn about health effects of smoking, but with the caveat 
that no definite evidence existed to link cigarettes and lung cancer. By the 1950s the link with 
lung cancer started to become apparent, following publications by Doll and Hill in the UK 
and Hammond and Wynder in the USA.8 
Landmark retrospective studies published in the USA and the UK in the 1950s showed 
definitively that smoking and lung cancer were linked. Levin in a case control study of 236 
lung cancer patients showed the risk of lung cancer to be ten times greater for heavy smokers 
than that for non-smokers.12 Doll and Hill compared the smoking habits of 1732 lung cancer 
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patients with 743 patients without lung cancer and found that those with cancer were fifty 
times as likely to be heavy smokers than non-smokers.13  
These studies were followed by prospective cohort studies, notably those by Doll and Hill in 
1956, Hammond and Horn in 1959 and Dorn in 19599 which all showed a strong association 
between smoking and lung cancer and a significant increase in mortality rates for smokers. 
These studies suggest that in men the risk of smokers developing lung cancer is 10 times the 
risk for non-smokers, with a slightly reduced excess risk for women. Approximately 85-90% 
of lung cancer in men is attributable to smoking and around 66% for women. In summarising 
the evidence, the US Surgeon General Leroy E Burney in 1958 concluded that ‘excessive 
cigarette smoking is one of the causative factors in lung cancer.’14 
The accumulated evidence indeed shows that tobacco fulfills all the requirements for a 
causative agent including biological plausibility (presence in tobacco smoke of substances 
known to cause cancer in experimental studies), consistency and strength of the relationship 
across studies, specificity, prior exposure and a dose-response relationship.15  
The increased risk of lung cancer in non-smokers through passive smoking has also been 
demonstrated, for instance through a case-control study by Brownson et al in 199216.This 
study compared non-smokers living with smokers with controls with no such exposure and 
found a 30% increased risk of lung cancer for subjects with the highest smoking exposure at 
home. A systematic review of 14 case-control or cohort studies examining the risk of lung 
cancer through workplace exposure to smoke found around a 40% increase in risk compared 
to people not exposed to smoke in the workplace.17 
Following the publication of the RCP and US Surgeon General reports, and strengthened 
tobacco control measures since, smoking rates have gradually reduced to current levels of 
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about 20% of adults. Lung cancer rates also began to fall for men in the UK following these 
reductions in smoking prevalence (see Figure 1), and rates for women are stabilising.  
Figure 1: Smoking Prevalence and Lung Cancer Incidence, by Sex, Great Britain, 1948-
2010
 
Source: Cancer Research UK using ONS data 
 
Tobacco use has been also been shown to be a major cause of other cancers including 
laryngeal, oral cavity, pharyngeal, and oesophageal cancer. It is also a contributory factor in 
the development of cancers of the pancreas, bladder and kidney, cervix, ovary, endometrium, 
gut, prostate, liver, brain and breast and in the development of adult leukaemia.18 Tobacco 
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smoking is estimated to have caused 20% of cancer cases (60,000 cases) in the UK19 and 
caused more than a quarter of cancer deaths in the UK, around 43,000 deaths in 2009.20 
 
Cigarette smoking has been shown to be a major cause of cardiovascular disease, including 
coronary heart disease (CHD), stroke or transient ischaemic attack (TIA), aortic aneurysm, 
and peripheral vascular disease. CHD is the most common cause of death in developed 
countries and the population attributable risk fraction for smoking in CHD deaths is estimated 
to be around 30%.21  
There is also strong evidence for the increased risk of cardiovascular disease with passive 
smoking, estimated to be between 30-60%, similar to that of light smokers.22 The risk of 
stroke for the wives of smokers has been found to be twice as high as those whose husbands 
did not smoke.23 
Smoking is a major cause of chronic lung diseases, particularly chronic obstructive 
pulmonary disease (COPD) and a range of other conditions such as peptic ulcer disease, 
osteoporosis and infertility.18 Smoking while pregnant is a cause of placental abruption and 
miscarriage,24  low birth weight and prematurity25 and adversely affects a child’s health 
throughout the life course.26 27 
Premature mortality 
 
Tobacco kills up to half of its users.  Nearly six million people die globally each year from 
smoking related diseases. Of these people, more than 5 million are users and ex users and 
more than 600 000 are non-smokers exposed to second-hand smoke.3  
 
Evidence from large prospective studies linking smoking with premature mortality has been 
well documented. One of the most compelling mortality studies was a prospective study of 
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34440 British doctors conducted by Richard Doll and Richard Peto.28 This showed that the 
ratio of death rates from any cause for smokers versus non-smokers was 2:1 for men under-
70 years and 1.5:1 for men over-70 years. The most common cause of death was 
cardiovascular disease, followed by lung cancer, followed by chronic respiratory disease. 
Ischaemic heart disease is today the most common cause of death caused by smoking (see 
Figure 2). The cohort was followed up for further 30 years and Doll and Peto published 
reports in 199429 and 2004.30 The authors concluded that one in two long-term smokers die 
from the habit, a quarter of these between the ages of 35-69. On average, smokers die around 
10 years earlier than non-smokers. However, the authors found (page 9) ‘stopping smoking at 
age 60, 50, 40 or 30 gains, respectively, about 3, 6, 9, or 10 years of life expectancy.’  
 
Figure 2: Mortality attributable to smoking by disease area in England, 2009 
 
Source: Department of Health ‘Healthy Lives, Healthy People: A Tobacco Control Plan for England 2010’ 
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How smoking causes disease 
 
Nicotine is the main pharmacologically active compound in tobacco smoke and produces its 
effects through binding to nicotinic acetylcholine receptors. Scientists have known since the 
early 19th Century that the pure form of nicotine is a dangerous poison. Now over 4,000 
components have been identified in smoke, and these differ in the smoke inhaled 
(mainstream smoke) and the smoke issued from the lit end of the cigarette (side stream 
smoke), see Figure 3 from Thielen et al.31  
Figure 3: The burning cigarette 
 
Source: Thielen et al, 200831 
Exhaled mainstream smoke and side stream smoke together are referred to as environmental 
tobacco smoke (ETS). Tobacco smoke is composed of an aerosol of liquid droplets 
suspended in gases and semi-volatile molecules. The droplets are filtered through the 
cigarette filter and the gaseous products are inhaled, and include carbon monoxide, carbon 
dioxide, nitric oxide, and other compounds such as 1,3-butadiene, formaldehyde, 
acetaldehyde, acrolein, benzene and hydrogen cyanide which are known toxins and 
carcinogens such as polynuclear aromatic hydrocarbons (PAHs).31 Much of the analysis of 
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tobacco smoke was undertaken by Dietrick Hoffman and his colleagues since the 1980s who 
produced lists of compounds with biological or toxic effects (the ‘Hoffman analytes’). 
The carcinogens in smoke cause cancer principally through the formation of bonds between 
carcinogens in smoke and deoxyribonucleic acid (DNA) in cells, leading to genetic damage 
and tumour formation. Components in smoke also interfere with the body’s repair 
mechanisms leading to tumour growth and spread. 
Smoking causes COPD through damage to the lining of the airway directly by noxious 
components present in tobacco smoke32 and through the lungs’ own repair processes. The 
resulting inflammation leads to thickening of the walls of the bronchi and bronchioles, and in 
some individuals the repair processes are inadequate even after stopping smoking. Tobacco 
smoke also paralyses the cilia in the bronchi, which are responsible for clearing debris and 
mucus from the lungs, predisposing to infection. These processes lead restricted airflow and 
accumulation of mucus. 
Components of smoke cause cardiovascular disease through vasomotor dysfunction, 
inflammation, and modification of lipids. This leads to atherosclerosis, narrowing of vessels 
and subsequently to thrombosis in those vessels from endothelial damage, platelet 
dysfunction and alterations in the balance of antithrombotic/prothrombotic factors and 
fibrinolytic factors. These risks increase with the number of cigarettes smoked and the length 
of time smoking.33 
 
Tobacco Industry response to the evidence 
 
When the first studies linking tobacco with lung cancer were published in the 1950s, 
followed by the RCP and US Surgeon General’s reports in the 1960s, the major US tobacco 
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companies were quick to discredit the research. Despite privately acknowledging the link, 
they responded with a statement that ‘statistics purporting to link cigarette smoking with 
[lung cancer] could apply with equal force to any one of many other aspects of modern life’ 
and formed the Tobacco Industry Research Council to help ‘the research effort into all phases 
of tobacco use and health.’ They focused their public relations efforts on reassuring the 
public whilst developing alternative ‘healthier’ cigarettes, with filters and low-tar options. 
Victims of lung cancer tried to take tobacco manufacturers to court for compensation without 
success as cases failed through the difficulty of proving causation. Tobacco manufacturers 
even in the 21st Century continue to cast doubt on the scientific techniques employed in 
proving the links between smoking and disease.34 
 
Why people smoke 
 
In order to develop successful smoking cessation strategies we need to understand both the 
addictive nature of tobacco and also smokers’ beliefs about their ability to stop smoking.  
Nicotine addiction 
Nicotine is the major component of tobacco responsible for addiction. A third of people who 
try smoking progress to daily smoking, illustrating how highly addictive nicotine is, 
comparable with heroin and cocaine.35  
Several factors contribute to nicotine addiction. These include tolerance, whereby the smoker 
requires more cigarettes to achieve the same effects as previously, due to up regulation of 
nicotine receptors. Nicotine acts on the midbrain causing chemical changes which lead to 
‘nicotine hunger’ if the smoker stops smoking, in addition to other withdrawal symptoms 
(irritability, anxiety, depression). Positive reinforcement (reward effects from the 
psychoactive or stimulant effects of nicotine), and avoidance or reduction of negative states 
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(e.g. stress), also play a strong role in addiction. In addition, the behaviour becomes a learned 
response, subject to environmental cues, which makes relapse very likely when the smoker is 
presented with those cues, for example the association between having a cup of coffee or 
reading the paper and having a cigarette. Nicotine dependence is so strong that most quit 
attempts fail within a week, unless the smoker has pharmacological or other support to stop.36 
Despite this, up to 75% of ex-smokers stop without such support.37 However, most will have 
made repeated attempts in order to do so. In a paper reporting results from the International 
Tobacco Control Four Country cohort survey published in 2011, Borland and colleagues 
found 40.1% (95% CI: 39.6–40.6) of 21 613 smokers surveyed tried to quit in a given year 
and reported an average of 2.1 attempts. The authors suggest (page 678), ‘the average 40-
year-old smoker who started in their teens will have made more than 20 failed quit attempts. 
This speaks clearly to the difficulty of quitting successfully, even when most smokers have at 
some time abstained for at least a month before relapsing.’38 
Evidence from twin studies and molecular genetic research suggests there are both genetic 
and environmental influences on smoking initiation and persistence.35 Social factors such as 
familial and peer modeling may influence experimentation with smoking in adolescence, 
whereas other factors such as genetics, psychiatric co-morbidity, tendency to externalizing 
disorders (e.g. attention deficit/hyperactivity disorder or conduct disorder) rather than 
internalizing disorders (anxiety or depression), and propensity to develop tolerance to 
nicotine may be more important in persistent smoking in adolescence and adulthood.35 Other 
external influences are availability, packaging and price.39 
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Health beliefs about smoking  
Health psychologists have examined health beliefs about health-impairing behaviours such as 
smoking since the 1970s. Models such as the following were developed to explain such 
behaviours and to devise behavioural means for addressing them.40  
 
Early models developed from Attribution Theory, developed by Heider in the 1940s and 
1950s suggested that individuals need to understand cause and effect, and the influence of 
self or others to explain events. For example people may attribute illness to internal causes 
(e.g. my developing a smoking-related illness is due to my choosing to smoke) or external 
causes (my developing a smoking-related illness is due to the tobacco companies 
encouraging me to smoke). These attributions also affect an individual’s view of the solutions 
to the problems. People may attribute internal (self) or external (doctor) solutions to the 
illness, otherwise known as having an internal or external health locus of control.  
 
The most commonly used health belief model for smoking cessation support is the Stages of 
Change, or Transtheoretical model by Prochaska and Diclemente, developed in 1982: 
 
1. Pre-contemplation (not intending to make a change) 
2. Contemplation (considering a change, weighing up pros and cons) 
3. Preparation (making small changes) 
4. Action (actively changing behaviour) 
5. Maintenance (continuing the change over time) or Relapse. 
 
Health belief models continued to be developed during the 20th Century, incorporating 
cognitive elements into the models to predict behaviour and behaviour change. These 
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constructs include individual perception of susceptibility and risk of disease, costs and 
benefits of changing behaviour and cues to action (for example, the Health Belief Model, 
HBM, Rosenstock, 1966); self-efficacy (for example, Protection Motivation Theory, PMT, 
Rogers, 1975, 1983, 1985); social norms and the influence of important others (Theory of 
Reasoned Action, TRA, Fishbein 1967; Ajzen and Fishbein, 1970); and beliefs about one’s 
own capacity to change unhealthy behaviour (Theory of Planned Behaviour, TPB, Ajzen et 
al, 1986). More recently the Health Action Process Approach was developed, incorporating 
elements from the earlier theories (Schwarzer, 1992). 
 
Smoking cessation support has drawn upon these health belief models and proposed a stage 
model approach, suggesting that cessation is influenced by action plans, goal setting and 
transition through stages.40 Research has also used these models to examine success in 
quitting. For example, one study by Normal and colleagues published in 1999 examined the 
ability of the TPB to predict intentions to quit smoking, and quit attempts, in smokers 
attending primary care health promotions clinics. They found that cognitions of susceptibility 
and perceived control are associated with intentions to quit, and intentions to quit predicted 
quit attempts and the number of attempts.  
 
Contrary to theories of planned behaviour more recent evidence suggests people are more 
likely to quit spontaneously. West and Sohal in their 2006 cross-sectional study of quit 
attempts made by around 2000 smokers and ex-smokers found that almost half had made 
unplanned quit attempts and that unplanned attempts were more likely to be successful than 
planned attempts.41 They suggest that long-term smoking cessation may be the result of 
‘catastrophes’, in which a person’s beliefs, past experiences and current situation create 
tension, so a relatively small trigger can spontaneously motivate cessation.  
26 
 
Healthcare and social costs of smoking  
 
The annual cost to the NHS of treating smoking-related diseases is estimated at around £3.3 
billion42 but these are not the only costs to take into account. Costs to the UK due to 
smoking-cessation efforts and reduced taxes due to premature mortality, absenteeism and 
costs of disability benefit in addition to NHS costs are given in Figures 4 and 5, taken from 
the all party parliamentary group on smoking and health: inquiry into the effectiveness and 
cost-effectiveness of tobacco control. As can be seen for the tables, the total costs of tobacco 
use (almost £14 billion) far outweigh the costs gained through taxation on tobacco, estimated 
to be around £10.5 billion in 2009/10.43 
 
Figure 4: Annual costs of tobacco control measures 
Measure Estimated cost Year of 
estimate 
Graphical scope 
NHS Stop Smoking 
Services 
£74m 2008/09 England 
NHS pharmacotherapies £61m 2007/08 England 
Anti-smuggling measures £100m 2008/09 UK 
Mass media campaigns £20-£25m Various England & Wales 
Enforcement of other 
restrictions (e.g. ban on sale 
of tobacco products to 
children) 
Unknown n/a n/a 
Source: APPG inquiry into the effectiveness and cost-effectiveness of tobacco control 
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Figure 5: Estimates of the overall annual cost of smoking to the public purse 
Cost/benefit Revenue loss/gain (2010) 
Costs to the NHS for treating smoking-related 
diseases 
£3.3 billion 
Reduced tax revenue from premature mortality £1.9 billion 
Reduced tax revenue from workplace absenteeism £1.5 billion 
Increased disability benefit payments due to poor 
health 
£3.2 billion 
Reduced pensioner benefit payments as a result of 
premature mortality 
-£0.9 billion 
TOTAL £9.0 billion 
Source: APPG inquiry into the effectiveness and cost-effectiveness of tobacco control 
 
Health inequalities and smoking 
 
Inequalities in health 
 
Health inequalities can be defined as ‘differences in health experience and health outcomes 
between different population groups, according to socioeconomic status, geographical area, 
age, disability, gender or ethnic group.’ (Health Development Agency self-assessment tool 
for local authorities, page 344). Dimensions of inequality include: inequality due to the wider 
determinants of health (housing, education, transport, employment, food); financial and 
geographical inequality (whereby different areas receive different financial resources based 
on historical provision rather than need); inequality of service provision or access to services; 
inequality of service uptake (either due to lack of awareness of services, or due to services 
being, or seeming, inappropriate to some groups); and inequality of heath and illness between 
individuals and groups due to biology or behaviour.45  
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The major focus for research and policy addressing inequalities in health has been mainly on 
the effects of socio-economic status. Health outcomes evaluated include morbidity, mortality, 
years of life lost or quality of life measures. 
 
Smoking is the principal behaviour leading to health inequalities. In ‘Fair Society, Healthy 
Lives,’ published in 2010, Professor Sir Michael Marmot concluded (page 145) ‘smoking 
accounts for approximately half of the difference in life expectancy between the lowest and 
highest income groups. Smoking-related death rates are two to three times higher in low-
income groups than in wealthier social groups.’46 
 
Classification of socio-economic status 
 
The UK government has included questions about socio-economic status in the decennial 
national Census from the early 20th Century and this has allowed researchers to examine 
health outcomes by socio-economic status. Initially socio-economic status was classified 
using the ‘Registrar General’s social classes’ (RGSC). These were introduced in 1913 and 
renamed in 1990 as ‘Social class based on occupation’. Each category, as far as possible, 
represented similar levels of occupational skill, but did not use any validated sociological 
framework, rather the judgments of the staff in the Registrar General’s Office.47 
The RGSC did not take account of differences in individuals within each occupational 
category, such as educational level, or of social mobility. By the end of the 20th Century the 
‘National Statistics Socio-economic Classification’ (NS-SeC) replaced the Registrar 
General’s classification in 2001. This system took account of ‘employment relations’ 
characteristics that are widely recognised as significant in the literature (such as mode of 
payment, career prospects and autonomy,47 the main distinction being between employers, 
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employees, the self-employed and those excluded from work. The categories used for both 
systems are shown in Figure 6. 
Figure 6: Classifications for Socio-economic status in the UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: www.ons.gov.uk/ 
 
Other socio-economic measures used in research include educational level and income, 
which both correlate well with health outcomes. However, where such individual level data 
 
Registrar General 
I  Professional 
II  Managerial/Technical 
IIIN  Skilled (non-manual) 
IIIM  Skilled (manual) 
IV  Partly Skilled 
V  Unskilled 
 
National Statistics Socio-economic Classification (NS-SeC)  
Senior professionals / managers  
Associate professionals /junior managers  
Other clerical, administrative and sales workers 
Self-employed 
Supervisors / technicians 
Intermediate workers (semi-routine)  
Other workers 
Never worked / other inactive 
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are not available, composite area-based measures were developed such as the Carstairs and 
Townsend scores and the Index of Material Deprivation (IMD)48.  
 
The Carstairs score49 takes into account the proportion of households in the area that are 
overcrowded; the proportion of household in the area that are in social classes IV and V or 
unemployed and the proportion of households in the area that are in non-owner occupied 
properties. The Townsend score49 includes the proportion of unemployed residents over 16; 
the proportion of households in the area with one person per room and over; the proportion of 
households with no car; and the proportion of households not owning their own home. IMD 
uses seven domains (income; employment; health and disability; educational skills and 
training; crime, housing and services; and living environment) and was designed to measure 
deprivation at ward level.50 
One of the main limitations of using area-based measures to assign deprivation levels is 
‘ecological fallacy,’51 making incorrect inferences about individuals from observations made 
about groups of people. For example, not all people living in deprived areas are deprived, and 
this is especially true of people living in cities. However, IMD based on individual-level and 
general practice postcodes has been extensively validated as proxies for resident’s socio-
economic status for researching associations between deprivation and health outcomes.52 
 
31 
 
Emergence of evidence for health inequalities: The Black Report 
The welfare state and the NHS were set up in 1948 by the UK Labour Government with the 
intention of improving access to healthcare for people in lower socio-economic backgrounds 
and thus reduce inequalities in mortality rates and life expectancy between richest and 
poorest. However, by the late 1970s it had become apparent that socio-economic inequalities 
in health outcomes were actually increasing.  
These findings led to the then Labour Government to commission a research working group 
in 1977 to look into health inequalities, chaired by Sir Douglas Black. The report was 
published in 198053 but the incoming Conservative government rejected its findings and tried 
to suppress the promotion of the report due to cost implications and lack of political interest. 
However this was not successful and the findings of the report proved to be highly influential 
in bringing health inequalities into the spotlight for research and policy.54  
 
Using 1971 mortality statistics, the Black Report showed wide disparities in health between 
the richest and poorest. For example, the age standardized mortality ratio was far greater in 
unskilled workers compared with professionals (123 vs 79 per 100,000 aged 15-64) and 
showed a gradient through the intermediate classes. The report also found large class 
differences for infant mortality and mortality from specific diseases. Children from families 
in social class V were twice as likely to die as those in social class I. Black suggested four 
reasons why this might be the case: 
1. Measurement artefact (e.g. measurement of ‘social class’during census and on death 
certificate could differ); 
2. Natural or social selection (e.g. health related social mobility – healthier people move up 
the social hierarchy and unhealthy people move down); 
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3. Cultural / behavioural (class differences in behaviours, such as smoking, diet, alcohol 
intake, physical activity); 
4. Materialist (factors which contribute to inequalities are due to the way society is organised. 
Behaviours such as smoking occur in a social and economic context).  
The report concluded that materialist factors were the most likely explanation for socio-
economic health inequalities and made wide-ranging recommendations for policy and 
research (Figure 7), including for prevention (including banning of tobacco advertising) and 
health education.55 The Committee considered (Davey Smith, page 1465) that the ‘preventive 
way to attack [inequalities in health] is in childhood and, in the light of massive research, the 
first years of life.’24 This hypothesis has been strengthened out by subsequent research 
examining the origins of disease in early life and across the life-course.56-58 
Other authors proposed that a combination of all the proposed causes is more likely 
responsible than merely materialist factors, and also other mechanisms not considered by 
Black. For instance, Stringhini et al suggest in their 2011 paper (page 1) ‘Health damaging 
behaviours are often strongly socially patterned; material constraints, lack of knowledge, and 
limited opportunities to take up health promoting messages may act as barriers for lower 
socioeconomic groups to adopt a healthy lifestyle.’59 Graham proposed that smoking in 
women was seen a reward or compensation for the hardships resulting from material 
deprivation.60 
 The large-scale Whitehall studies, following up a cohort of 10,308 civil servants aged 35 to 
55 years since 1985, suggested that some of the gradient in health outcomes, such as life 
expectancy, can be partially explained by the gradient in prevalence of behaviours such as 
smoking which vary with socio-economic status. For example, in Stringhini et al’s 
longitudinal study of mortality in the Whitehall II study found that 32% of the age and sex-
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adjusted excess all-cause mortality seen between highest and lowest socio-economic groups 
could be explained by smoking, which was more prevalence in the lower socio-economic 
group (Hazard ratio, HR, 1.60, CI 1.06 to 2.04, reduced to HR, CI 1.36 1.06 to 1.74 when 
adjusting for smoking).  In the fully adjusted model, taking into account smoking (and the 
reduction in prevalence over the study period), alcohol, diet and physical activity the excess 
risk dropped by 72% (HR 1.14, CI 0.89 to 1.47),61 showing how great an influence behaviour 
has on health inequalities.  
Work by Marmot, Wilkinson and colleagues, suggests a large contribution to health 
inequalities comes from psychological stress resulting from an individual’s awareness of their 
own level of deprivation in relation to others or from a feeling of lack of control in the 
workplace, which generate a stress response with increased cortisol levels and other 
neuroendocrine changes which affect blood lipid levels and clotting factors, predisposing 
individuals to cardiovascular disease.62 Other contributory factors include differences in 
social capital (which includes community networks, relationships with friends and relatives, 
sense of belonging and safety, and reciprocity).63  
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Figure 7: Recommendations of the Black Report  
For policy within the health sector the Black Report had three priorities: 
1.  For children to have a better start in life;  
2.  For disabled people bearing the brunt of cumulative ill health and deprivation;  
3.  For preventive and educational action to encourage good health.  
 
For broader social policy it had two main priorities:  
1.  A comprehensive anti-poverty strategy;  
2.  Improving education.  
 
For research it had six main priorities:  
1.  Surveillance of the development of children, especially in relation to accidents;  
2.  Better understanding of the health effects of such aspects of behaviour as smoking, 
diet, alcohol consumption and exercise;  
3.  The development of area social conditions and health indicators for use in resource 
allocation;  
4.  Study of health hazards in relation to occupational conditions and work;  
5.  Better measures of the prevalence and course of disability;  
6.  Study of the interaction of social factors implicated in ill health over time and 
within small areas. 
Souce: Macintyre 199755 
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Key policy responses to health inequalities 
The Acheson Report 
The Black Report, despite highlighting the importance of health inequalities, did not result in 
much change of policy whilst the Conservatives were in government and evidence for 
growing inequalities in health status as well as mortality grew over the next 10 years.64 The 
Labour Government was elected in 1997 and commissioned an Independent Inquiry into 
Health Inequalities. The resulting Acheson report was published in 1998.65 This documented 
further evidence for health inequalities being explained mainly by socio-economic 
differences between groups and recommended substantial changes in policy.  
 
The report found an increasing gap between social classes despite an overall improvement in 
health outcomes such as life expectancy. This may be because initiatives to improve 
particular conditions, such as cardiovascular disease, are taken up more readily by affluent 
people than those from more deprived backgrounds.  
 
The report made 39 recommendations, with the following three being described as crucial: 
 
• All policies likely to have an impact on health should be evaluated in terms of their 
impact on health inequalities; 
• A high priority should be given to the health of families with children; 
• Further steps should be taken to reduce income inequalities and improve the living 
standards of poor households. 
 
The report specifically mentioned the impact of smoking on health and emphasised that 
people from most deprived groups were more likely to smoke, and less likely to give up, than 
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those from the most affluent groups. It suggested that smoking was an important cause of 
differences in mortality between social classes and recommended restrictions on smoking in 
public places, banning of tobacco advertising and promotion and large-scale education about 
the dangers of smoking. It also recommended increasing the price of tobacco products, 
introducing smoking cessation programmes for pregnancy, focused on those less well off, 
and for nicotine replacement therapy to be prescribed on the NHS.  
 
Only three of the recommendations addressed healthcare, illustrating the importance of socio-
economic and societal influences on health. Despite receiving some criticism for the 
recommendations being vague, not being fully evidence-based or costed, and lacking a 
hierarchy of importance,24 the government accepted the findings of the Acheson report and 
incorporated the recommendations into its policies (see Figure 8).  
 
Figure 8: UK Policy Addressing Health Inequalities following the Acheson Report 
Domains of Policy Examples 
Life-course approach: early childhood 
 
Sure Start program  
Family Nurse Partnership 
Area based initiatives: focus on 
disadvantaged communities   
Health Action Zones 
 
 
Redistributions: welfare to work 
 
Tax credits 
Healthcare Organisational reform in the NHS 
Primary Care Trusts 
 
Targets and performance culture  
 
Public Service Agreements 
Structures and processes: joined up   
government 
Cross-cutting review of health      
inequalities 
 
Source: Exworthy et al, 200366 
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In particular, two key documents set out the government’s plans to address health 
inequalities. The white paper Our Healthier Nation (published in 1998) which aimed to 
promote healthier living and reduce inequalities, including tackling the contribution of 
smoking to health inequalities through another white paper, Smoking Kills published in 1998, 
which proposed a ban on tobacco advertising and sponsorship.  Our Healthier Nation focused 
on ‘the main killers’; cancer; coronary heart disease and stroke; accidents; and mental illness, 
and set out targets for improvement by 2010 (see Figure 9): 
 
Figure 9: Targets in Saving Lives Our Healthier Nation 
 
 
 
 
 
 
 
 
The government then published an Action Report in 1999 with the aim to ‘improve the health 
of the worst off in society and to narrow the health gap’ whereby health and social services, 
were required to work together to set up health programmes and health action zones with 
local targets to address areas of particular local health inequalities.67 
• Cancer: to reduce the death rate in people under 75 by at least a fifth; 
• Coronary heart disease and stroke: to reduce the death rate in people under 
75 by at least two fifths; 
• Accidents: to reduce the death rate by at least a fifth and serious injury by at 
least a tenth; 
• Mental illness: to reduce the death rate from suicide and undetermined injury 
by at least a fifth. 
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The NHS Plan followed in July 2000 and stated the government’s plan to reform the NHS; to 
target prevalent diseases through prevention and improved management; to reduce 
inequalities in access to health services; and to improve child health. The NHS plan also set 
out national health inequalities targets to narrow the gaps in infant mortality and life 
expectancy. It also set out a major expansion in smoking cessation services. Local targets for 
reducing health inequalities were strengthened by the introduction of Public Service 
Agreements (PSA), in which targets were agreed between the Treasury and government 
departments. The PSA targets for health inequalities are shown in Figure 10 below, and 
include tackling smoking. 
 
Figure 10: Public Service Agreement (PSA) targets for health inequalities 
 
 
 
 
 
 
• Starting with children under one year, by 2010 to reduce by at least 
10% the gap in mortality between routine and manual groups and the 
population as a whole; 
• Starting with local authorities, by 2010 to reduce by at least 10% the 
gap in life expectancy between the fifth of areas with the worst health 
and deprivation indicators (the Spearhead Group) and the population as 
a whole; 
• To reduce the inequalities gap between the fifth of areas with the 
worst health and deprivation indicators and the population as a whole 
by at least 40% for cardiovascular disease and by at least 6% for 
cancer; 
• To reduce adult smoking prevalence in routine and manual groups 
to 26% or less by 2010. 
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Following on from these initiatives the Government carried out a cross cutting review on 
health inequalities in 2002. The review found inequalities in access to prevention, screening, 
diagnostic and treatment services for CHD and cancer. It recommended developing service 
provision, access and quality in areas and among underserved populations and improving the 
quality of preventive and treatment services for coronary heart disease, stroke, diabetes and 
cancer through National Service Frameworks. The Government published a 10-year review 
in 2009, ‘Tackling health inequalities: 10 years on,’ showing progress in reducing 
inequalities in health (Figure 11). 
Figure 11: Improvements in health over the last 10 years 
  
1995-97 
 
2005-07 
Difference 
over 10 
years 
Life expectancy: males (years)    
England 74.6 77.7 +3.1 
Spearhead areas* 72.7 75.6 +2.9 
Absolute gap 1.9 2.1  
Life expectancy: females (years)    
England 79.7 81.8 +2.1 
Spearhead areas 78.3 80.2 +1.9 
Absolute gap 1.4 1.6  
Infant mortality (per 1,000 live 
births) 
   
England 5.8 4.7 -1.1 
Spearhead areas 6.6 5.4 -1.2 
Absolute gap 0.8 0.7  
 
*The spearhead group comprises the 70 local authority areas with the worst health and deprivation indicators. 
This is the basis for the life expectancy targets. The routine and manual group covers groups 5-7 in the ONS 
NS-SEC socio-economic classification. This is the basis of the infant mortality target. 
 
Source: based on the Department of Health (2008) Tackling Health Inequalities: 2005-07 Policy and Data 
Update for the 2010 National Target. Absolute gap and difference over 10 years based on rounded figures 
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The Marmot Review 
The World Health Organization’s Commission on Social Determinants of Health 
published a critical report in 2008, Closing the gap in a generation. The chair of the 
commission, Professor Sir Michael Marmot, was then asked by the UK government to chair 
an independent review of health inequalities and to come up with evidence-based strategies to 
reduce variation. The Review had four aims: 
1. To identify, for the health inequalities challenge facing England, the evidence most 
relevant to underpinning future policy and action 
2. To show how this evidence could be translated into practice 
3. To advise on possible objectives and measures, building on the experience of the PSA 
target on infant mortality and life expectancy 
4. To publish a report of the Review’s work that will contribute to the development of a post-
2010 health inequalities strategy. 
The final report, Fair Society Healthy Lives, was published in 2010 and showed that socio-
economic disparities persist.46 For example, in England, the health expectancy (disability-free 
life expectancy) for people living in the poorest areas is 17 years lower than for people living 
in the most affluent areas. The review found (page 62), ‘Risk factors for cancer and 
circulatory diseases, such as smoking, physical inactivity and obesity, are elevated along the 
social gradient. The burden of disease falls disproportionately on people living in deprived 
conditions, and for some health conditions falls particularly heavily on certain ethnic groups’. 
 
Marmot stated (page 46). ‘While there have been improvements in health across the social 
spectrum, there has been no narrowing of the gap between rich and poor despite several 
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attempts over the years to tackle health inequalities, and there is some evidence of the gap 
widening.’ The report recommended the following six policy objectives: 
1. Give every child the best start in life; 
2. Enable all children, young people and adults to maximize their capabilities and have 
control over their lives; 
3. Create fair employment and good work for all; 
4. Ensure healthy standard of living for all; 
5. Create and develop health and sustainable places and communities; 
6. Strengthen the role and impact of ill-health prevention. 
 
Within recommendation 6 (page 142) is the specific recommendation to: 
 ‘Implement evidence-based ill health preventive interventions that are effective across the 
social gradient by: 
• Increasing and improving the scale and quality of drug treatment programmes, 
diverting problem drug users from the criminal justice system;  
• Focusing public health interventions such as smoking cessation programmes and 
alcohol reduction on reducing the social gradient;  
• Improving programmes to address the causes of obesity across the social gradient.’ 
42 
 
The report emphasizes the importance of tobacco control to reducing health inequalities, 
particularly pricing, and (page 145) ‘at local levels, greater emphasis in smoking cessation 
initiatives on the psychosocial reasons for smoking and prioritizing deprived and 
marginalised groups is required, focused particularly on routine and manual socioeconomic 
groups, and people with mental health problems.’ 
 
Inequalities in health between ethnic groups 
 
As described previously, the Marmot review found (page 62) ‘The burden of disease falls 
disproportionately on people living in deprived conditions, and for some health conditions 
falls particularly heavily on certain ethnic groups.’ Ethnicity is a complex concept, which 
varies according to context and has a wide sociological literature. One definition given by 
Nazroo in a paper published in 1998 (page 712) is that ethnicity ‘reflects self-identification 
with cultural traditions that both provide strength and meaning, and boundaries (perhaps 
fluid) between groups.68  
The censuses in 1991 and 2001 classified ethnicity as shown in Figure 12. However, there are 
several concerns about the validity and reliability of ethnic group classifications when used in 
research. Self-selected ethnicity may not match researcher-assigned ethnicity. Limited 
choices such as ‘White; Black; Asian’ may mask within group differences and exaggerate 
between-group differences. Ethnicity is not recorded on death certificates, so mortality data 
usually uses country of birth as a proxy, which would not pick up people from minority 
ethnic groups who were born in the UK. 
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Figure 12: Census ethnic categories 
 
1991 census ethnic categories 
1. White 
2. Black-Caribbean 
3. Black-African 
4. Black Other please describe 
5. Indian 
6. Pakistani 
7. Bangladeshi 
8. Chinese 
9. Any other ethnic group please describe 
 
 
The 2001 census ethnic categories 
A. White 
• British 
• Irish 
• Any other white background, please write in 
B. Mixed 
• White and black Caribbean 
• White and black African 
• White and Asian 
• Any other mixed background, please write in 
C. Asian or Asian British 
• Indian 
• Pakistani 
• Bangladeshi 
• Any other Asian background, please write in 
D. Black or Black British 
• Caribbean 
• African 
• Any other black background, please write in 
E. Chinese and other ethnic group 
• Chinese 
• Any other, please write in 
 
Source: ONS 
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Despite the limitations in classifying ethnicity, evidence for health inequalities across ethnic 
groups has been extensively demonstrated in the United States and the United Kingdom69 For 
example, for cardiovascular disease, in the United Kingdom people who were born in South 
Asia have far higher mortality rates from ischaemic heart disease, and those born in the 
Caribbean have higher mortality rates from strokes and other outcomes resulting from 
hypertension, than those born in England.70 
One theory, extrapolated from the Black Report, is that these variations are due to socio-
economic causes rather than directly due to differences in genetics or behaviour, including 
differences in ability to access services.71 However, other authors suggest health is adversely 
affected by the stress of racism.72 For example, Salway et al, in a rapid response to a BMJ 
editorial by Hunter in 2010,73 suggest ‘Socioeconomic deprivation inter-relates closely with 
racialised hierarchies of exclusion and discrimination across the life-cycle. There is evidence 
that health outcomes of some minority ethnic groups are worse than would be expected on 
the basis of their socioeconomic circumstances alone, and that the direct and indirect 
experience of racism in everyday life is an important contributory factor.’  
The Acheson report recommended addressing ethnic group inequalities in the socioeconomic 
determinants of health through improved data collection and monitoring of disparities and 
through considering the needs of ethnic minority groups when designing health services. The 
report specifically recommended: 
• The needs of minority ethnic groups are specifically considered in the development 
and implementation of policies aimed at reducing socioeconomic inequalities; 
• Further development of services which are sensitive to the needs of minority ethnic 
people and which promote greater awareness of their health risks;  
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• The needs of minority ethnic groups are specifically considered in needs assessment, 
resource allocation, health care planning and provision.  
The focus on reducing inequalities due to ethnicity was strengthened by the Race Relations 
(Amendment) Act 2001. This Act promotes race equality by all public sector authorities and 
requires them to show that their policies do not discriminate against any ethnic group though 
equality impact assessments.  
 
Inequalities and smoking 
 
Ferguson et al, 201274 
 
The Whitehall studies and others previously described have shown that smoking contributes 
between a third and a half of the excess risk of morbidity and mortality seen between people 
from the most and least deprived backgrounds. In the Whitehall II study, 32% of the age and 
sex-adjusted excess all-cause mortality seen between highest and lowest socio-economic 
groups could be explained by smoking. The hazard ratio (HR) for all-cause mortality for the 
lower socio-economic group compared with the higher socio-economic group was 1.60 (CI 
1.06 to 2.04) before smoking was taken into account. The HR reduced to 1.36 (CI 1.06 to 
1.74) after adjusting for smoking, which more prevalence in the lower socio-economic group 
(29.7% vs 10.1% in the higher socio-economic group).61 In a study by Jha et al looking at 
mortality from lung cancer, the mortality rate among men aged 35 to 69 years in England and 
Wales was 43% for men from the lowest socio-economic group compared to 21% for men in 
the highest socio-economic group.75  
 
“Smoking prevalence is strongly associated with social disadvantage and is the 
largest cause of social health inequalities.”  
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People from low-income backgrounds are more likely to start smoking as adolescents and 
less likely to quit as adults,6 and so prevalence rates are higher in more deprived groups. In 
2010, 28% of adults in routine and manual households smoked compared with 13% of those 
in managerial and professional households (See Figure 13).1 Children from deprived families 
are more likely to be exposed to second-hand smoke and women from low-income 
backgrounds are more likely to smoke while pregnant.35 
 
Figure 13: Cigarette smoking status among adults, by socio-economic classification of 
household reference person, 2010 
 
 
Source: General Lifestyle Survey 2010. © The Office for National Statistics, 2012, 
 
There are also differences in smoking prevalence with respect to gender and geography, with 
rates varying from 27% of men in the North East of England to 20% of women in the West 
Midlands, the East of England, London and the South East.76 
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The main sources of data for smoking prevalence among adults in Great Britain are the 
General Lifestyle Survey (GLS), formerly the General Household Survey (GHS), published 
as reports by the Office for National Statistics (ONS). The Health Survey for England (HSE) 
also contains questions about smoking. The smoking statistics for England published in 2012 
showed a continuing trend for higher smoking prevalence in men aged 20-34 (33%) and 
women aged 20-24 (29%).1 Smoking rates then tend fall with age, as people give up smoking 
or die from smoking-related illnesses, and are also lower in people aged under 20, see Figure 
14. 
 
Figure 14: Adult smoking prevalence by gender and age, Great Britain, 2010 
 
 
Source: General Lifestyle Survey 2010. ©The Office for National Statistics, 2012 
 
Research examining inequalities between ethnic groups in smoking prevalence and the 
provision of smoking cessation interventions in the UK is sparse but studies using the Health 
Survey for England in 2004 and 201077 have shown the following differences. Both surveys 
showed higher smoking rates in men than women in all age groups. In the 2004 survey the 
highest smoking rates were in Bangladeshi, Irish and Pakistani men (Fig 15). For women, 
there were far lower smoking rates in women from South Asian and Chinese ethnic groups.76  
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Figure 15: Adult smoking prevalence by ethnicity and gender 
 
 
 
Source: ‘Tackling Health Inequalities: 10 Years On’ using data from the Health Survey for England, 2004 
 
 
In the 2004 General Household Survey which specifically looked at smoking among ethnic 
minorities, smoking prevalence ranged from 20% for Indian men, to 40% for Bangladeshi 
men, compared with a National average for men of 24%. For women, smoking prevalence 
ranged from 2% for Bangladeshi women to 26% for Irish women, compared with a National 
average at the time of 23% for women.78 The same report showed that smoking prevalence 
tends to fall with age for all ethnic groups, with the highest prevalence being in those aged 
16-34 years. However in Bangladeshi and Caribbean men this was not the case, and the 
highest prevalence was found in those aged 35-53 years.  
 
In a more recent study by Karlsen et al using combined data from the HSE 2006-08,77 the 
authors found higher age-standardised smoking rates among black Caribbean men (37%) and 
Bangladeshi men (36%) compared with white British men (27%). The authors also found 
higher smoking rates for White women and black Caribbean women (28% and 25%, 
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respectively) than for women from other ethnic groups. Studies from the USA have shown 
higher smoking prevalence among Whites and African-Americans,79 80 and for non-White 
smokers to be less likely to receive smoking cessation advice.81 82 These disparities are an 
important cause of health inequalities, given the higher risk of smoking-related diseases 
among south Asian and African-Caribbean populations,77 and higher mortality rates in these 
groups particularly for circulatory disease linked to smoking. For example, a study by Wild et 
al using Census data from 2001 examined mortality rates by ethnicity, where ethnicity was 
classified by country of birth (although acknowledging this would miss people from different 
ethnic groups born in England and Wales), linked with mortality data from ONS.83 The 
authors found standardized mortality rates for ischaemic heart disease were statistically 
significantly higher among man and women aged over-20 years born in Ireland, East Africa, 
Bangladesh, Pakistan or India compared with rates for England and Wales, with the highest 
rates seen in Bangladeshi men (SMR 1.75, CI 158 to 193). 
 
Smoking rates are particularly high among people with severe mental health conditions, such 
as major depression, schizophrenia and bipolar disorder, and studies have shown that people 
with these conditions find it particularly difficult to stop smoking. For example, in a survey 
study of 168 patients with schizophrenia in Scotland, Kelly et al found that 58% of the 135 
respondents smoked compared with 28% in the general population.84 In a US study of 4411 
respondents aged 15 to 54 years, using the National Comorbidity Survey, Lasser et al found 
current smoking rates for people with no mental illness, lifetime mental illness, and past-
month mental illness were 22.5%, 34.8%, and 41.0%, respectively (p<0.001). Smokers with a 
history of mental illness had a self-reported quit rate of 37.1% (p = 0.04), and smokers with 
past-month mental illness had a self-reported quit rate of 30.5% (p<0.001) compared with 
smokers without mental health problems (42.5%).85 The authors suggest that people with 
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such mental health conditions may be self-medicating with tobacco, but also cite evidence 
suggesting that smoking may cause mental health problems in susceptible people, also 
suggested by Kelly et al, who found that 90% of the smokers with schizophrenia in their 
study started smoking before diagnosis.  
 
Key points from Chapter 1 
• Smoking causes a range of serious diseases and leads to premature mortality. 
• Smoking costs the UK in the region of £14bn each year. 
• Smoking is the biggest cause of health inequalities. 
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Chapter 2: Policies to reduce smoking prevalence  
 
Reducing the incidence of smoking-related diseases is a key international public health 
objective. World Health Organisation’s (WHO) Framework Convention on Tobacco Control 
(FCTC)86 was developed in response to what WHO calls ‘the globalisation of the tobacco 
epidemic’ and suggests tackling the problem through demand reduction strategies in addition 
to reducing the supply of tobacco products. The core provisions are summarised in Figure 16. 
 
Figure 16: Core demand and supply reduction provision in the WHO FCTC 
 
 
 
 
 
The core demand reduction provisions are contained in articles 6-14:   
Price and tax measures to reduce the demand for tobacco, and Non-price 
measures to reduce the demand for tobacco, namely:  
• Protection from exposure to tobacco smoke;   
• Regulation of the contents of tobacco products;   
• Regulation of tobacco product disclosures;   
• Packaging and labeling of tobacco products;   
• Education, communication, training and public awareness;   
• Tobacco advertising, promotion and sponsorship; and,  
• Demand reduction measures concerning tobacco dependence and 
cessation.  
The core supply reduction provisions in the WHO FCTC are contained in 
articles 15-17:   
Illicit trade in tobacco products;   
Sales to and by minors;  
Provision of support for economically viable alternative activities. 
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Article 14 recommends that countries implement ‘demand reduction measures concerning 
tobacco dependence and cessation’ alongside population level strategies such as the 
introduction of smoke-free workplaces, restricting advertising and raising taxation on 
tobacco.  To ensure these measures are carried out, WHO introduced the ‘MPOWER 
measures’ to ‘assist in the country-level implementation of effective interventions to reduce 
the demand for tobacco, contained in the WHO FCTC,’ and the website provides detailed 
guidance about how to carry out the measures (http://www.who.int/tobacco/mpower/en/). 
The six components of MPOWER are: 
1. Monitor tobacco use and prevention policies; 
2. Protect people from tobacco smoke; 
3. Offer help to quit tobacco use 
4. Warn about the dangers of tobacco 
5. Enforce bans on tobacco advertising, promotion and sponsorship; 
6. Raise taxes on tobacco. 
UK policy has followed these measures through regular surveys to monitor prevalence as 
described in Chapter 1, through its tobacco control policy, described in the next section, and 
through the provision of NHS stop smoking services, described below and in more detail later 
in this chapter. 
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UK tobacco control policy 
Tobacco control efforts began in the UK following the first RCP report in 1962, which set out 
to prove ‘the overwhelming case against tobacco’ and recommended restrictions on tobacco 
advertising, smoking in public places and the sale of tobacco to children, plus increased 
taxation of tobacco. These recommendations were echoed in the first US Surgeon General’s 
report ‘Smoking and Health’ in 1964. Cigarette advertising on television and radio was 
banned in the UK in 1965, and this has been followed over the decades by more 
comprehensive efforts by the UK government to reduce deaths from smoking and to reduce 
inequalities, as described in the previous chapter, resulting from higher levels of tobacco use 
among people from more deprived backgrounds. Current policy under the UK Coalition 
Government39 targets five areas, with promotion through a marketing and education strategy: 
• Stopping the promotion of tobacco;  
• Making tobacco less affordable;  
• Effective regulation of the sale of tobacco products (including packaging, displays 
and vending machines);  
• Helping tobacco users to quit;  
• Reducing exposure to second-hand smoke. 
 
Stopping promotion of tobacco 
The Tobacco Advertising and Promotion Act 2002 prohibits tobacco advertising but the 
Tobacco Industry has strategies to circumvent this, including targeted packaging, point-of-
sale displays and through the entertainment sector, including the internet. Through the Health 
Act 2009, displays are being removed from large shops from April 2012 and from all shops 
by 2015. Sale of cigarettes from vending machines was discontinued in 2011. There is 
currently a consultation about introducing plain packaging for cigarettes and means of 
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reducing promotion through films and the internet. Health warnings on cigarette packets have 
been in place since 1971, and from 2003 large pictorial health warnings have been 
compulsory. 
 
Making tobacco less affordable 
The use of tobacco is highly sensitive to price (see Figure 17, taken from the All Party 
Parliamentary Group on Smoking and Health’s Inquiry42 into the effectiveness and cost-
effectiveness of tobacco control), so raising the price of tobacco through taxation is one way 
to reduce consumption. Efforts have also been made through UK Border Agency and Her 
Majesty’s Revenue and Customs to reduce the illegal importation of tobacco products as 
tobacco smuggling undermines the effect of price rises. The government estimates that this 
action has reduced the market share of smuggled cigarettes in the UK from 20% in 2000 to 
around 12% in 2010. 
 
Figure 17: Effect of increasing cost of cigarettes on smoking prevalence 
 
Source: Source: APPG on Smoking and Health Inquiry using data from General Household Survey/General 
Lifestyle Survey. Cigarette prices: Tobacco Manufacturers’ Association 
 
 
Retail 
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Effective regulation of the sale of tobacco products 
In 1986 the sale of any tobacco product to children under 16 years was made illegal. In 2007 
the legal age for purchase was increased from 16 years to 18 years. The effect of this increase 
was examined by Millett et al, who analysed data from the Smoking, Drinking and Drug Use 
among young people in England (SDDU) survey.50 The authors found that the age increase 
was associated with reduced prevalence of regular smoking among young people (adjusted 
OR 0.67, p<0.001) and that this reduction was seen in across all socio-economic groups. The 
government’s Tobacco Plan seeks to strengthen enforcement of the age limits and also 
restrict the sale of niche tobacco products such as waterpipe (shisha) tobacco.  
 
Helping smokers to quit 
Action on Smoking and Health (ASH) was set up in 1971 by the Royal College of Physicians 
in order to educate the public about the dangers of smoking and to campaign for tobacco 
control policies. The Department of Health also provides information and advice through a 
website (http://gosmokefree.nhs.uk/) and with television advertising campaigns. In March 
1984 National No Smoking Day was launched in the UK and remains an annual event. The 
government set up the NHS Stop Smoking Service, in 1999/2000, following 
recommendations of the White Paper Smoking Kills in 1998. This is discussed further in the 
section ‘Individual level smoking cessation interventions’, below. Smoking surveillance 
through surveys helps to inform policy and service delivery  
 
Reducing exposure to second-hand smoke 
In 2002 the International Agency for Research on Cancer reported that regular exposure to 
environmental tobacco smoke increased the risk of lung cancer by 20% to 30% and evidence 
suggests the risk of cardiovascular diseases increases by 25%.87 In 2004 the WHO 
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Framework Convention on Tobacco Control was ratified and Ireland became the first country 
in the world to ban smoking in public places, public transport and workplaces, followed by 
Scotland and England in 2007. 
 
Effect of tobacco control policies 
As several tobacco control initiatives were introduced from 2000 onwards, the effect of 
individual components of tobacco control policy to the reduction in smoking prevalence in 
the UK after 1998 is difficult to determine. However, before-and-after studies and time-series 
analyses show improvements. For example, after the smoking ban in the UK evaluations 
showed improved health outcomes52 including reduced hospital admissions for myocardial 
infarction88 a reduction in asthma admissions89 and a reduction in premature and low birth 
weight babies.90   
 
Helping smokers to stop smoking 
 
Individual level smoking cessation interventions by health care professionals are highly 
effective and, if delivered equitably, have the potential to reduce health inequalities resulting 
from tobacco use.91-93 In order to improve smoking cessation rates, effective pharmacological 
treatments are usually required, as well as advice or behavioural support.36  
Smoking cessation services in the UK 
 
NHS stop smoking services 
NHS stop smoking services were set up in England in 1999 following the publication of the 
tobacco white paper Smoking Kills.94 Treatment was based on the ‘Maudsley model’95 with 
evidence-based guidelines first published in the journal Tobacco Control96 97 and 
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incorporating pharmacological treatments for tobacco addiction and health belief models 
about smoking cessation. The evidence base for smoking prevention and cessation treatment 
has been extensively reviewed by the Cochrane Tobacco Addiction Group 
(http://tobacco.cochrane.org/our-reviews) and summarised by Aveyard.98  
About 150 clinics now exist, providing counselling and support to smokers wishing to quit, 
either in groups or one-to-one, together with pharmacological therapy such as Nicotine 
Replacement Therapy (NRT) and Bupropion (Zyban) or Varenicline (Champix) available 
free of charge or on prescription. There is also an NHS smoking and pregnancy helpline and 
midwives and GPs offer help to pregnant women to stop smoking. The advisers are nurses or 
pharmacists trained in smoking cessation techniques. Primary Care Trusts were required to 
provide regular reports of the numbers of smokers accessing service, the number setting a 
quit date, and the number of successful four week quitters.  
Smoking cessation advice in Primary Care 
Opportunistically identifying smokers in routine primary care consultations and then giving 
them brief advice to stop smoking results in more referrals to stop smoking services, more 
quit attempts,99  and a small increase in successful quit attempts compared with receiving no 
help.100 Despite these modest effects, they lead to a large public health benefit as 
approximately 80% of the population visit a general practice each year.101 
Effectiveness of NHS Smoking cessation service 
Even brief advice to smokers to stop smoking has been shown in a recent systematic review 
and meta-analysis to have some benefit in helping smokers to stop smoking102 and this can be 
amplified by the addition of pharmacological treatments and behavioural support.98 The 
systematic review included 13 randomised controlled trials and the meta-analysis found that, 
compared to no intervention, advice from a physician to quit smoking increased the 
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frequency of quit attempts (Relative risk, RR, 1.24, CI 1.16 to 1.33). Adding in behavioural 
support or medication increased this further (RR 2.17, CI 1.52 to 3.11 with behavioural 
support; RR 1.68, CI: 1.48 to 1.89 with medication). Compared with advice only, adding in 
other support resulted in more quit attempts (RR 1.69, CI 1.24 to 2.31 with behavioural 
support; 1.39, CI 1.25 to 1.54 with medication). However, the evidence for these 
interventions leading to increased quit rates was inconclusive.  
 
A Cochrane systematic review published in 2012 and looking at the effect of both 
counselling and pharmacotherapy identified 41 relevant randomised or quasi-randomised 
controlled trials. One trial used a particularly intensive treatment regimen so was not included 
in the meta-analysis due to heterogeneity of effect size. The pooled estimates from the 
remaining 40 studies (15,021 participants) found good evidence for a benefit from 
pharmacotherapy and behavioural therapy for smoking cessation compared to usual care, 
brief advice, or less intensive support. (RR 1.82, CI 1.66 to 2.00). There was more of an 
effect when patients were recruited from healthcare settings than in community-based trials 
(RR 2.06, CI 1.81 to 2.43 compared with RR 1.51, CI 1.33 to 1.76).103 
 
Another Cochrane systematic review of behavioural therapies to help smoking cessation in 
pregnant women identified 76 randomised controlled trials (20,000 patients) and showed a 
significant reduction in rates of smoking compared to information or ‘usual care’ (risk ratio 
0.94, CI 0.93 to 0.96).65 However, the evidence for pharmacotherapy (NRT) in pregnancy is 
less compelling. A Cochrane systematic review of randomised controlled trials of NRT in 
pregnancy identified only six relevant randomised controlled trials (1745 patients) and found 
no statistically significant difference between NRT and placebo (risk ratio 1.33, CI 0.93 to 
1.91) and there were also no differences in rates of stillbirth, miscarriage, premature birth or 
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low birth weight.24 A recent randomised controlled trial of NRT in pregnancy by Coleman et 
al recruited 1050 women and found a validated quit rate at delivery of 9.4% in the NRT 
group compared to 7.6% in the placebo group (OR 1.26; 95% CI, 0.82 to 1.96).104 
 
Early evaluations of NHS stop smoking services found around 15% of people accessing the 
service and successfully quitting were still not smoking at 52 weeks105 and there was a 
modest reduction in health inequalities.6 The service has been evaluated more recently. For 
example, Brose et al,106 used data from 24 stop smoking services (127,000 consecutive 
attendances) to determine at the effectiveness of different interventions after adjusting for 
client characteristics. The authors found that smokers who attended specialist stop smoking 
clinics, had group treatment and who received Varenicline, or NRT plus Varenicline, were 
more likely to quit (assessed at four weeks after a designated quit date) than those receiving 
treatment in primary care, one-to-one and receiving just NRT. Four week quit rates are 
typically higher than 52 week quit rates due to high rates of relapse. For example, in one 
study by Bauld et al107 comparing group treatment to pharmacy 1:1 treatment, four week quit 
rates (validated by carbon monoxide readings of patients’ breath) were 22.5% but by 52 
weeks this had fallen to 6.3% for smokers receiving group treatment and 3.6% for those 
receiving 1:1 treatment, but both treatments were considered highly cost-effective in the 
accompanying cost-benefit analysis. This study had a very low 52 week quit rate compared to 
other studies but was conducted in a deprived area of Glasgow where the environmental cues 
may be more difficult to overcome. A recent systematic review of 20 studies by Bauld et al 
published in 2010 and looking at the effectiveness of NHS stop smoking services confirmed 
earlier studies’ findings with average 52 week quit rates of 15%.108  
Research suggests the NHS stop smoking services have been successful in reaching 
disadvantaged people and so could reduce the inequalities caused by smoking.105 107 109 For 
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instance, Bauld et al, in a national study examining smokers in receipt of NHS stop smoking 
services, published in 2007, found a modest contribution to reducing smoking prevalence in 
the most deprived areas. They found that although short-term cessation rates were lower in 
disadvantaged areas than in other areas (52.6% vs 57.9%, p<0.001), the proportion of 
smokers being treated was higher (16.7% compared with 13.4%, p<0.001).6 
Despite evidence of effectiveness of smoking cessation advice, it tends to be under-provided 
in primary care,110 111 even though patients think it is appropriate for GPs to give smoking 
cessation advice.112 To maximise the effectiveness of smoking cessation advice in primary 
care guidelines have been published36 and research has focused on examining the barriers to 
providing such advice.113 114 In a systematic review of studies examining GPs’ attitudes and 
beliefs about providing smoking cessation advice, which identified 19 studies, eight themes 
were identified.114 The systematic review found that GPs believe that smoking cessation 
advice is time-consuming within the timeframe of a routine appointment (weighted 
proportion: 42%), ineffective (38%), that they lacked confidence in their skills to provide 
effective advice (22%), 18% thought such discussions were unpleasant and 16% lacked 
confidence in their knowledge. A few thought that it intruded on patients’ privacy (5%), was 
not their duty (5%) or that it was not appropriate. In a postal survey of 468 Leicestershire 
GPs published in 1996, Coleman et al found that 97% of GPs felt that smoking cessation 
advice was more effective when linked to the presenting complaint but they were also 
concerned about damaging the doctor-patient relationship.113 Although not specifically stated, 
lack of time equates to lack of finance, as with more resources, additional staff can be 
employed for smoking cessation work. A survey study of general practitioners by Bass in 
British Columbia in 1996 found that lack of financial reimbursement was a barrier to 
providing smoking cessation advice.115 
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To address GPs’ concerns about lack of training, researchers have looked at the effect of 
specifically training health professionals in primary care to delivery smoking cessation 
interventions. A Cochrane systematic review by Carson et al published in 2012 identified 17 
randomised controlled trials in which the intervention was training of health care 
professionals in smoking cessation work.116 The authors found that training health 
professionals results in them being more likely to give advice, including: asking patients to 
set a quit date, making follow-up appointments, providing counselling, providing self-help 
material (difference between training and no-training groups clinically and statistically 
significant for all interventions). However, there was no difference in the chance of 
prescribing NRT between trained and not-trained groups. Meta-analysis of eight studies that 
reported continuous abstinence from smoking showed that training was effective compared 
with no training (OR 1.60, 95% CI 1.26 to 2.03, p = 0.03). The authors concluded (page 20), 
‘Overall, a moderately large amount of methodologically rigorous evidence has been 
presented to support the effectiveness of training health professionals in smoking cessation.’ 
The Quality and Outcomes Framework provides financial incentives for smoking indicators 
and so goes some way to addressing GPs’ concerns about lack of financial incentives for this 
work. I will discuss this in more detail in Chapter 3. 
 
Key points from Chapter 2 
• Tobacco control measures have been successful in reducing smoking rates in the UK 
but reductions may now be plateauing. 
• Effective and cost-effective treatments are available through NHS stop smoking 
services and in primary care. However, they tend to be underprovided in primary care. 
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• Research into the reasons for this under provision has identified several possible 
reasons including practitioners’ concern about effectiveness and whether they are 
skilled in providing advice, but also time constraints and lack of financial incentives. 
• Financial incentives may therefore be one means of encouraging smoking cessation 
work in primary care. 
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Chapter 3: Improving the quality and delivery of smoking 
cessation interventions in health care settings 
 
Defining and measuring quality in healthcare 
Defining quality 
Healthcare quality has for many years defied a consensus definition due to the different 
perspectives of clinicians, managers and patients, and whether applied to individual patients 
or populations.  Definitions include ‘generic’ and ‘disaggregated’ versions.  Examples of 
generic versions include that of the Institute of Medicine in 1990, described in a paper by 
Campbell et al published in 1982, citing Lohr, which defined healthcare quality as (page 
1614) ‘the degree to which health services for individuals and populations increase the 
likelihood of desired health outcomes, and are consistent with current professional 
knowledge.’117  
 
Disaggregated definitions are summarised by Campbell et al in their paper published in 
1982118 They list the different components of healthcare individual authors regard as 
important and relate quality to the achievement of standards for these different components. 
For instance, Donabedian, cited by Blumenthal et al (page 892), defined high quality care as 
‘that kind of care which is expected to maximise an inclusive measure of patient welfare, 
after one has taken account of the balance of expected gains and losses that attend the process 
of care in all its parts.’119 The items included in models by Donabedian and other authors are 
compared in Figure 18. 
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Campbell and colleagues have therefore stated (page 1862) that ‘there is no universally 
accepted definition of care, quality or quality of care’ and that patient access is key to 
quality.120 The authors contribute their own definition as ‘quality of care for individual 
patients is defined by their ability to access effective care with the aim of maximising health 
benefit in relation to need.’ Blumenthal suggests taking a pragmatic approach, quoting 
Donabedian’s advice (page 892) that ‘several formulations are both possible and legitimate, 
depending on where we are located in the system of care and on what the nature and extent of 
our responsibilities are.’118 
Figure 18: Comparison of dimensions of quality of healthcare included in different 
models 
Donabedian 
1990 
HSRG  
1992 
Maxwell  
1992 
O’Leary & O’Leary 
1992 
- Accessibility Accessibility Accessibility 
- Patient-centeredness - Patient perspectives 
Effectiveness Effectiveness Effectiveness Effectiveness 
Efficiency Efficiency Efficiency Efficiency 
- Continuity/ 
Co-ordination 
- Continuity 
Efficacy - - Efficacy 
Acceptability - Acceptability - 
Equity - Equity - 
Legitimacy - - - 
- Comprehensiveness - - 
- - Relevance - 
Source: Adapted from Campbell et al118    HSRG = Health Services Research Group 
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Evaluating quality 
Quality of care can be evaluated by quantifying and measuring items relating to structure, 
process, or outcome, as devised by Donabedian.121 Structure relates to the numbers of staff, 
equipment, beds and services provided at hospitals or in the community. Process data are 
what Brook and Appel describe in their 1973 paper (page 1323) as ‘what physicians do to 
patients.’122 These are components of management the patient receives such as blood tests 
ordered, or having blood pressure measured. Outcome data they describe (page 1323) as 
‘what happened to the patient.’122 They measure the patient's subsequent health status and 
include mortality, myocardial infarction or stroke, or an improvement in quality of life or 
symptoms. Intermediate outcome measures are frequently applied to capture short-term 
improvements in quality, such as cholesterol control, or four-week smoking quit rates. 
For structure or process outcomes to be useful for evaluation they must predict outcome in 
some credible and validated way.  So it must be shown that, for instance, measuring the blood 
pressure of hypertensive patients regularly and having blood pressure reduced to 
recommended levels leads to a reduced chance of myocardial infarction, stroke or death.123  
Disadvantages of the use of process data include the following. The measures may not be 
sufficiently good at predicting outcomes; there may be associations of good care with poor 
outcomes, e.g. sicker patients, who may go on to die despite treatment, often have received 
all the required process measures; they need constant updating in the light of new 
evidence.124  
On the other hand, critics of outcome measures believe they are not as useful as they should 
be given that they can be influenced by factors other than medical care.125 Even with shorter-
term outcomes such as recovery from surgery, patients receiving the same treatment can have 
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different outcomes, with variation in patient-level characteristics having greater influence on 
the outcome. In practice, adjusting for case-mix (such as co morbidity or age) allows both 
process and outcome measures to contribute to quality evaluation.  
Brook et al121 in their 1996 paper suggest five methods of using process and/or outcome 
measures to evaluate quality. The first three are ‘implicit’ whereby there are no previously 
agreed standards of good quality and the patient’s episode of care is reviewed in order to 
answer three questions (page 966): ‘was the process of care adequate (first method)? Could 
better care have improved the outcome (second method)? Considering both the process and 
outcome of care, was the overall quality of care acceptable (third method)’? 
The fourth and fifth methods are ‘explicit’. In the first, the assessment of quality is made by 
determining the proportion of patients who received components of (usually) evidence-based 
management. For example, national QOF rewards quality on the basis of the proportion of 
patients with diabetes registered at a general practice for whom a range of indicators have 
been met, such as having a record of retinal screening in the last 15 months.126 In the second 
method, actual outcomes for a population are compared to those predicted by a validated 
statistical model using pre-set criteria for high, average or poor quality care. 
 
Explicit methods are stricter than implicit methods and outcome measures. Brook et al used 
the five methods to evaluate the care of 296 patients with urinary-tract infection, 
hypertension or ulcerated gastric or duodenal ulcers.122 Evaluating outcomes using explicit 
criteria the authors found that only two percent of patients received adequate care, but when 
they used implicit outcome methods 63% of patients received adequate care. The authors also 
suggest that process measures may be better than outcome measures in evaluating healthcare 
quality, because they allow timely routine monitoring, and patients often get better even 
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when care is sub-optimal. For instance, they suggest (page 967) that ‘it is therefore not 
surprising that when physicians are asked to describe what they mean by quality of care, they 
define it in terms of process rather than outcome (i.e., they would find it unacceptable if 
patients who were ideal candidates for thrombolytic therapy but did not receive it were 
considered to have received good care because they were lucky enough to live)’. 
 
Setting standards 
The process of setting guidelines, standards, criteria or indicators to assess quality requires a 
strong evidence base or well-established consensus.  Definitions for these terms are given in 
Figure 19. Guidelines have been shown to change practitioner behaviour and to improve 
patient outcomes.125  
Indicators can be identified from process measures recommended in guidelines, and used to 
develop criteria and standards to reflect intended quality of care. Data to evaluate whether 
standards have been reached, or guidelines followed, is available from a number of sources, 
each having advantages and disadvantages, as summarised in Figure 20.  
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Figure 19: Definitions of guidelines, standards, criteria and indicators 
 
A guideline (clinical practice guideline) is a ‘systematically developed statement to assist 
decisions for practitioner and patient about appropriate healthcare for specific clinical 
circumstance’. Institute of Medicine 
An indicator is a ‘measureable element of practice performance for which there is evidence 
or consensus that it can be used to assess the quality, and hence change in the quality, of care 
provided’. Lawrence and Olesen 
A criterion (review criterion) is a ‘systematically developed statement that can be used to 
assess the appropriateness of specific healthcare decisions, services’ Institute of Medicine 
or a ‘discrete, definable and measureable phenomenon, relevant to the definition of quality, 
and so clearly defined that we can say whether it is present or not’. Donabedian 
A standard is ‘the level of compliance with a criterion’. Black 
or ‘the percentage of events that comply with a criterion’. Baker and Fraser 
Source: Lawrence and Olesen (page 105), 1997125  
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Figure 20: Advantages and disadvantages of types of data for measuring quality of care 
Types of data 
 
Advantage Disadvantage 
Secondary data 
(administrative) 
Easily available inexpensive Lacks specificity and detail 
Medical record data Available 
Richer in detail than 
administrative data 
If standardised in an 
electronic medical record, 
reduces data collection 
burden 
Expensive to obtain 
May have insufficient detail 
Prospectively collected 
clinical data 
Most specific 
Can define exactly what data 
are required 
Quality control of data 
collection 
Not readily available 
Expensive to obtain unless 
already incorporated into 
EMR 
Survey data Can collect what is important 
to patients 
Collects data not otherwise 
available 
Not readily available 
Expensive to collect  
Valid instrument required 
Recall bias 
Source: Rubin et al (page 494), 2001127 
 
 
Quality improvement initiatives in the UK 
In addition to an explicit aim to reduce health inequalities, the previous Labour Government 
also intended to improve the quality of care provided by the NHS.128 This aspect of health 
policy was developed in response to rising healthcare costs, increasing public expectation and 
the evidence for variation in health outcomes between different socio-economic groups and 
geographical areas previously discussed. Importantly there was growing evidence that the 
UK was lagging behind other European countries in health outcomes such as survival rates 
from cancers.48 In addition, highly publicised healthcare failures, such as poor outcomes from 
paediatric heart surgery at the Bristol Royal Infirmary, prompted the government to introduce 
quality standards and to make hospitals and doctors accountable for quality assurance. This 
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led to the introduction of regular appraisal for clinicians, the National Performance 
Framework for the NHS, and clinical governance for NHS organisations. 
The government introduced National Performance Framework for the NHS in 2009. This 
brought in a series of indicators across the domains of Finance, Operational Standards and 
Targets, Quality and Safety and User Experience in order to identify ‘unsustainable’ NHS 
organisations.129 
 
Clinical governance was introduced by the government in 1997 along with a huge increase in 
funding for the NHS (£1.5bn in the first year) to counter years of underinvestment, and 
substantial reorganisation of the NHS with the introduction of Hospital Trusts and Primary 
Care Trusts.130 Clinical governance is defined by the Department of Health as ‘a framework 
through which NHS organisations are accountable for continually improving the quality of 
their services, safeguarding high standards by creating an environment in which excellence in 
clinical care will flourish,’ cited by Campbell et al in their paper published in 2001.131 This 
includes leadership, staff training, learning from patient safety incidents, and regular clinical 
audit. The government also introduced a body to monitor the performance of healthcare 
organisations, the Commission for Health Improvement, subsequently named the Healthcare 
Commission, a role now undertaken by the Care Quality Commission. 
 
Other quality improvement initiatives brought in by the then Labour government included the 
introduction of guidelines called National Service Frameworks (NSFs) which set national 
minimum standards for the management of chronic diseases (e.g. for coronary heart disease 
and for diabetes). The government also established the National Institute for Clinical 
Excellence (subsequently the National Institute for Health and Clinical Excellence, NICE), to 
evaluate and publish guidance on clinical treatments.  Such guidelines are devised from 
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evidence-based measures intended to prevent further disease and maintain or improve a 
patient’s health status once they have been diagnosed with a chronic disease (secondary 
prevention).  
 
The Labour government also brought in the Quality and Outcomes Framework (QOF)126 as 
part of a reform of the GP contract in 2004. This financially rewards general practices for 
meeting evidence-based targets for clinical care, mainly chronic disease management. QOF is 
further described below. 
 
Changes in the quality of care resulting from these initiatives have been extensively 
examined, usually using process measures for the reasons described in the previous section. 
These are relatively easily-extractable items which are routinely recorded on electronic 
medical records,132 such as whether blood pressure has been measured and what the result 
was of that measurement. Generally these studies have shown improvements following the 
introduction of quality improvement initiatives.133 However, a systematic review of studies of 
the quality of care provided in primary care in the UK, Australia and New Zealand found that 
practices still fell short of providing all the standards set by national guidelines. For example, 
11 studies examining hypertension management found that the proportion of hypertensive 
patients who were prescribed hypertension medication ranged from 51% to 64% when the 
standard was 100%.54 
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The Conservative-Liberal Democrat Coalition government, which came into power in 2010, 
introduced its Health and Social Care Bill in 2011 which detailed radical plans to reorganise 
the NHS, abolishing Primary Care Trusts and setting up clinical commissioning groups, 
overseen by a new authority called NHS England, and setting up Public Health England to 
oversee public health provision across England. The reforms had the stated aim of 
decentralising control of the NHS, increasing clinical autonomy and patient input to services, 
and encouraging competition between providers, in order to improve value for money and 
quality of care.134 Critics have expressed concern about the cost and scope of this 
reorganization and have concerns that quality will in fact fall in the short term.135 
The Coalition government has also introduced the NHS constitution,136 which states a 
commitment to quality (page 3), ‘The NHS aspires to the highest standards of excellence and 
professionalism – in the provision of high-quality care that is safe, effective and focused on 
patient experience; in the planning and delivery of the clinical and other services it provides; 
in the people it employs and the education, training and development they receive; in the 
leadership and management of its organisations; and through its commitment to innovation 
and to the promotion and conduct of research to improve the current and future health and 
care of the population’. 
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Quality improvement initiatives for smoking cessation interventions in 
the UK 
 
National Service Frameworks (NSFs) and clinical guidelines for chronic disease management 
recommend that smokers should be advised to stop smoking in order to reduce the risk of 
further cardiovascular events or exacerbations of respiratory conditions (secondary 
prevention). Lifestyle advice such as smoking cessation is also important for primary 
prevention (to avoid disease in healthy people). The NHS Futures Forum has recommended 
that ‘every contact counts’ in the NHS (page 10),137 whereby healthcare professionals take 
the opportunity to discuss weight loss, exercise, health eating and alcohol intake, as well as 
providing smoking cessation advice as appropriate, when they see patients for other routine 
appointments. The current government is consulting on how this might be taken up by the 
NHS.  
Overview of financial incentives 
There is increasing international interest in financial incentives, also known as ‘pay-for-
performance’ or P4P schemes. Financial incentives are interventions to support quality 
improvement in which a proportion of the remuneration of providers is related to the 
achievement of quality indicators.138 These schemes aim to reward performance in reaching 
evidence-based targets, with the intention of improving healthcare quality and reducing 
inequalities.  
Definitions of incentives and financial incentives are shown in Figure 21. Incentives work on 
a person’s motivation to act in a particular way. Motivation may be internal, such as wishing 
to do a good job for personal satisfaction or to help others, or external, such as for payment or 
other reward. 
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Figure 21: Definitions of incentives 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Flodgren et al, 2011 (page 3)139  
 
Financial incentives may target patients or healthcare providers. There is evidence that 
providing incentives directly to patients may help them change health behaviours140 including 
smoking.141 The use of payments to patients is controversial, particularly for the treatment of 
drug misuse. Financial incentives aimed towards healthcare organisations or individual 
practitioners, with an emphasis on primary care, are the subjects of this thesis. 
 
A variety of pay-for-performance schemes for primary care practitioners have been 
developed to strengthen or transform the capacity to provide a foundation for high-quality, 
efficient care. The United Kingdom and the United States have the most established 
schemes,142-145 but other countries are initiating them, such as Australia,146 Canada,147 
Germany,148 the Netherlands,149 and New Zealand.150 Most countries have mixed payment 
systems. The main components of financial incentives are described in Figure 22. 
 
An incentive is any factor (financial or non-financial) that provides motivation for 
a particular course of action, or counts as a reason for preferring one choice over 
all alternatives. 
 
A financial incentive is defined as an external source or motivation, and exists 
when an individual can expect a monetary transfer which is made conditional on 
acting in a particular way. 
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Figure 22: Types of financial incentives  
 
1. Salary or sessional payment (payment for working for a specified time 
period); 
2. Fee-for-service (payment for each service, episode or visit); 
3. Capitation (payment for providing care for a patient or for a special 
population);   
4. Target payments and bonuses (payment for providing a pre-specified level or 
change in a specific behaviour or quality of care). 
 
Source: Flodgren et al, 2011 (page 3)139 
 
Pay-for-performance has been recommended by influential health organisations such as 
WHO, to encourage purchasers of healthcare services to move from passive purchasing of 
health care services to more strategic, outcome-focused purchasing. The IOM also 
recommended using financial incentives to encourage evidence-based practice as a means to 
improve quality in their report Crossing the Quality Chasm.  
 
All payment systems have good and bad points. Robinson recommends ‘blended systems’ 
and condemns sole use of the first three incentives described above, stating (page 149) ‘Fee 
for service rewards the provision of inappropriate services, the fraudulent up coding of visits 
and procedures, and the churning of ‘ping-pong’ referrals among specialists. Capitation 
rewards the denial of appropriate services, the dumping of the chronically ill, and a narrow 
scope of practice that refers out every time-consuming patient. Salary undermines 
productivity, condones on-the-job leisure, and fosters a bureaucratic mentality in which every 
procedure is someone else’s problem.’151 Roland counters (page 1), ‘All payment systems can 
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have perverse consequences - we rely on the professionalism of doctors to minimise these 
adverse effects. All incentives must therefore be as closely aligned to professional values as 
possible.’152 
 
Financial incentive schemes can also have unintended adverse consequences on practitioner 
behaviour, such as taking away doctors’ internal motivation, also known as ‘crowding out’ 
whereby external drivers such as financial incentives impair self-determination and damage 
self-esteem if doctors believe their professionalism is not valued and their work is subject to 
bureaucratic regulatory activity.153  
Financial incentives may also encourage more obviously detrimental practitioner behaviours, 
as described by McDonald and Roland.154 Such actions includes adverse patient selection or 
exclusion (‘cherry-picking’), whereby practitioners choose to register and treat patients 
without complex problems or de-list patients who do not comply with medical treatment, 
which may lead to widening of inequalities for some groups. Financial incentives may also 
result in practitioners neglecting types of care for which quality is not measured. They may 
also interfere with the doctor-patient relationship as the patient’s agenda is supplanted by the 
need to meet incentivised targets or the practitioner’s attention is displaced from the patient 
to the computer screen. 
Reviewers of the UK’s pay-for-performance scheme, the Quality and Outcomes Framework 
(QOF, described below), such as Dixon et al (page 1) suggest they entrench ‘a medicalised 
and mechanistic approach to managing chronic disease that does not support holistic care or 
promote self-care and self-management.’ 155 There is also evidence that performance may 
revert to previous levels after incentives have been removed.156 
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Pay for performance programmes in the US and UK 
United States 
The United States has over 100 private and federal Medicare reward and incentive 
programmes.157 Pay-for-performance programmes differ between public and privately funded 
healthcare schemes, between health plans within either sector, and even from state to state. 
Such differences include the level of incentives offered, the performance outcomes measured, 
and whether thresholds are reached in order to trigger reward, or whether payment follows 
improvement from baseline. In some programmes primary care organisations are incentivised 
and in others secondary care organisations or individual healthcare practitioners receive 
incentive payments.  
UK (Quality and Outcomes Framework) 
In the UK capitation, salary and fee for service payments are the main methods of payment 
used in primary care.158 However, in 2004 a major pay-for-performance scheme, the Quality 
and Outcome Framework (QOF), was introduced to provide up to 25% of general practice 
income. Its goal was to incentivise general practitioners to achieve evidence-based quality 
targets, mainly for chronic disease management, supported by investment in improved 
information technology and prompts on patients’ electronic medical records (EMRs).132 QOF 
has been described by authors such as Gillam and Roland as (page 461) ‘arguably the most 
comprehensive national primary care pay-for-performance (P4P) scheme in the world.’142 159 
Participation in QOF is voluntary but almost all general practices have signed up to it. When 
QOF was first introduced the scheme was funded by an £1.8 billion investment. Payments 
now account for around one-third of average practice earnings and expenditure associated 
with QOF is over £1 billion a year in England (around 15% of the primary medical care 
budget).160 
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QOF has been refined over the intervening years as the Department of Health’s initial 
expectations of GPs’ achievements were vastly exceeded, resulting in unexpected large 
performance payments.161 In 2005/06, the average QOF points achieved by practices in 
England were 1010.5 (96.2% of the total 1050 points available per practice at the time). In 
the clinical domains achievement was even higher with the average practice attaining 97.1% 
of the maximum 550 points available.162 
New indicators and more demanding thresholds for existing indicators have been added since 
2004, although the General Practitioners’ Committee has resisted ambitious changes 
proposed for 2013/14. Other indicators have been phased out if high levels were consistently 
achieved. In 2009 the National Institute for Health and Clinical Excellence (NICE) was given 
responsibility for developing QOF indicators, particularly primary prevention and public 
health targets. Changes to QOF are negotiated between NHS Employers (mandated by the 
Department of Health) and the General Practitioners Committee (GPC), part of the British 
Medical Association (BMA). 
QOF is now on its fifth revision. There are currently 148 performance indicators, which are 
measures of achievement against which practices are awarded points, within four domains, as 
shown in Figure 23.126  
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Figure 23: Domains and indicators of the Quality and Outcomes Framework 
Domain Indicator 
Clinical 
 
Secondary prevention of coronary heart disease 
Cardiovascular disease: primary prevention 
Heart failure 
Stroke and transient ischemic attack 
Hypertension 
Diabetes mellitus 
Chronic obstructive pulmonary disease 
Epilepsy 
Hypothyroidism 
Cancer 
Palliative care 
Mental health 
Asthma 
Dementia 
Depression 
Chronic kidney disease 
Atrial fibrillation 
Obesity 
Learning disabilities 
Smoking 
Peripheral arterial disease 
Osteoporosis: secondary prevention of fragility 
fractures 
Organizational 
 
Records and information 
Information for patients 
Education and training 
Practice management 
Medicines management 
Quality and productivity 
Patient Experience 
 
Length of consultations 
Additional Services 
 
Cervical screening 
Child health surveillance 
Maternity services 
Contraception 
Source: http://www.qof.ic.nhs.uk/ 
QOF’s indicators broadly align to Donabedian’s framework for assessing quality:  
• Structure (e.g. keeping disease registers);  
• Process (e.g. recording risk factors, delivering evidence-based tests or treatments);  
• Outcomes (e.g. achieving targets for treatment outcomes, such as control of blood 
pressure).162  
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The points for each indicator are weighted according to practice factors, prevalence and 
workload through the ‘Carr-Hill allocation formula’. There are currently a maximum of 1,000 
QOF points available, worth £130 each in 2012/13, and payments depend on practices 
reaching the targets for each indicator i.e. the proportion of patients for whom practices have 
achieved the set thresholds.  
Achievement of QOF indicators is assessed through the presence of relevant Read Codes and 
associated dates on the patient’s EMR. Achievement is assessed annually via the QOF 
Management and Analysis System (QMAS), software specifically developed for QOF,163 
which also allows estimations of national disease prevalence. There are random checks by 
Primary Care Trusts and national comparisons of practices with similar patient populations 
for quality assurance. The development of the QOF business rules for extracting the data and 
determining achievement of indicators has been the responsibility of the NHS Information 
Centre for Health and Social Care (NHS IC) since 2010. QOF business rules also allow 
‘exception reporting’ which was introduced to avoid penalizing practices where it was 
impossible or inappropriate to pursue the indicator, for example when patients do not attend 
or refuse treatment, or are on maximum treatment, or for whom the proposed treatment is 
contra-indicated.  
QOF rewards absolute achievement, which means practices are rewarded for reaching pre-set 
thresholds, rather than relative achievement, or improvements in performance from baseline, 
because the second method is administratively burdensome. So practices that start from a low 
baseline achievement may improve more than those who started from a higher level of 
achievement and yet not be rewarded for their effort. For example, for asthma, one of the 
indicators is ‘the percentage of patients with asthma between the ages of 14 and 19 years in 
whom there is a record of smoking status in the previous 15 months.’ There are 6 points 
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available, paid in stages depending on achievement from a minimum of 45% of eligible 
patients to a maximum of 80%. If a practice had recorded the smoking status of only 6% of 
their patients at baseline then managed 50%, improving by 46%, then it would get fewer 
points than a practice that improved from 70% to 80%. 
 
However, QOF still encourages improvement from whatever baseline each practice starts by 
setting a minimum and maximum threshold for which payment is released162 and, for some 
indicators where the target is difficult to attain, by setting two targets. For example, for 
patients with diabetes general practices are rewarded for the percentage of patients with 
diabetes who have a high degree of blood pressure control (last blood pressure is 140/80 
mmHg or less, 10 points, payment stages 40% to 65%) but for practices who do not achieve 
the higher level, there are points for the percentage with a lower degree of control (150/90 
mmHg or lower) are awarded up to eight points, with payment in stages of 45% to 71%. 
 
Impact of financial incentives on quality of healthcare 
Current evidence on the effectiveness of financial incentives on healthcare quality has been 
described by Glasziou et al (page 1) as ‘modest and inconsistent,’156 with little attention to 
possible unintended consequences, despite many reviews of the literature on financial 
incentives. Van Herck et al, in their systematic review of P4P schemes in 2010, noted that 16 
literature reviews had been conducted on the subject prior to their own study being 
published.138 The authors identified 128 studies with a mixture of study designs including 
randomised controlled trials, before-and-after studies and interrupted time series analyses. 
The studies were published between 1990 and 2009, and 79 had not been included in earlier 
reviews. Sixty-three studies were from the USA, 57 from the UK, two from Australia, two 
from Germany, two from Spain, one from Argentina and one from Italy. There were 111 
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studies evaluating P4P in primary care settings and 30 in hospital settings, and 13 covered 
both settings. The studies looked at the effects of P4P on preventive services, acute care and 
chronic care. 
 
In general Van Herck et al found there was about 5% improvement due to pay-for-
performance, but with much variation, depending on the measure and program. The pay for 
performance schemes frequently failed to affect results in acute care. In chronic care, diabetes 
and asthma had the highest rates of quality improvement following the introduction of P4P. 
The authors found conflicting results for preventive care and little or negative effects on non-
incentivised quality measures.138 
 
A 2011 Cochrane meta-review of four systematic reviews of financial incentives in 
healthcare by Flodgren et al found none had examined the effect on patient outcomes.139 The 
authors found that financial incentives had mixed effects on consultation or visit rates (three 
studies showed improvements in 10 of 17 outcomes) and improved process measures of care 
(19 studies, showing improvements for 41 of 57 outcomes). They also showed reduced 
prescribing costs (10 studies, with 28 of 34 outcomes showing improvements). However, 
they did not improve compliance with guidelines (five studies identified for this outcome, in 
which only five of 17 outcomes showed improvements).  
Another 2011 Cochrane review, by Scott et al, found seven eligible studies in primary care, 
randomised controlled trials, controlled before-and-after studies or time series analyses. The 
outcomes examined ranged from prevention (mammography, cervical screening, Chlamydia 
screening, smoking cessation) to chronic disease management (diabetes and asthma care). 
The authors found that financial incentives were effective in six of the seven studies but not 
for all outcomes, and all studies had methodological weaknesses. This review excluded all 
83 
 
QOF studies because they were observational studies, necessitated by QOF being introduced 
nationally. The authors concluded (page 13) that there was ‘insufficient evidence to support 
or not support the use of financial incentives to improve the quality of primary health care. 
Implementation should proceed with caution and incentive schemes should be more carefully 
designed before implementation.’164 
Other reviews have examined financial incentives for preventive care. Hillman et al (1989) 
looked at their effect in improving physician delivery of breast, cervical and colorectal cancer 
screening, and found there were no statistically significant differences in cancer screening 
rates between the two groups (an intervention group, which got feedback plus bonuses, and a 
control group). The authors concluded that the small incentive size, lack of physician 
awareness of the incentive program and the type and length of the intervention might explain 
the ineffectiveness of explicit financial incentives to improve physician delivery of 
preventive service.  
 
Kouides et al165 examined the effect of performance-based incentives on the influenza 
immunizations rate in primary care practices participating in the 1990 Medicare Influenza 
Vaccination demonstration Project. Practices were randomly assigned to an intervention 
group (a financial bonus per shot if the practice attained a certain immunization rate) and a 
control group. Their findings suggest that assignment to the intervention group resulted in a 
7% increase in the immunization rate among older persons. The authors concluded that small 
explicit financial incentives improve immunization rates. 
 
A Cochrane review in 2009166 by Giuffrida et al examined the effects on professional practice 
and health outcomes of target payments in primary care and included the study by Kouides et 
al together with an interrupted time series analysis by Ritchie et al, which also looked at the 
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effect of payments on immunization rates. 167 The review found that although both studies 
showed positive effects (increased rates), the improvements were not significant, probably 
due to insufficient power. The authors concluded there was insufficient evidence to show that 
such payments improved quality of care.166 
 
Impact of QOF on quality of care and inequalities 
Evidence as to whether the QOF is influencing improvements in clinical care is equivocal. 
For instance, in 2007 Campbell et al published a longitudinal analysis of primary care data 
from the records of patients with diabetes, asthma and coronary heart disease (CHD) from a 
random selection of 60 general practices from six geographical regions of England. The 
authors computed an overall quality improvement score for each condition using data from 
1998, 2003 and 2005 and compared the outcomes with those predicted on the basis of the 
trend seen prior to the introduction of QOF (resulting from other quality improvement 
measures as previously discussed). Across the study period there were large improvements in 
the scores for all three conditions but compared with the predicted improvements these were 
only statistically significant for diabetes and asthma but not for CHD. For example, for 
diabetes the mean score increased from 61.6% in 1998 to 81.4% in 2005, compared with a 
predicted score of 73.2%, mean difference between transformed observed score and predicted 
score was 0.68 (CI 0.27 to 1.1, p=0.002). The authors also showed that improvements were 
only seen in incentivised conditions and not for unincentivised conditions.168  
In a follow up study published in 2009 Campbell et al conducted an interrupted time series 
analysis with data from the electronic medical records of patients with diabetes, asthma and 
CHD from 42 practices. Comparing data extracted pre-QOF (1998 and 2003) and post-QOF 
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(2005 and 2007) the authors found that improvements stabilized and did not increase 
substantially after the first two years of QOF.169  
Higher QOF scores appear to be associated with modest reductions in hospital admissions for 
some conditions. For example, linking primary care data with hospital admissions in a large 
cross-sectionals study with 1.8 million patients with diabetes registered at 8441 general 
practices across England, Bottle et al found a 10-fold variation in admission rates for diabetes 
and showed that higher QOF scores were significantly but weakly associated with lower 
hospital admission rates for patients aged over-60.170 
Some authors have raised concerns about gaming with QOF, for example through exception 
reporting, as previously described. Fleetcroft et al, looking at QOF data from 8407 English 
general practices in the National Primary Care Database and exception reporting data from 
the Information Centre in 2005/06, found exception reporting accounted for around 48% of 
the gap between the percentage of maximum incentive gained and the percentage of patients 
receiving indicated care at the practice level.171 However, Doran et al found a median of only 
5.3% of patients had been exception reporting when examining 2005/06 QMAS data from 
8105 general practices in England, and concluded (page 274), ‘rates of exception reporting 
have generally been low, with little evidence of widespread gaming.’172  
There is now a large body of research examining the effects of QOF on different quality-of-
care measures within different disease areas. In order to summarise the literature on the 
impact of QOF, Gillam et al published a systematic review in 2012.173 Studies were included 
with a range of designs, including before-and-after and interrupted time series observational 
analyses and qualitative studies, methodologies regarded as appropriate for researching 
complex interventions. The review identified 94 studies for inclusion, and found results on 
effectiveness and equity or inequalities, with similar results to those described above, and 
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also identified studies that looked at effects on patient experience and healthcare 
professionals’ experiences of the QOF and impact on team working. There were no studies 
examining the impact on patient safety.  
For effectiveness, Gillam et al identified 47 studies. The authors suggest that QOF has helped 
consolidate evidence-based practice by increasing the use of computers (with decision 
support software and prompts, patient reminders and recalls). It has improved recording, led 
to increased recording of processes of care and improved intermediate outcomes, particularly 
for diabetes. However, improvements peaked after the first year after the introduction of 
QOF, then reached a plateau or have merely followed the pre-existing trends in improvement 
thereafter. There was no effect on unincentivised conditions in the first few years, but after 
that achievement was well below that predicted by trend (for example, Doran et al, 2011174). 
For efficiency and costs Gillam et al found limited evidence from five studies that QOF led to 
reduced admissions and hence costs for some conditions. For example, patients with epilepsy 
had fewer epilepsy related emergency conditions following the introduction of QOF. 
For equity or inequalities the authors identified 25 studies, but point out that QOF was not 
designed to reduce inequalities resulting from socio-economic disadvantage. The systematic 
review showed that inequalities in process of care measures for some conditions appear to 
have narrowed. For example, Doran et al found that median overall achievement for practices 
from most and least deprived quintiles narrowed from 4% to 0.8% between 2004 and 2007.175 
However, disparities between men and women for management of cardiovascular diseases 
and diabetes persisted or increased. Ashworth and colleagues, in a retrospective longitudinal 
survey of primary care data from 8515 general practices from 2005 and 2007, found evidence 
for both improvements in outcomes and a narrowing of inequalities related to deprivation.176 
For example, achievement of target blood pressure levels in 2005 for practices from the least 
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deprived areas ranged from 71.0% (95% CI 70.4% to 71.6%) for diabetes to 85.1% (CI 
84.7% to 85.6%) for coronary heart disease, whereas practices in the most deprived achieved 
68.9% (CI 68.4% to 69.5%) and 81.8 % (CI 81.3% to 82.3%) respectively. Post-QOF, 
achievement for the least deprived practices had risen to 78.6% (CI 78.1% to 79.1%) and 
89.4% (CI 89.1% to 89.7%) respectively. Target achievement in the most deprived practices 
rose similarly, to 79.2% (CI 78.8% to 79.6%) and 88.4% (CI 88.2% to 88.7%) respectively. 
Ashworth et al concluded (page 7), ‘Improvements in achievement have been accompanied 
by the near disappearance of the achievement gap between least and most deprived areas.’ 
For variation between different ethnic groups, Millett et al found larger improvements in 
blood pressure control for Black patients with diabetes than White patients such that 
differences in 2003 were attenuated by 2005.177  
Gillam e al’s findings on inequalities echo those of Alshamsan et al in their earlier systematic 
review of pay-for-performance schemes in healthcare,178 which identified 22 studies, of 
which 20 were evaluations of QOF. The authors found weak evidence that financial 
incentives reduced inequalities in the management of patients with chronic diseases from 
different socio-economic groups but that inequalities associated with age, gender and 
ethnicity persisted after the use of these incentives.  
For patient experience, Gillam et al identified seven studies, which found no significant 
changes in patient ratings of overall satisfaction, nursing care, communication or co-
ordination of care. There were modest improvements in access to urgent appointments for 
patients with chronic diseases (but not for other patients) but continuity of care worsened. 
For team working and professionalism, the authors identified six studies that suggested that 
QOF had positive effects on practice organisation and enhanced roles for nurses in managing 
chronic diseases. In qualitative studies healthcare professionals expressed concern that ‘box-
88 
 
ticking’ due to QOF distracted them from patient-led consultations and also impacted on non-
incentivised quality improvement and practice development. They also expressed regret over 
declining continuity of care. 
 
QOF and smoking cessation 
The Quality and Outcomes Framework initially rewarded smoking cessation activities in 
primary care mainly as a part of secondary prevention management of particular long-term 
conditions (coronary heart disease, stroke or transient ischaemic attack (TIA), diabetes 
mellitus, chronic obstructive pulmonary disease (COPD), asthma and hypertension). For 
these patients QOF rewarded general practices for recording smoking status within the last 15 
months (unless, as is the case with the current version of QOF, the patient has never smoked, 
in which case their status only needs to be recorded once, or if they have three consecutive 
ex-smoker codes, in which case their status does not need to be ascertained again) and 
providing stop smoking advice to smokers within the last 15 months.  
There was initially little focus in QOF on smoking cessation for patients without smoking-
related conditions (primary prevention). In the 2004 version of QOF the requirement for 
patients with relevant co-morbidities (coronary heart disease, diabetes mellitus, chronic 
obstructive pulmonary disease (COPD), transient ischaemic attack (TIA) or stroke, asthma, 
hypertension), smoking status had to be recorded within the previous 15 months (except for 
never-smokers, for whom their status only needed to be recorded once) and smoking 
cessation advice offered to smokers in this group within the previous 15 months.  However, 
for patients without smoking-related co-morbidity the requirement was that the smoking 
status of patients aged 15 to 75 years should be recorded for at least 75% of patients but there 
was no requirement for repeated recording for this group or for offering advice.  
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Targets for smoking indicators were revised in 2006, 2008 and 2011. In 2006, for the first 
time, regular recording of smoking status for patients without smoking-related diseases was 
required every 27 months rather than ‘ever’ to meet the target. In 2008, chronic kidney 
disease (CKD) and mental illness  (schizophrenia, bipolar affective disorder and other 
psychoses) were added to the smoking-related diseases for which recording of smoking status 
and cessation advice every 15 months was required to meet the target. In 2011 peripheral 
arterial disease was added to the smoking-related conditions for which smoking indicators 
apply and the total number of points for the smoking indicators for these patients reduced 
from 60 to 50. Points for advising smokers over the age of 15 without smoking-related 
conditions were also added in 2011, plus points for lifestyle advice for cardiovascular 
primary prevention. So the points available for primary prevention have increased, although 
QOF still focuses more on secondary prevention than primary prevention, with 61 points 
available for smoking indicators associated with smoking-related conditions and 24 points 
available for those without smoking-related conditions. The current smoking indicators are 
shown in Figure 24. Overall, it is estimated that smoking related work contributes 8% to the 
total remuneration to general practices from QOF.179  
The Department of Health has announced plans to introduce a public health domain in next 
year’s QOF, which will be the responsibility of the incoming Public Health England. Fifteen 
percent of existing QOF points will be ring-fenced for indicators that prevent disease and 
tackle health inequalities. No new indicators have so far been proposed and the public health 
domain will contain the current QOF indicators on primary prevention of cardiovascular 
disease, blood pressure, obesity and smoking, indicators for cervical screening, child health 
surveillance, maternity services, and contraception. 
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Figure 24: QOF smoking indicators 2012/13 
Indicator Points Payment stages 
SMOKING 5. The percentage of patients with any or any 
combination of the following conditions: CHD, PAD, 
stroke or TIA, hypertension, diabetes, COPD, CKD, 
asthma, schizophrenia, bipolar affective disorder or other 
psychoses whose notes record smoking status in the 
preceding 15 months 
 
25 50-90% 
SMOKING 6. The percentage of patients with any or any 
combination of the following conditions: CHD, PAD, 
stroke or TIA, hypertension, diabetes, COPD, CKD, 
asthma, schizophrenia, bipolar affective disorder or other 
psychoses who smoke whose notes contain a record of an 
offer of support and treatment within the preceding 15 
months 
 
25 50-90% 
SMOKING 7. The percentage of patients aged 15 years 
and over whose notes record smoking status in the 
preceding 27 months 
 
11 50-90% 
SMOKING 8. The percentage of patients aged 15 years 
and over who are recorded as current smokers who have a 
record of an offer of support and treatment within the 
preceding 27 months 
 
12 40-90% 
Cardiovascular disease Primary Prevention 2. The 
percentage of patients diagnosed with hypertension 
(diagnosed after 1 April 2009) who are given lifestyle 
advice in the preceding 15 months for: increasing 
physical activity, smoking cessation, safe alcohol 
consumption and healthy diet 
 
5 40-75% 
ASTHMA 10. The percentage of patients with asthma 
between the ages of 14 and 19 years in whom there is a 
record of smoking status in the preceding 15 months 
 
6 45-80% 
Information 5. The practice supports smokers in 
stopping smoking by a strategy which includes providing 
literature and offering appropriate therapy 
 
2 Yes/No 
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Impact of QOF on smoking 
Studies investigating the effect of QOF on smoking recording and advice using UK primary 
care data up to 2005/06 showed large increases in the recording of smoking status and 
cessation advice to smokers following the introduction of QOF, with far higher rates of 
recording in patients with smoking-related conditions incentivised by QOF.160 180 For 
example, the study by Millett et al180 examined changes in the recording of smoking status 
and advice to smokers in 4284 patients with diabetes using primary care data from 32 general 
practices in Wandsworth, London, between 2003 and 2005. The authors found that 
significantly more patients had their smoking status ever recorded in 2005 compared with 
2003 (90% in 2003 and 98.8% in 2005, p<0.001) and there was also a large increase in the 
proportion of smokers receiving stop smoking advice (from 48.0% in 2003 to 83.5% in 2005, 
p<0.001). The prevalence of smoking among diabetic patients also reduced across the study 
period, from 20.0% in 2003 to 16.2% in 2005 (p<0.001). The study also looked at variation in 
smoking outcomes between patients from different demographic groups and found that the 
improvement in recording of smoking status was greatest for women and for non-white 
ethnic groups (except Bangladeshi). There were no significant differences with age, gender, 
ethnicity or deprivation in the chance of receiving smoking advice before or after the 
introduction of QOF. There were differences in smoking prevalence with higher rates seen in 
men, younger patients and white British patients. Reductions in smoking prevalence seen 
after the introduction of QOF were lower among women than men (AOR 0.71, CI 0.53 to 
0.95) and lower in black African and Bangladeshi patients than in white British patients 
(AOR 0.33, CI 0.17 to 0.67; AOR 0.12, CI 0.02 to 0.72, respectively). 
A study by McGovern and colleagues in 2008, examining the impact of QOF on smoking 
indicators for patients with coronary heart disease in Scotland using data from 310 general 
practices, found statistically significant increases in the recording of smoking status from 
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69.5% in 2004 to 95.7% in 2005, and for advice given from 81.0% to 96.2%. They also found 
variation in the chance of recording smoking status and advice between men and women and 
between different age groups, and patients from deprived areas were less likely than those in 
affluent areas to have their smoking status recorded (Pre-QOF AOR 1.04, CI 0.86 to 1.26; 
Post-QOF AOR 0.78, CI 0.62 to 0.99).  
  
Recent studies have looked at whether improvements in the recording of smoking status and 
advice to smokers were sustained and what happened with the changes in the smoking targets 
for patients without smoking-related conditions. The first, by Simpson et al,181 looked at UK 
primary care data from 2001 to 2007 using the QRESEARCH database, containing 
anonymised data from 525 UK general practices and regarded as representative of UK 
primary care patients. They looked at data from around 2.7 million patients aged over 15 
years in a cross-sectional before-and-after study and found that the proportion of patients 
with their smoking status recorded increased from 46.6% in 2001/02 to 79.5% in 2006/07. 
There was also a large increase in the proportion of smokers given stop smoking advice (from 
43.6% to 84.0%), or who were referred to stop-smoking services (from 1.0% to 6.6%). They 
also observed a reduction in smoking prevalence across the study period, from 28.4% to 
22.4%.   
 
The authors also looked for evidence of variation in care between different demographic 
groups and found some significant differences. For instance, in 2001/02 women and people 
from more deprived areas were more likely to have smoking status recorded compared with 
men and people from more affluent areas (p<0.001). In 2006/07 the difference with gender 
persisted but there was no longer a difference with deprivation. Also, by 2006/07 older 
patients were more likely to have had smoking status recorded compared with younger 
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patients. Men, younger patients and those from more deprived areas were more likely to be 
smokers, and this was still the case in 2006/07. For smoking advice, older people, men and 
people from more deprived areas were more likely to have received stop smoking advice in 
2001/02. By 2006/07 more women than men were given such advice, there were similar rates 
of advice for people from different socio-economic backgrounds, but the age differences 
persisted. The authors did not look at differences with ethnicity. 
 
In another study, Taggar et al179 looked at the response to the QOF smoking indicators using 
The Health Improvement Network (THIN) primary care data for each year from 2000 to 
2008 in a serial cross-sectional study. The THIN database contains over 6 million patient 
records from 446 practices throughout the UK, and has been validated as broadly 
representative of the UK primary care population. The authors found rapid large increases in 
recording smoking status and advice to smokers following QOF’s introduction in 2004 with a 
subsequent leveling off of achievement after 2005. The proportion of all patients for whom 
practices met the targets rose from around 5% of all patients having status recorded within 27 
months and 18% of smokers having advice within 15 months in 2000, to 58% and 45% 
respectively in 2005, then 64.5% and 50.5% in 2008. They also found greater improvements 
for patients with the smoking-related conditions for which greater incentives were available, 
that for those without those conditions. For example, patients with COPD were 3.37 times 
more likely to have their smoking status recorded in 2004 compared to patients without 
smoking-related conditions (OR 3.37, CI 3.11 to 3.65, p<0.001), rising to 15.38 times more 
likely in 2008 (OR 15.38, CI 13.70 to 17.27, p<0.001). 
 
Although studies from QOF have shown improvements in the recording of smoking status 
and recording of advice being given to smokers, there has not been any synthesis of the 
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published evidence on effectiveness of financial incentives for smoking cessation activities in 
healthcare. My systematic review will address this deficit. There has also been little 
published on the effects of financial incentives such as QOF on primary prevention or on 
inequalities relating to smoking, which my work will also address.  
 
Key Points from Chapter 3 
 
1. The use of financial incentives in health care, such as the Quality and Outcomes 
Framework in the UK, is increasing internationally; 
2. Such schemes have been introduced to accelerate quality improvements in healthcare; 
3. Financial incentive schemes may produce unintended consequences, including 
widening inequalities in access to and outcomes from smoking cessation activities 
provided by healthcare organisations. 
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Chapter 4: Aims, objectives and overall methodology 
 
Justification for this research 
As discussed in the previous three chapters, smoking is an important public health problem, 
the leading cause of morbidity and premature mortality.2 It is the main cause of health 
inequalities6 and costs the UK around £14 billion pounds annually.42 Population-wide 
tobacco control measures may be the most cost-effective ways to reduce smoking prevalence, 
but there is still a need for effective smoking cessation advice and treatments to help smokers 
to quit.182 183  
Primary care provides a good opportunity to reach smokers as around 80% of patients visit 
their general practice annually.101 However, smoking cessation activities tend to be under-
provided in primary care.111  
Financial incentives, including the UK’s Quality and Outcomes Framework, have been 
shown to improve healthcare quality, assessed mainly through process outcomes. They may 
therefore improve the identification of smokers in primary care and so enable advice to be 
given to smokers.  
However, the evidence for the effects of financial incentives on smoking cessation activities 
in healthcare is mixed, and there has been no synthesis of the literature. In addition, there are 
few studies examining the effects of financial incentives on smoking cessation activities in 
patients without existing smoking-related conditions (primary prevention), and the evidence 
for their effects on inequalities in the provision and outcomes of such advice is also sparse. 
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Hypothesis 
The null hypothesis for this research is that financial incentives do not affect healthcare 
providers’ behaviour in the provision of smoking cessation activities in primary care and 
therefore also do not affect smoking prevalence in people with or without long-term 
conditions, regardless of demographic group. The alternative hypothesis is that financial 
incentives do affect these prevention activities in primary care and may therefore influence 
inequalities in healthcare provision and outcomes. 
Main research question 
What are the effects of financial incentives on smoking cessation activities undertaken in 
healthcare, and do they affect inequalities in the provision of smoking cessation activities in 
primary care? 
Aims 
I plan to examine the effect of financial incentives for the provision of smoking cessation 
activities to people without smoking-related diseases (primary prevention) as well as for 
secondary prevention in people with smoking-related long-term conditions by undertaking a 
systematic review of the literature as well as statistical analyses of general practice datasets. I 
also aim to look at smoking outcomes with respect to inequalities in provision for people 
from different disease groups (primary and secondary prevention), and from different 
demographic groups based on age, gender, ethnicity and socio-economic status. 
Objectives 
• To undertake a systematic review of the effects of financial incentives for smoking 
cessation activities by healthcare providers. 
• To examine the effects of a financial incentive scheme (QOF) on smoking cessation 
activities (the proportion of patients whose smoking status is recorded and who then 
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receive smoking cessation advice, or referral to other smoking cessation services) 
provided to patients with and without smoking-related long-term conditions in general 
practices, and the effect on smoking prevalence in these patients, using data from 
general practices in Wandsworth, London, UK. 
• To examine the effects of a local financial incentive scheme (QOF+) on smoking 
cessation activities and smoking prevalence for adult patients without smoking-related 
long-term conditions using data from general practices in Hammersmith & Fulham, 
London, UK. 
• To examine the effects of a local financial incentive scheme (QOF+) on smoking 
cessation activities and smoking prevalence for pregnant women using data from 
general practices in Hammersmith & Fulham, London, UK. 
• To examine the effects of QOF and QOF+ on inequalities in the provision of smoking 
cessation activities to different groups (defined by age, gender, ethnicity and socio-
economic status and, for QOF data, by disease group). 
Methodology 
1. Systematic review of the effectiveness of financial incentives to health care 
professionals for smoking cessation activities using Medline, Embase, PsychInfo, 
Cochrane, and Web of Science databases, the methodology and findings of which are 
discussed in Chapter 5.  
2. Cross-sectional study of the effect of QOF on ethnic disparities in the ascertainment 
of smoking status, smoking prevalence, and smoking cessation advice to smokers 
with and without long-term conditions (cardiovascular disease; chronic obstructive 
pulmonary disease or asthma; depression; and none of these conditions) using 
anonymised data from general practices in Wandsworth, London, UK. The 
methodology and findings of this study are discussed in Chapter 6.  
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3. Before-and-after study of smoking outcomes for patients without smoking-related 
long-term conditions using anonymised QOF+ data from Hammersmith & Fulham, 
London, UK (2008 to 2011). The methodology and findings of this study are 
discussed in Chapter 7.  
4. Before-and-after study of smoking outcomes for pregnant women using anonymised 
QOF+ data from Hammersmith & Fulham, London, UK (2008 to 2011). The 
methodology and findings of this study are discussed in Chapter 8.  
 
Ethics approval 
For Wandsworth study 
Wandsworth Local Research Ethics Committee granted ethics approval for the use of general 
practice data to examine the effects of QOF on a number of health outcomes including 
smoking in the population. 
For Hammersmith & Fulham QOF+ study 
I submitted an application to the South East Research Ethics Committee (SE REC) to set up a 
General Practice Research Database using QOF+ data from general practices in 
Hammersmith & Fulham PCT using the on-line application system (IRAS). The application 
was approved in August 2010.  
The subsequent application to the SE REC to use data from the database for evaluations of 
QOF+ with respect to smoking cessation activities and other prevention work received an 
unfavourable decision from the committee. I re-wrote the proposal and the ethics application 
following feedback from the committee and these received a favourable decision from the 
London Queen Square Research Ethics Committee meeting on 16 June 2011. 
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Chapter 5: Systematic review of the effectiveness of 
financial incentives to health care professionals for 
smoking cessation activities 
 
Background 
Individual-level smoking cessation interventions by healthcare professionals are effective and 
can reduce health inequalities related to tobacco use.92 102 However, smoking cessation 
interventions tend to be underprovided in healthcare.184 Healthcare practitioners have 
negative attitudes towards discussing smoking cessation with their patients, doubt their 
personal effectiveness in providing cessation advice, worry about compromising their 
relationship with the patient, and lack time in the average consultation,114 although 
practitioners consider disease prevention activities to be important and worth spending time 
on during the consultation.185  
 
Pay-for-performance schemes are becoming more mainstream in healthcare, particularly in 
the USA186 187 and the UK.142 188 They aim to improve the quality of healthcare by financially 
rewarding practitioners for achieving performance targets. Financial incentives may 
encourage more systematic use of smoking cessation interventions and have been 
incorporated into many quality improvement programmes. For example, the Quality and 
Outcomes Framework (QOF), introduced in the UK in 2004, rewards smoking cessation 
activities, although mainly for secondary prevention of long term conditions such as coronary 
heart disease, diabetes and chronic obstructive pulmonary disease.180 I carried out a 
systematic review to examine the evidence for the effectiveness of providing financial 
incentives to healthcare professionals for smoking cessation.  
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I wrote up the review as first author. Co-authors commented on the first draft and it was 
published in a peer-reviewed journal and it was published in a peer-reviewed journal 
(Tobacco Control) in 2011 (See Appendix C). 
 
Methods 
Search strategy for identification and selection of studies 
I identified studies by searching the electronic databases MEDLINE, EMBASE, PsychINFO, 
the Cochrane database of systematic reviews, and ISI Web of Science and included papers in 
languages other than English in the search. The titles and abstracts of those studies identified 
by the initial searches were scanned and, for those that appeared relevant, the full paper was 
obtained and reviewed. Further papers were identified by looking at the citations and 
reference lists of review papers and papers identified in the initial search. 
For MEDLINE I searched from 1947 to 1 May 2011 using Medical Subject Heading (MeSH) 
terms: (Motivation/ or Reimbursement, Incentive/ or financial incentive.mp or 
Reimbursement Mechanisms/ or payment.mp or “Salaries and Fringe Benefits”/ or pay.mp) 
and (general practice.mp or Family Practice/ or Primary Health Care/) and (Disease 
Management/ or Chronic Disease/ or “Quality of Health Care”/ or chronic disease 
management.mp or Diabetes Mellitus/ or Cardiovascular Diseases/ or Bronchitis/ or 
Pulmonary Disease, Chronic Obstructive/ or Respiratory Tract Diseases/ or Lung Diseases/ 
or respiratory disease.mp or Asthma / or Lung Diseases, Obstructive/ or Primary Prevention/ 
or Secondary Prevention/ or “Tobacco Use Disorder”/ or Smoking/ or Smoking Cessation/). 
For EMBASE I searched from 1947 to 1 May 2011 using the following terms: (motivation/ 
or Incentives/ or policy/ or incentive*.mp or finance*.mp or fee/ or payment.mp or pay*.mp 
or “salary and fringe benefit”/ or P4P.mp) and (health care quality/ or chronic disease/ or 
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long term condition.mp or diabetes mellitus/ or copd.mp or chronic obstructive lung disease/ 
or cardiovascular disease/ or asthma/ or coronary heart disease.mp or ischemic heart disease/ 
or smoking/ or smoking cessation program/ or cigarette smoking/ or smoking.mp or smoking 
cessation/ or tobacco dependence/ or health education/ or secondary prevention/ or 
prevention/ or primary prevention/) and (primary care.mp or primary medical care/ or family 
practice.mp or general practice/ or gp.mp). 
For PsychINFO I searched from 1967 to 1 May 2011 using the following terms: (exp 
Incentives/ or exp Monetary Incentives/ or pay.mp or exp Salaries/ or exp Employee 
Motivation/ or exp Motivation/ or exp Extrinsic Motivation/) and (exp Primary Health Care/ 
or exp General Practitioners/ or general practice.mp) and (exp Chronic Illness/ or long term 
condition.mp or exp Diabetes/ or exp Diabetes Mellitus/ or copd.mp or exp Chronic 
Obstructive Pulmonary Disease/ exp Cardiovascular Disorders/ or ischemic heart disease.mp 
or coronary heart disease.mp or exp Heart Disorders) and (exp Smoking Cessation/ or 
smoking.mp or exp Tobacco Smoking/). 
For ISI Web of Science I searched using keywords: (financial incentive and smoking); 
(payment and smoking). For the Cochrane Collaboration, I searched all titles of reviews and 
protocols produced by the Tobacco Addiction group and the Effective Practice and 
Organisation of Care (EPOC) group in the Cochrane database of systematic reviews (CDSR) 
for relevant studies. I searched the Cochrane Database of Abstracts and Reviews of 
Effectiveness (DARE) using keywords (smoking, payment and financial incentive). I 
searched the Cochrane Central Register of Controlled Trials (CENTRAL) using key words 
(financial incentive, payment, and smoking). 
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Inclusion criteria for studies to review 
1. Types of studies: randomised controlled trials, controlled trials, and observational 
studies with before-and-after, longitudinal or time series analysis designs, and 
reporting quantitative results. 
2. Participants: participants aged 15 and over, with and without chronic disease, 
registered with any healthcare provider. 
3. Types of financial incentives: studies that examined the effects of financial incentives 
(pay-for-performance) for individual and groups of healthcare providers to provide 
smoking cessation advice, referral and/or prescription of medication to help with 
smoking cessation. 
Exclusion criteria 
1. Studies examining the effects of financial or other rewards to patients, patient 
competitions, or provision of reduced cost or free medication to help with smoking 
cessation (unless this was associated with a provider financial incentive). 
2. Studies reporting results as a composite quality score including other measures of 
chronic disease management if it was not possible to isolate impacts on smoking-
related activities. 
Assessment of methodological quality and data extraction 
I and another researcher scored each paper for methodological quality using the Downs and 
Black guidelines for assessing the quality of both randomised and non-randomised studies of 
healthcare interventions,189 the scoring system for which is given in Downs and Black paper 
reproduced in Appendix A. The scores were collapsed to give four categories: 1 (poor), 2 
(acceptable), 3 (good), 4 (excellent), using a similar method as that employed by Petersen et 
al in their 2006 systematic review of financial incentives for quality of healthcare.190 Any 
differences of opinion were resolved by discussion with my supervisor.  
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I then extracted the numerical results from the identified papers for the results section of the 
review. These included summary measures (odds ratios, rate ratios, mean differences in 
observed versus predicted scores and differences in proportions) for changes in outcomes 
such as the recording of smoking status, advice given, referrals to smoking cessation services 
and prescriptions given to aid smoking cessation, as well as changes in smoking rates. I used 
the data reported to estimate the effect size (odds ratio, OR) for each outcome for each study 
if this was not reported. I did not calculate a summary measure of effect for the studies by 
meta-analysis as they used different settings, population groups and outcome measures and I 
did not consider them to be combinable. 
 
Results 
Search results 
The flow chart of the search strategy for included studies is given in Figure 25. Most of the 
papers initially identified by the search could be excluded after scanning the abstracts, as they 
were descriptive articles, editorials, commentaries or reviews.  
Excluded papers and reasons for exclusion  
Two sets of papers were duplicates, reporting results from the same datasets. The first set 
were papers by Twardella and Brenner, published in 2007191, and Salize et al, published in 
2009.192 The paper by Salize et al included cost effectiveness analysis so I included this one. 
The other set were two papers by Coleman et al, published in 2007160 with a follow up study 
in 2010.193 I excluded the later paper as this reported results only in the form of graphs, and it 
was not possible to extract numerator and denominator data in order to calculate effect size 
(odds ratio) for outcomes.  
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Included studies 
The final set of studies consisted of 11 observational studies examining the effect of QOF in 
the UK, in which reaching pre-set targets is rewarded (Table 1a); and eight studies looking at 
specific financial incentives for smoking cessation on individual physicians or groups of 
physicians in which reimbursement depended on performance (Table 1b).  
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Figure 25: Flow diagram of study selection for inclusion in a systematic review of 
financial incentives for smoking cessation activities in healthcare  
 
 
 
 
Rejected after reading 
abstract if obviously 
not about financial 
incentives and chronic 
disease management or 
smoking cessation or 
prevention activities    
(n = 950) 
Excluded papers: 
Duplicates  
 (n = 2) 
Papers included in the 
systematic review  
(n = 19) 
 
Papers that met eligibility 
criteria for inclusion in the 
systematic review:  
Original papers exploring effect 
of financial incentives to 
healthcare providers for 
recording smoking status of 
patients, +/- providing cessation 
advice to smokers, and reporting 
providing quantitative results  
(n = 21) 
 
Potential papers identified by 
search strategies in Medline, 
Embase, PsychInfo, ISI Web of 
Science and Cochrane 
Collaboration databases 
(n = 1030) 
Papers identified by 
reading reference list 
of papers reviewed 
in detail  
(n = 1) 
Full papers reviewed in 
detail after reading abstract 
(n = 81) 
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Table 1a: Studies evaluating the effectiveness of the Quality and Outcomes Framework in the UK on smoking-cessation activities 
Author 
Year 
Country 
Design Incentive Setting Population Outcome 
measure 
reported 
Results  Quality 
score  
Smoking status as main outcome 
Millett et al, 
2008194 
UK 
Comparison of 
two cross-
sectional 
surveys using 
electronic 
patient records 
Introduction of QOF in 2004, 
with financial incentives for 
quality of care for people 
with chronic diseases, 
including smoking cessation 
activity For details of 
smoking indicators in QOF 
see Chapter 3 
32 general 
practices in 
south London, 
UK 
2,891 patients with 
coronary heart disease 
(CHD) registered with 
participating practices 
in 2003 and 3,101 in 
2005 
Proportion of patients 
with CHD whose 
smoking status was 
recorded in the 2003 
and 2005 study 
periods 
Recorded smoking status increased between 2003 and 
2005 in the three ethnic groups studied: from 70.6% to 
89.8% (OR 3.6, CI 2.5-5.4) in White patients; from 
76.6% to 92.0% (AOR 3.5, CI 2.2-5.7) in Black 
patients; and from 70.1% to 92.4% (AOR 5.3, CI 3.0-
9.5) in Asian patients 
Combining these results gives overall improvement in 
recording smoking status from 72.4% in 2003 to 91.4% 
in 2005 (OR 3.12, CI 2.80 to 3.48)  
3 
 
Sutton et al, 
2010195 
 UK 
Cross-sectional 
historic before-
and after study 
of recording of 
risk factors, for 
which practices 
were either 
incentivised or 
QOF 315 general 
practices 
contributing 
data to the 
Scottish 
Programme for 
Improving 
Clinical 
391326 patients aged 
> 45 in one of the 
following disease 
categories: COPD 
(1.7%), CHD (9.0%), 
diabetes (6.6%), 
hypertension (15.6%), 
stroke (2.7%), 
Proportion of patients 
with smoking status 
recorded annually 
between 2000/1 and 
2005/6 
The overall effect of all incentivised factors was 
substantially larger on the targeted patient groups 
(+19.9%) than on unincentivised (+5.3%) 
For the recording of smoking status, we were unable to 
calculate an OR for improvement for all patients as the 
results were only given for CHD as an illustration. For 
CHD the proportion of patients with recorded smoking 
2 
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not, including 
smoking data, 
for chronic 
disease. 
Analysis used 
dynamic probit 
models 
Effectiveness 
in Primary Care 
untargeted or no 
disease (64.4%) 
status increased over the study period from around 12% 
in 2000/1 to 60% immediately pre-QOF and to 80% in 
2005/6.  The improvement from 2003/4 to 2005/6 was 
20% (OR 2.67, CI 2.58 to 2.76) 
Smoking status and smoking cessation advice as outcomes 
Campbell et al, 
2007168 
UK 
Cohort study QOF  Random 
sample of  42 
nationally 
representative 
general 
practices in 
England  
Patients with CHD, 
asthma and Type 2 
diabetes registered at 
participating general 
practices 
Smoking status 
recorded during the 
previous 5 years 
Smoking advice to 
smokers recorded 
during the previous 5 
years 
The authors reported mean difference in observed and 
predicted quality scores at practice level in 1998 and 
2003 (pre-QOF) and 2005. For CHD recorded smoking 
status increased by 0.87 (CI 0.47-1.27, p<0.001); for 
asthma recorded smoking status increased by 0.59 (CI 
0.16-1.01, p=0.008); for type 2 diabetes recorded 
smoking status increased by 0.58 (CI 0.13 to 1.03, 
p=0.01). Smoking advice increased at all three time 
points for all conditions but the authors did not report 
differences in observed vs predicted scores for this 
Combining results for all three chronic diseases the 
proportion of patients having smoking status recorded 
increased from 86.5% to 97.6% between 2003 and 2005 
(unadjusted OR 9.82, CI 7.30 to 13.22). For smoking 
2 
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advice the proportion increased from 80.6% to 97.0% 
between 2003 and 2005 (unadjusted OR 7.87, CI 5.68 
to 10.90) 
Campbell et al, 
2009169 
UK 
Follow up study 
to earlier study 
using additional 
data from 2007 
and using an 
interrupted 
time-series 
analysis 
QOF As above Same patient 
population as for 
earlier study 
Smoking status 
recorded during the 
previous 5 years 
Smoking advice to 
smokers recorded 
during the previous 5 
years 
Mean difference in observed versus predicted scores for 
recording smoking status and advice given to smokers 
at practice level in 1998 and 2003 (pre-QOF) and 2005 
improved for patients with CHD, asthma and diabetes 
(described above, with OR) 
 The mean score for recording smoking status for CHD, 
asthma and diabetes improved slightly more between 
2005 and 2007, from 97.6% to 99.2%, and the 
proportion receiving smoking cessation advice also 
slightly improved, from 97% to 98.2% 
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McGovern et al, 
2008196 
UK 
Serial cross-
sectional study 
with 
multivariate 
analyses to 
assess variation 
with respect to 
gender, age, 
QOF 310 general 
practices in 
Scotland 
Patients with a 
computer record of 
coronary heart disease 
registered at 
participating practices 
Proportion of patients 
with a recording of 
smoking status 
Proportion of smokers 
recorded as receiving 
smoking cessation 
advice 
The proportion of eligible patients with smoking status 
recorded increased from 69.5% to 95.7% between 2004 
and 2005, OR 22.86 (CI 21.70 to 24.0, p<0.05), and the 
proportion of smokers given advice increased from 
81.0% to 96.2%, OR 5.94 (CI 5.53 to 6.38, p<0.05). 
The multivariate analysis identified that pre-QOF older 
patients were the only group less likely to be asked 
about smoking or given advice if smokers (OR 0.54, CI 
3 
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deprivation 0.48 to 0.60 for over-75s compared with younger 
patients for being asked (OR 0.56, CI 0.48 to 0.66 for 
being offered advice). Post-QOF there was no 
difference with age in being asked about smoking, and 
those from more affluent areas were somewhat less 
likely to be asked about smoking (OR 0.78, CI 0.62 to 
0.99 compared with least deprived); female smokers 
were more likely to be offered advice compared with 
males (OR 1.19, CI 1.05 to 1.34); but smokers over-75 
were less likely to be offered advice compared with 
younger smokers (0.44, CI 0.36 to 0.53).  
Simpson et al, 
2006197 
UK 
Serial cross-
sectional study 
with 
multivariate 
analyses 
QOF 310 general 
practices in 
Scotland 
Patients with a 
computer record of 
transient ischaemic 
attack or stroke 
registered at 
participating practices 
Proportion of patients 
with a recording of 
smoking status 
Proportion of smokers 
recorded as receiving 
smoking cessation 
advice 
The proportion of eligible patients with smoking status 
recorded increased from 41.1% to 90.6% between 2004 
and 2005and the proportion of smokers given advice 
increased from 79.0% to 95.9%  
The OR of smoking status being recorded in 2005 
compared with 2004 was 13.73 (CI 13.09 to 14.39) and 
for smokers receiving smoking cessation advice was 
6.21 (CI 5.54 to 6.97)  
3 
 
Tahrani et al, 
2007198 
Observational 
retrospective 
before-and-after 
QOF 66 general 
practices in 
15,628 patients on the 
diabetes register of 
participating general 
Proportions of patients 
with smoking status 
recorded across the 
Recorded smoking status increased over the study 
period, from 44% in 2004 to 96% in 2005 and stabilised 
at 95% in 2006 (p<0.001). Smoking cessation advice 
3 
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UK study Shropshire, UK practices in April 
2004, 16,121 in March 
2005 and 16,867 in 
March 2006 
study period 
Proportion having 
received smoking 
cessation advice across 
the study period 
increased over the study period from 83.8% in 2004 
(my estimate from October 2004 data in paper as April 
2004 data not reported) to 95% in 2005 and 96% in 
2006 (p<01.01) 
OR for recording smoking status in 2006 compared 
with 2004 was 24.19 (CI 22.42 to 26.11) and for 
smokers receiving smoking cessation advice was 4.64 
(CI 4.25 to 5.06)  
Smoking status, smoking cessation advice, and providing prescription as outcomes 
Coleman et al, 
2007160 
UK 
Historic trend 
analysis for 
effect on 
smoking 
cessation 
activities of 
QOF in UK 
using data from 
The Health 
Improvement 
Network 
(THIN) 
database for 
QOF UK primary 
care 
Registered patients 
aged 15-75: data 
available on THIN for 
776,302 patients in 
1990, rising to 
1,569,177 in 2000 and 
1,607,782 in 2004 
Smoking status 
recorded 
Smokers given advice 
to stop smoking  
Prescriptions to help 
stop smoking 
Comparing data from 2000 and 2004, there was an 
increase in recording of smoking status from 14% to 
39% (OR 3.93, CI 3.91 to 3.95) and in brief advice to 
smokers from 7% to 37% (OR 7.80, CI 7.70 to 7.90)  
The absolute increase in annual recording of smoking 
status and advice was more marked in the chronic 
diseases groups from around 10% in 2000 to over 80% 
in 2004 for patients with COPD, ischaemic heart 
disease or diabetes, 75% for those with TIA/stroke; 
66% for those with hypertension; 57% for those with 
asthma 
NRT/Bupropion prescriptions increased from around 
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each year 
between 1990 
and 2005 
1% of smokers in 2000 to around 6% of smokers in 
2004 (OR 6.32, CI 5.85 to 6.83). Nicotine addiction 
treatments were prescribed more often for patients with 
COPD than for those with other conditions 
Smoking status and smoking prevalence as outcomes 
Cupples et al, 
2008199 
UK 
Cross-sectional 
study to 
compare 
baseline 
cardiovascular 
risk 
management 
between 
different 
healthcare 
systems 
QOF 16 randomly 
selected 
general 
practices in 
Northern 
Ireland (P4P) 
and 32 in the 
Republic of 
Ireland (no 
P4P). Data 
were collected 
between 
October 2004 
and January 
2006 
903 patients with CHD 
registered at the 
general practices, 
mean age 67.5 years, 
69.9% male 
Recorded smoking 
status during previous 
year 
Smoking status ever 
recorded 
Recorded smokers 
Self-reported smokers 
Fewer RoI than NI patients had their smoking status 
recorded over the previous year (22% vs 84%, OR 
21.11, CI 14.68 to 30.36, p<0.001). Recorded smoking 
prevalence was lower in NI than RoI but the difference 
was not statistically significant (13.4% vs 16.9%, OR 
0.76, CI 0.50 to 1.15, p=0.19). Self-reported smokers 
prevalence conversely was higher in NI than RoI, but 
the difference again was not statistically significant 
(16.9% vs 13.8%, OR 1.27, CI 1.27 to 1.86, p=0.22) 
3 
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Millett et al, 
2007180 
UK 
Population 
based 
longitudinal 
study using 
electronic 
patient records 
QOF 32 general 
practices in 
Wandsworth, 
London, UK  
4,284 patients (>18 
years) with diabetes 
registered at 
participating general 
practices in 2003 and 
2005 
Of patients with 
diabetes: 
Proportion with 
smoking status 
recorded in the 15 
months before the 
2003 and 2005 study 
periods  
Proportion who 
smoked who were 
given smoking 
cessation advice 
Prevalence of smoking  
Significantly more patients had their smoking status 
recorded within 15 months in 2005 than in 2003 (86.7% 
vs 67.6%, OR 5.62, CI 5.08 to 6.21, p<0.001). 
The prevalence of smoking declined (from 20.0% to 
16.2% , OR 0.77, CI 0.69 to 0.86, p<0.001). 
The proportion of patients with documented smoking 
cessation advice also increased significantly (from 
48.0% to 83.5%, OR 5.46, CI 4.30 to 6.95, p<0.001).    
 
2 
 
Simpson et al, 
2010181 
UK 
Cross-sectional 
study with 
historic before-
and-after 
analysis 
QOF 525 general 
practices 
contributing to 
QRESEACH 
database 
(anonymised 
aggregated data 
from about 
All patients aged >15 
years registered at the 
general practices 
contributing to the 
database 
Numbers with 
smoking status 
recorded in 2001/2 
(pre-QOF) and 2006/7 
Proportions of 
smokers given 
smoking cessation 
advice in the two study 
The proportion of people with smoking status recorded 
increased by 32.9% (from 46.6% in2001/2 to 79.5% in 
2006/7, OR 4.45, CI 4.43 to 4.46) 
There was a large increase in provision of smoking 
cessation advice (43.6% in 2001/2, 84% in 2006/7, OR 
6.75, CI 6.66 to 6.85)  
The proportion of patients referred to stop smoking 
2 
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2,710,000 
patients) 
periods 
Proportions of 
smokers referred to a 
stop smoking service 
in the previous 12 
months in the two 
study periods 
Smoking prevalence 
clinics increased (from 0.95% to 6.56%, OR 7.32, CI 
6.92 to 7.73) 
The proportion of people recorded as being a smoker 
reduced from 28.4% in 2001/2 to 22.4% in 2006/7 (OR 
0.73, CI 0.72 to 0.73)  
UK = United Kingdom; QOF = Quality and Outcomes Framework; NI = Northern Ireland; RoI = Republic of Ireland; P4P = pay for performance; GP = general practitioner; CHD = coronary heart disease;               
TIA = transient ischaemic attack; CI = 95% confidence interval; RR = relative risk; OR = odds ratio; AOR = adjusted odds ratio 
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Table 1b Specific financial incentives for performance in smoking cessation activities 
Author 
Year 
Country 
Design Incentive Setting Population Outcome 
measure 
reported 
Results  Quality 
score  
Providing smoking cessation advice, medication or referral as outcomes  
An et al, 2008200 
USA 
RCT US$5000 for 50 faxed 
referrals of smokers by 
physicians to a stop smoking 
telephone advice service 
(also providing NRT for free 
or with insurance copayment) 
plus US$25 for each referral 
after the initial 50 and 
feedback on referral numbers 
Incentives were paid into 
clinics’ general operating 
fund, not to individual 
physicians, administrators or 
other staff 
24 clinics with 
incentive vs 25 
clinics with 
usual care in 
Minnesota, 
USA. 32 of the 
49 clinics used 
an electronic 
medical record 
system (EMR) 
Smokers >18 years old 
who visited the clinics 
and were intending to 
quit 
Number of referrals to 
the tobacco quitline 
Percentage of clinic 
smokers taking up 
smoking cessation 
services 
Numbers of referrals: 11.4% of smokers (CI 8% to 
14.9%; total referrals 1483) for clinics with financial 
incentive vs 4.2% (CI 1.5% to 6.9%; total referrals 441 
for usual care clinics), p=0.001. OR 2.93 (CI 2.63 to 
3.27) for referral with financial incentive compared to 
control  
There was no association between clinic specialty 
(family practice; internal medicine; obstetrics-
gynaecology; multispecialty), number of physicians at 
the clinic, or the use of EMRs and the proportions of 
smokers referred to the quitline. Overall percentage of 
clinic smokers who then enrolled in the quitline 
smoking cessation service was higher in incentivised 
clinics (3.0%, CI 2.2% to 3.8%) compared with controls 
(1.3%, CI 0.4% to 2.1%), p=0.005 
Costs for referral/enrolment were higher for the 
intervention clinics (US$65/US$232) than for the 
3 
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control clinics (US$20/US$72) but resulted in 1042 
additional referrals and 289 additional enrolments. 
Marginal cost for the incentivisation was US$83 per 
additional referral and US$300 per additional enrolment 
Chang et al 
2010201 
Taiwan 
Before-and-
after analysis of 
data from the 
Taiwan Adult 
Tobacco Survey 
2004-2007 
Increase of reimbursements 
for physicians in all medical 
specialties to provide 
smoking cessation services. 
From January 2005 
participating physicians 
received 350 New Taiwan 
Dollars (NT$, equivalent to 
US$11) for providing brief 
cessation counselling during 
each routine outpatient visits 
vs $NT 250 (US$8) in 2004.  
Also, increased medication 
subsidy for eligible patients 
(aged >18 years and smoking 
>10 cigarettes a day) of up to 
NT$400 (US$13), up from 
NT$250 (US$8) in 2005. 
General 
population in 
Taiwan 
Adults aged >18 
selected and phoned 
via random digit 
sampling: 16,788 
(2004); 16,749 (2005); 
16,922 (2006); 16,588 
(2007) 
Of these 5,358; 4,846; 
5,220; and 4,866 
respectively were 
ever-smokers and 
3,290; 3,131; 3,072; 
and 2,953 were current 
smokers 
Numbers of ever 
smokers and current 
smokers receiving 
smoking cessation 
advice from health 
professionals  
Prevalence of smoking 
in 2004, 2005, 2006 
and 2007 
After adjusting for other variables, the increased 
funding in 2005 was associated with an increase in the 
prevalence of receiving smoking cessation advice 
during the previous year from 21.1% in 2004 to 26.8% 
in 2005 (adjusted OR 1.26, CI 1.11 to 1.42 compared 
with 2004) and 28.2% in 2006 (adjusted OR 1.39, CI 
1.25 to 1.56 compared with 2004). The rate reduced 
slightly to 27.6% in 2007 when funding reduced to 
2005 level (adjusted OR 1.37, CI 1.22 to 1.53) 
compared with 2004)  
The multivariate analysis results suggested that 
increasing financing for smoking cessation services in 
2005; being male; older; smoking daily; previously 
having attempted to stop smoking; having a self-
assessment of poor health; and being aware of the 
benefits of smoking cessation services were 
significantly positively associated with receiving quit 
advice 
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In 2006 funding fell to the 
2005 level but with low 
income patients receiving  
higher subsidies (US$16 per 
week) 
The prevalence of smoking in each of the years 
surveyed was 23.9%, 22.2%, 21.4% and 21.1% 
respectively. The prevalence of ex-smokers for each of 
the years was 6.4%, 5.7%, 7.4% and 7.4% respectively 
Coleman et al, 
2001202 
UK 
Before-and-
after-after study  
Pilot health promotion 
payment aimed at increasing 
GP stop smoking advice to 
smokers. All members of 
participating primary care 
teams received training in 
helping patients stop 
smoking. The numbers of 
patients who quit were 
recorded for a control period 
of nine months, followed by 
nine months with a financial 
incentive. Individual general 
practitioners could claim £15 
(approximately US$24) for 
each patient who stopped 
smoking (the authors 
estimated each GP could 
31 GPs 
working at 13 
general 
practices in 
Leicester, UK 
Patients registered at 
participating general 
practices: 1,878 
patients participated in 
the control period and 
1,647 participated in 
the intervention period 
Proportion of patients 
who had stopped 
smoking during the 
previous year who 
recalled receiving stop 
smoking advice from 
their GP before and 
after the intervention 
21% of smokers recalled receiving antismoking advice 
after the intervention period compared with 19% in the 
control period (OR 1.17, CI 0.85 to 1.62). The 
difference was not significant and neither was the 
difference in proportions who had tried to stop smoking 
during the previous year (44% after the intervention 
period compared with 39.6% in the control period) 
However, a greater proportion of patients said they 
wanted to stop smoking (60.5% vs 52.2%) and intended 
to try to stop smoking in the next month (27.8% vs 
18.8%) 
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claim between £285 and 
£1125 a year). Patients 
attending a random selection 
of general practices in both 
time periods completed 
questionnaires to determine 
proportion of smokers who 
had been given smoking 
cessation advice 
McMenamin et 
al, 2003203 
USA 
Cross-sectional 
survey of 
physician 
organisations. 
Multivariate 
analysis of 
survey data 
Organisations receive or do 
not receive financial 
incentives from HMOs to 
support smoking cessation 
interventions. Figures for 
financial incentives received 
were not given in the paper 
1,104 physician 
organisations in 
US with >20 
physicians 
Representatives 
(president; chief 
executive officer; or 
medical director) of 
the physician 
organisations  
Numbers of HMOs 
providing smoking 
cessation advice and 
other interventions 
such as self help 
materials and NRT 
5% of organisations polled received direct financial 
incentives from HMOs to provide smoking cessation 
interventions and 40% received additional income from 
health plans for scoring well on quality measures 
including smoking cessation activities 
Adjusted OR for supporting smoking cessation 
interventions for those organisations with financial 
incentives:  
Offering health promotion programme, OR 3.63 (CI 
1.70 to 7.76, p<0.001); providing NRT starter kit OR 
2.75 (CI 1.33 to 5.65, p=0.006); providing written 
materials on (a) pharmacotherapy OR 2.13 (CI 1.04 to 
4.33, p=0.034), (b) counselling OR 3.11 (CI 1.50 to 
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6.44, p=0.002), (c) self-help OR 2.33 (CI 0.93 to 5.84) 
Stevens et al, 
2005204 
USA 
Cross-sectional 
study with three 
components: 
HMO policy 
survey; patient 
survey; survey 
of primary care 
physicians 
Financial incentives provided 
in some HMOs for 
physicians to provide 
smoking cessation services 
(5As: Ask, Advise, Assess, 
Assist and Arrange) vs no 
incentive. All provided 
coverage for smoking 
cessation medications and 
counselling. Figures for 
financial incentives received 
were not given in the paper 
11 non-profit 
HMOs, 9 
affiliated with 
Cancer 
Research 
Network in 
USA 
Random selection of 
64,764 patients in the 
9 CRN HMOs who 
had a primary care 
consultation in the 
previous 12 months. 
Patients completed 
mail or telephone 
survey 
For patients who were 
self-reported smokers: 
Proportion who 
reported being asked 
about tobacco use at 
their last clinic visit; 
were given advice to 
quit; were asked about 
readiness to quit; 
received assistance in 
quitting; were 
scheduled for follow 
up visits to help in 
quitting  
Five HMOs had policies for tobacco control and 
smoking cessation activities. A greater proportion of 
patients at HMOs with incentives reported receiving 
smoking cessation advice (74% vs 67%, OR 1.40, CI 
1.23 to 1.60); assessment of readiness to quit (60% vs 
52%, OR 1.23, CI 1.23 to 1.57); received smoking 
cessation materials (28% vs 22%, OR 1.38, CI 1.20 to 
1.59) or received counselling by a physician (34% vs 
29%, OR 1.26, CI 1.11 to 1.44). For all comparisons 
p<0.01 using chi-squared tests 
3 
 
Quit rates as outcome 
Salize et al 
2009192 
Germany 
Cluster-
randomised 
smoking 
cessation trial. 
Main outcome 
1.GP training and a financial 
incentive of (€130, 
approximately US$152 using 
exchange rate of 
1€=US$1.17 in 2003) for 
94 GPs 
working in 82 
General 
practices in 
Germany: 20 
577 patients aged 36 to 
75 years who smoked 
at least 10 cigarettes a 
day and who visited a 
GP for a general health 
Abstinence rates 12 
months after 
recruitment (self-
report confirmed by 
serum cotinine levels) 
The TI intervention was not effective compared with 
TAU. The point prevalence of abstinence at 12 months 
was 3.5% vs 2.7%, OR 1.29, CI 0.25 to 6.84, p=0.75 
However, the point prevalence of abstinence at 12 
months with TM (12.1%) and TI/TM (14.6%) differed 
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was cost-
effectiveness 
but abstinence 
rates also 
compared with 
mixed logistic 
regression 
each abstinent patient (TI) 
2.GP training plus cost-free 
smoking cessation 
medication (TM) 
3.A combination of 1 & 2 
(TI/TM) 
4.Treatment as usual (TAU) 
practices were 
randomised to 
group 1; 21 to 
group 2; 21 to 
group 3; 20 to 
control group 
examination (offered 
biannually and, free 
for all patients covered 
by compulsory health 
insurance) 
significantly from TAU (2.7%) and for TM compared 
with TAU, OR 4.98, CI 1.22 to 22.16, p=0.05. For 
TI/TM compared with TAU, OR 6.16 (CI 1.44 to 26.37, 
p=0.02) 
TM and TI/TM were cost-effective compared with 
TAU but TI was not. The total intervention costs per 
treated patient in each of the arms were €14.16 
(US$16.57) for TI, €39.10 (US$45.75) for TM and 
€50.04 (US$58.55) for TI/TM against €0 for TAU. This 
translated to an investment of €92.12 (US$107.78) per 
patient in the programme to gain one additional quitter 
with TM whereas for TI/TM  €82.82 (US$96.90) would 
be required  
Providing smoking cessation advice and quit rates as outcomes 
Chang et al, 
2008205 
Taiwan 
Historic before-
and-after and 
after cross-
sectional 
database study 
of claims from 
physicians for 
providing 
Increase of reimbursements 
for smoking cessation 
activities as described above 
for Chang et al 2010 
Private and 
public 
healthcare 
organisations 
(clinics and 
hospitals) in 
Taiwan. 
Physicians of 
Patients aged >18 
attending clinics or 
hospitals for routine 
visits who were then 
offered a six-minute 
counselling session 
with a five-point 
agenda (5As: Ask, 
Numbers of patients 
receiving smoking 
cessation services in 
2004 and 2005 
Quit rates in 2004 and 
2005 
The increased reimbursement rates and medication 
subsidies for smoking cessation were positively related 
to the number of physicians enrolling in the programme 
(1,841 in 2004 vs 3,466 in 2005), the number of 
cessation consultations per month per physician (5.1 vs 
14.6) and number of cessation visits per year per patient 
(2.0 vs 2.5) 
The number of patients receiving cessation counselling 
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smoking 
cessation 
advice. 
Multivariate 
and GEE 
statistical 
analysis 
Logistic 
regression was 
used to examine 
quit rates after 
conducting a 
six-month 
follow up of 
patients using 
three datasets 
(Patient Claims 
data; Patient 
intake survey; 
Patient six-
month follow-
up survey) 
any specialty 
were eligible 
from 2005. 
Previously only 
family 
practitioners, 
psychiatrists 
and internal 
medicine 
physicians 
Advise, Assess, Assist 
and Arrange) 
including a 
prescription of 
medication to help 
smoking cessation 
 increased from 22,167 (0.50%) in 2004 to 109,508 
(2.75%) in 2005, OR 5.05 (CI 4.98 to 5.12) 
However, the 2005 increase in funding was not 
associated with an increase in quit rates (25.2% in 2004 
vs 21.3% in 2005, OR 0.96, CI 0.87 to 1.06) 
The average cost for smoking cessation consultations 
and medication per quitter was more expensive with the 
new system (US$135 in 2004 and US$300 in 2005) 
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Asking about smoking and providing smoking cessation advice or assistance and quit rates as outcomes 
Roski et al, 
2003206 
USA 
RCT (3 arms) 1) Financial incentives of 
US$5000 for clinics with up 
to 7 providers, US$10,000 
for clinics with 8 or more 
providers, available for 
superior performance (if 
>75% of patients >18 years 
had their smoking status 
recorded and if >65% of 
smokers had smoking advice 
recorded)  
 2) Financial incentives plus 
a smoker registry and 
telephone support for 
smoking cessation for 
patients ready to quit within 
30 days at no cost to patients. 
Clinics received weekly 
updates of numbers of 
referrals and could see their 
performance compared with 
40 primary care 
clinics in USA: 
15 clinics 
received 
financial 
incentives; 10 
received 
financial 
incentives plus 
registry and 
telephone 
support; 15 
were controls 
 Patients aged  >18 
visiting clinics 
completed exit surveys 
at baseline (May 1999) 
and follow up (June 
2000) to determine 
smoking status and 
whether they received 
quit advice or 
assistance (advice 
about or prescription 
for smoking cessation 
aids) during their 
appointment 
4,435 patients were 
surveyed at baseline, 
4,377 at follow up. Of 
these, 873 smokers 
were surveyed at 
baseline and 863 at 
follow up 
Smoking status 
Quit advice given to 
smokers 
7 day sustained 
abstinence from  
smoking 
 
There was no difference between the intervention 
clinics and the control clinics in identifying patients’ 
smoking status at baseline (40.5% for control clinics, 
39.9% for incentive clinics, 40.3% for registry clinics), 
but at follow up the proportion identified was greater in 
the incentives clinics compared with control clinics 
(54%, vs 46.7%, OR 1.34, CI 1.17 to 1.54) than for 
registry clinics compared with control clinics (48.4% vs 
46.7%, OR 1.07, CI 0.92 to 1.25) 
There was no difference between the intervention 
clinics and the control clinics in the proportion of 
patients receiving advice to quit at the last visit, and at 
follow up the proportion was not statistically greater in 
the incentives clinics compared with the control clinic 
(55.5% vs 53%, OR 1.07, CI 0.79 to 1.44) or the 
registry clinics compared with the control clinics 
(57.3% vs 53.7%, OR 1.15, CI 0.79 to 1.65) 
There was no statistically significant difference in the 
proportion of patients from the incentives clinics 
receiving assistance to quit at the last visit compared 
with control clinics (31.4% vs 34%, OR 0.89, CI 0.65 to 
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other clinics 
3) Control (printed smoking 
cessation guidelines) 
Clinics were aware of their 
performance levels prior to 
the start of the study and 
were aware if they were 
eligible for financial 
incentive 
In addition, in 
July/August 2000 a 
baseline mail survey 
of 2,729 patients with 
clinic visits subsequent 
to the interventions 
was carried out with 
follow up six months 
later looking at 7 day 
quit rates and at 
assistance received for 
stopping smoking 
 
1.23) or of patients from the registry clinics compared 
with control clinics (36.7% vs 34%, OR 1.13, CI 0.77 to 
1.65)  
There was no difference in 7 day quit rates for smokers 
from the incentive clinics compared with those from 
control clinics (22.4% vs 19.2%, OR 1.21, CI 0.98 to 
1.49) or for those from the registry clinics compared 
with those from the control clinics (21.7% vs 19.2%, 
OR 1.16, CI 0.91 to 1.48)  
Patients accessing registry clinics accessed counselling 
programmes more often than patients in the incentives 
or control clinics (p<0.001) but there was no difference 
between any of the groups in the proportions using 
medication to quit smoking or other aids 
UK = United Kingdom; USA = United States of America; HMO = Health Management Organisation; GP = general practitioner; 5As = Ask, Advise, Assess, Assist and Arrange; NRT = nicotine replacement therapy; 
CHD = coronary heart disease; TIA = transient ischaemic attack; TI = training and incentive; TM = training and medication; TAU = treatment as usual; CI = 95% confidence interval; RR = relative risk; OR = odds 
ratio; GEE = generalised estimating equations 
 
 
  
 
 123 
 
Type of incentive 
Eleven papers looked at the effect of QOF in the UK on smoking cessation activities. The 
financial rewards are paid to general practices rather than to individual general practitioners 
and the amount paid depend on the number of points achieved (as described in Chapter 3). 
Several of the papers looked at smoking cessation in patients with particular chronic diseases 
such as coronary heart disease, asthma, diabetes and stroke, while others examined results for 
all registered patients. Also most papers used data from different regions of the UK, only two 
used data from general practices from all of the UK. Only two of the studies took account of 
secular changes in smoking prevalence resulting from new guidelines for smoking cessation 
interventions, recent fiscal policy or legislation such as banning smoking in public places. 
They did this either by comparing actual outcomes against those predicted by modeling,168 or 
by using interrupted time series analysis.169 
 
The other group of studies I identified examined the effect of fee for service or bonuses on 
targeted smoking cessation activities in the UK, Germany, Taiwan and the US. They included 
two randomised controlled trials,192 200 one cluster randomised trial,206 two serial cross-
sectional studies comparing health maintenance organisations (HMOs) with and without 
financial incentives for smoking cessation work,203 204 and three before-and-after designs.201 
202 205 However, the designs of the before-and-after studies did not take account of secular 
changes in smoking prevalence. 
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Individual practitioners or organisation receiving incentives 
Four studies examined the effect of financial incentives on individual doctors.192 200 201 205 In 
one of the studies it was unclear whether the incentive payment was to individual doctors or 
to groups of doctors.204 The remainder looked at the effects on providing incentives to groups 
of healthcare professionals working in clinics or general practices. 
 
Amount of incentive provided 
Incentives included large bonuses such as that provided in An et al’s study200 whereby 
US$5000 was given to participating clinics for achieving 50 referrals to a stop smoking 
telephone advice line, then US$25 per patient after the first 50. In the study by Roski et al206 
the incentive was US$5000 to US$10,000 if >75% of patients at participating clinics had 
their smoking status recorded and if >65% had been given smoking cessation advice. In the 
studies by Chang et al201 205 the bonus was paid per smoker advised and was of the order of 
US$24. In two of the papers the payment was paid per smoker who stopped smoking, varying 
from US$24202 to US$152.192 For the cross-sectional studies of HMO funding203 204 the 
amount of the incentive was not reported and had not been collected (correspondence with 
the authors). 
 
Outcome measures 
Most of the studies examined process measures such as the recording of smoking status, 
smoking cessation advice and/or referral to stop smoking services. For these measures most 
of the studies showed statistically significant increases in the proportion of subjects receiving 
the outcome measures of interest after financial incentives were introduced compared to the 
prior period. Three studies examined the impact of financial incentives on quit rates. For all 
outcomes there was too great a degree of statistical heterogeneity for the studies to be 
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combinable for a meta-analysis even when sub-analysis was undertaken by QOF and non-
QOF studies (I2 >90%, p<0.001 using RevMan207 software). 
 
• Smoking status 
For the QOF studies the absolute improvements in recording smoking status ranged from 
19%194 (72.4% in 2003, 91.4% in 2005, OR 3.12, 95% CI 2.80 to 3.48), to 52%198 (44% in 
2004 to 96% in 2005, OR 24.19, CI 22.42 to 26.11), summarised in Table 2a. The 
improvement in the RCT by Roski et al206 was 7.3% (54% for incentives clinics, 46.7% for 
control clinics, OR 1.34, CI 1.17 to 1.54) and 1.7% for incentive plus registry clinics (48.4% 
for incentive plus registry clinics, OR 1.07, CI 0.92 to 1.25). 
 
Table 2a: Summary measure of recording smoking status (odds ratio, OR) following 
introduction of a financial incentive in order of effect size 
Author and year Type of study, effect size for financial incentive on recording of smoking status 
Cupples et al, 2008199 QOF study. No statistically significant difference between area with incentive and area without: OR 0.76 (CI 0.50 to 
1.15) 
Roski et al, 2003206  RCT of incentives clinics compared with control clinics:  OR 1.34 (CI 1.17 to 1.54)  
Sutton et al, 2010195 QOF study. 2005/6 compared with 2003/4: OR 2.67 (CI 2.58 to 2.76) 
Millett et al, 2008194 QOF study. 2005 compared with 2003: OR 3.12 (CI 2.80 to 3.48)  
Coleman et al, 2007160 QOF study. 2004 compared with 2000: OR 3.93 (CI 3.91 to 3.95)  
Simpson et al, 2010181 QOF study. 2006/7 compared with 2001/2: OR 4.45 (CI 4.43 to 4.46)  
Millett et al, 2007180 QOF study. 2005 compared with 2003: OR 5.62 (CI 5.08 to 6.21)  
Campbell et al, 2007168 QOF study. 2005 compared with 2003: OR 9.82 (CI 7.30 to 13.22) 
Simpson et al, 2006197 QOF study. 2005 compared with 2004 was 13.73 (CI 13.09 to 14.39)  
McGovern et al, 2008196 QOF study, 2005 compared with 2004: OR 22.86 (CI 21.70 to 24.0) 
Tahrani et al, 2007198 QOF study. 2006 compared with 2004: OR 24.19 (CI 22.42 to 26.11)  
OR = odds ratio 
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• Smoking advice or referral 
For QOF studies, recorded smoking advice increased by between 12.2% (from 83.8% in 2004 
to 96% in 2006, OR 4.64, CI 5.23 to 5.34)198 to 16.4% (80.6% in 2003, 97.0% in 2005, OR 
7.87, CI 5.68 to 10.90).168 The findings on smoking advice from other studies were less 
consistent (see Table 2b). Roski et al206 and Coleman et al202 found no difference between 
control and financial intervention groups. Otherwise the improvement ranged from an 
increase of 2.25% in Chang et al’s patient database study (0.50% in 2004, 2.75% in 2005, OR 
5.05, CI 4.98 to 5.12)201 to 5.7% in the study by Chang et al using the Taiwan Tobacco 
survey (21.1% in 2004, 26.8% in 2005, adjusted OR 1.26, CI 1.11 to 1.42).205  
Table 2b: Summary measure for receiving smoking cessation advice (odds ratio, OR) 
following introduction of a financial incentive in order of effect size 
Author and year Type of study, effect size for financial incentive on recording of smoking status 
Roski et al, 2003206 RCT. There was no statistically significant difference between the intervention clinics and the control clinics in the 
proportion of patients receiving advice to quit: OR 1.07 (CI 0.79 to 1.44)  
Coleman et al, 2001202 Before-and-after-after study. Non-significant increase in proportion of smokers recalling receiving antismoking 
advice in the intervention period compared with the control period: OR 1.17 (CI 0.85 to 1.62) 
Chang et al 2010201 Before-and-after study. Increased funding in 2005 was associated with an increase in the prevalence of receiving 
smoking cessation advice compared with 2004:  OR 1.26 (CI 1.11 to 1.42) compared with 2004 
An et al, 2008200 RCT. Increased numbers of referrals from clinics with financial incentives compared with those without: OR 2.93 (CI 
2.63 to 3.27)  
McMenamin et al, 
2003203 
Cross-sectional survey of Outcomes for organisations with financial incentives compared with those without. 
Offering smoking cessation counseling: OR 3.11 (CI 1.50 to 6.44) 
Tahrani et al, 2007198 QOF study. 2006 compared with 2004: OR 4.64 (CI 4.25 to 5.06)  
Chang et al, 2008205 Before-and-after study. Patients receiving cessation counselling increased in 2005 compared with 2004: OR 5.05 (CI 
4.98 to 5.12) 
Millett et al, 2007180 QOF study. 2005 compared with 2003: OR 5.46 (CI 4.30 to 6.95)  
McGovern et al, 2008196 QOF study, 2005 compared with 2004: OR 5.94 (CI 5.53 to 6.38) 
Millett et al, 2007180 QOF study. 2005 compared with 2003: OR 5.48 (CI 4.86 to 6.17).    
Simpson et al, 2006197 QOF study. 2005 compared with 2004: OR 6.21 (CI 5.54 to 6.97)  
Simpson et al, 2010181 QOF study. 2006/7 compared with 2001/2: OR 6.75 (CI 6.66 to 6.85); Increase in proportion of patients referred to 
stop smoking clinics: OR 7.32 (CI 6.92 to 7.73) 
Coleman et al, 2007160 QOF study. 2004 compared with 2004: OR 7.80 (CI 7.70 to 7.90)  
Campbell et al, 2007168 QOF study. 2005 compared with 2003: OR 7.87 (CI 5.68 to 10.90) 
OR = odds ratio 
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• Prescriptions for nicotine replacement therapy (NRT)/Bupropion  
Two studies found financial incentives were associated with an increase in the proportion of 
smokers receiving prescriptions. For Coleman et al202 comparing pre/post-QOF, the OR was 
6.32, (CI 5.85 to 6.83). For McMenamin et al203 comparing HMOs with financial incentives 
to those without, the OR was 2.75 (CI 1.33 to 5.65). 
 
• Quit rates and changes in smoking prevalence 
Few studies examined quit rates and changes in smoking prevalence. A summary of the 
findings is shown in Table 2c, below. 
 
Table 2c: Summary measure for reduction in prevalence or quit rates (odds ratio, OR) 
following introduction of a financial incentive in order of effect size 
Author and year Type of study, effect size for financial incentive on recording of smoking status 
Chang et al, 2008205 Before-and-after study. 2005 compared with 2004: OR 0.96, CI 0.87 to 1.06) 
Roski et al, 2003206 RCT. There was no difference in 7 day quit rates for smokers from the incentive clinics compared with those from 
control clinics: OR 1.21 (CI 0.98 to 1.49)  
Simpson et al, 2010 QOF study. 2006/7 compared with 2001/2: OR 0.73 (CI 0.72 to 0.73)  
Millett et al, 2007 QOF study. 2005 compared with 2003: OR 0.77 (CI 0.69 to 0.86) 
OR = odds ratio 
 
Three non-QOF studies examined quit rates and longer-term abstinence but produced mixed 
findings. Chang et al205 found no improvement in quit rates over the previous 6 months when 
funding for smoking cessation activities in Taiwan increased between 2004 in 2005 (25.2% 
in 2004 vs 21.3% in 2005, OR 0.96, CI 0.87 to 1.06). Roski et al206 found no difference in 7-
day quit rates in their RCT (22.4% vs 19.2%, OR 1.21, CI 0.98 to 1.49 for incentive clinics 
compared with control clinics; 21.7% vs 19.2%, OR 1.16, CI 0.91 to 1.48 for registry clinics 
compared with control clinics). Salize et al192 also found no difference in effect in their 
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cluster RCT, for the financial incentive group (TI) compared with the usual care group 
(TAU). However, they did find an improved quit rate in the group with GP training plus 
patient reimbursed medications (TM) of 12.1% compared with 2.7% for TAU, OR 4.98 (CI 
1.22 to 22.16) and also in the group with GP training, patient reimbursement plus GP 
incentives (TI/TM), of 14.6%, OR 6.16 (CI 1.44 to 26.37), the large confidence intervals 
reflecting the relatively small sample size of the study. However, the TI/TM group did not 
significantly outperform the TM group, suggesting that the cost-free medication may have 
accounted for the effect observed. 
 
Three QOF studies looked at smoking prevalence. They were not able to examine quit rates 
as such as these are not specifically recorded on GP electronic medical records. Cupples et 
al199 found no difference between recorded smoking prevalence between patients with 
coronary heart disease (CHD) in the Republic of Ireland where there was no financial 
incentive scheme compared with Northern Ireland (QOF). Millett et al180 found a reduction in 
smoking prevalence in patients with diabetes following the introduction of QOF (from 20.0% 
to 16.2%, OR 0.73, CI 0.69 to 0.86). Simpson et al181 found a reduction in smoking 
prevalence in UK from 28.4% in 2001/2 to 22.4% in 2006/7, OR 0.73 (CI 0.72 to 0.73). 
However, it was not clear whether this reduction was due to smokers quitting through GP 
management or whether it can be explained by secular trends in the UK. Chang et al 201 also 
noted a reduction in smoking prevalence between 2004 and 2007 (23.9%, 22.2%, 21.4% and 
21.1% for each year respectively) and an increase in the proportion of ex-smokers in Taiwan 
(6.4%, 5.7%, 7.4% and 7.4% respectively) associated with the increase in funding for 
smoking cessation activities, but the authors acknowledge they could not distinguish whether 
this was due to the funding change or more widespread information about smoking through 
media campaigns and hospital-based smoker identification programmes. 
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• Inequalities 
Only three of the studies examined the effect on inequalities in the ascertainment of smoking 
status and provision of smoking cessation to smokers. Millett et al looked at differences with 
ethnicity in the likelihood of patients with CHD being asked about smoking pre/post-QOF 
and found a greater improvement among Asian patients compared with white British 
patients.177 In another study examining the effect of QOF on smoking outcomes among 
patients with diabetes, Millet et al found variations in outcomes post-QOF with respect to 
gender, age and ethnicity.180 Improvements in the recording of smoking status greater for 
women compared to men (AOR 2.01, CI 1.59 to 2.54) and for ethnic groups (except 
Bangladeshi) compared with white British patients after adjusting for age, sex, ethnic 
background, deprivation status and practice-level clustering. They also found that reduction 
in smoking rates post-QOF was lower among women (AOR 0.71, CI 0.53 to 0.95) although 
fewer women were smokers (11.5% of women smoked compared with 20.6% of men) and 
rates differed with age (from 10.6% for patients over-75 years to 25.1% for those aged 18-44) 
and by ethnicity (rates ranged from 4.9% for black African patients to 24.9% for white Irish) 
but there was no significant difference in the smoking rates between most and least deprived 
groups. 
 
McGovern et al in their QOF study of patients with CHD found that older patients were less 
likely to be asked about smoking pre-QOF but after the introduction of QOF this difference 
was no longer seen, and people from more deprived areas appeared to have benefitted more 
with those from more affluent areas being less likely to have been asked about smoking (OR 
0.78, CI 0.62 to 0.99 compared with least deprived). They also found that female smokers 
were more likely to be offered advice compared with males (OR 1.19, CI 1.05 to 1.34). 
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However, smokers over the age of 75 were less likely to be offered advice compared with 
younger smokers (0.44, CI 0.36 to 0.53).  
 
Methodological Quality 
Using the Downs and Black checklist, modified to give four categories, none of the studies 
were graded 1 (poor) so all were included in the review. Seven of the studies were graded 2 
(acceptable), of which five were QOF studies and two were non-QOF studies. Twelve studies 
were graded 3 (good), of which six were QOF studies and six were non-QOF studies. 
However, no study achieved 4 (excellent). This was because the QOF studies, cross-sectional 
and before-and-after studies scored poorly for lack of randomisation and blinding 
(unavoidable given the study designs) and the randomised controlled trials fell down on not 
considering possible adverse events (all studies), having short follow up times poorly 
described randomization or blinding or both (Roski et al,206 Coleman et al, 2001202) or a lack 
of power calculation (An et al,200 Salize et al192). 
 
Discussion 
Principal findings 
I identified 19 studies examining the effects of financial incentives for healthcare providers 
on smoking cessation activities and outcomes. The studies scored in the mid range for quality 
with a validated scoring guideline, so there were no methodologically poor studies, but 
equally there were no excellent studies. I had expected the randomised controlled trials to 
score higher than observational studies but this was not the case. This may be because the 
observational studies examined system-wide financial incentive schemes and so scored 
highly for having very representative samples and large sample sizes. 
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Most studies examined process measures (such as recording of smoking status, recording that 
smoking cessation advice had been given or that patients were referred to smoking cessation 
services). For these process measures, almost all studies showed improvements following the 
introduction of financial incentives. In the study by Coleman et al202 where the proportion of 
patients who recalled receiving smoking cessation advice did not increase following the 
financial incentive, the authors considered that the effect of the financial incentive may have 
been diluted by giving smoking cessation training to practice staff before the beginning of the 
control period. For the study by Roski et al,206 the authors suggested that management 
directives (to improve productivity and reduce costs) may have impacted negatively on 
practitioner behaviour and hence patients’ smoking outcomes.  
 
The two studies examining the effect of financial incentives on rates of prescribing nicotine 
replacement therapy (NRT) or Bupropion found an increase in prescribing rates.202 203 
However, Coleman et al202 found that the increase in the proportion of smokers receiving 
prescriptions (from 1% in 2000 to 6% in 2004) was far less than the increase in the 
proportion of smokers given advice (from 7% to 37%). The authors suggest that this might be 
because prescribing was not incentivised. Another explanation might be that patients were 
not ready to stop at the time, but later may have attended community stop smoking clinics 
where these medications are available, or decided to buy NRT at a pharmacy.  
 
Studies that examined quit rates had mixed results. Those examining system-level incentive 
schemes found a reduction in smoking prevalence, but limitations in study design meant it 
was not possible to determine the mechanism for this. Reductions may reflect increases in the 
number of never-smokers, or increases in the number of ex-smokers, which were not 
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examined. Smokers may have quit through doctor management or merely through being 
asked about smoking, or due to the influence of secular changes in smoking behaviour such 
as the ban on smoking in public places, or a combination of all three.  
 
QOF papers were not able to look at quitting smoking as an outcome as this is not recorded 
consistently by GPs, possibly because currently practices are not incentivised to do so. In any 
case smoking cessation recorded in general practice is from self-report rather than confirmed 
by carbon monoxide testing in exhaled breath or by the presence of nicotine metabolites in 
urine (cotinine). Another factor is that a large proportion of smoking cessation activity takes 
place outside primary care, in community pharmacies and stop-smoking clinics, and 
information about individual quitters is often not provided to GPs.  
 
The results from Salize et al’s cluster RCT192 suggested that financial incentives might 
influence quitting behaviour if combined with no cost NRT and/or Bupropion prescriptions 
and GP training, but a similar level of impact was seen with just the free medication group. 
This result is pertinent to the USA and the UK where assistance with the cost of prescriptions 
to treat smoking is available. In the USA, the Affordable Care Act208 has mandated Medicaid 
coverage of such medications for pregnant women since October 2010. Coverage for all 
Medicaid beneficiaries will be increased by January 2014, and tobacco-dependence drugs 
will no longer be excluded from benefits covered. In the UK, smokers can access nicotine 
replacement treatment (e.g. Bupropion or Varenicline) usually without charge from UK 
National Health Service smoking cessation services, or for the price of a prescription 
(currently £7.65) from their GP practice, or without cost if the patient is exempt from paying 
prescription charges.  
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The few studies examining the effect of QOF on inequalities in smoking cessation activities 
in primary care found mixed results. Women were more likely to be asked about smoking 
compared with men and more likely to receive advice, but were less likely to smoke. Patients 
over the age of 75 years were less likely to be asked about smoking and, if smokers, to be 
offered advice compared with younger smokers. Patients from ethnic minority groups and 
from more deprived areas benefitted more from the improvement in smoking outcomes 
associated with QOF compared with white British patients. There were also greater 
reductions in smoking prevalence post-QOF in patients from ethnic minorities and for 
women but no significant difference in the changes in smoking rates between most and least 
deprived groups.  
 
Strengths and weaknesses of the review  
I employed a comprehensive search strategy to identify relevant papers and included those 
with observational designs as well as randomised controlled trials, as is appropriate for 
examining complex interventions such as smoking cessation.138 This meant that a larger 
number of papers were included in the review compared to previous systematic reviews. 
Petersen et al,190 looking at the effects of pay for performance schemes on improving 
healthcare quality, identified nine studies that looked at prevention activities, of which two 
were for smoking cessation. This review was conducted in 2005 before pay-for-performance 
schemes became more popular, which might explain the small number of relevant studies. In 
a recent systematic review of strategies to increase the delivery of smoking cessation 
activities in primary care settings, Papadakis et al209 identified only three papers examining 
the effect of financial incentives. The authors excluded trials that were not indexed within 
Medline as randomised controlled trials, controlled clinical trials, or evaluation studies, 
whereas I did not limit my search strategy in this way. Observational studies are inherently 
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less robust methodologically compared with cohort or randomised controlled trials and I 
acknowledge this. However, as interventions for smoking cessation are necessarily complex, 
I felt it was important to include these studies to attempt a comprehensive view of the 
literature currently available.  
 
Most studies focused on process measures (recording smoking status and advice given or 
referral made) rather than quit rates as outcomes. Improvements may therefore reflect 
improved recording rather than increased delivery of smoking cessation interventions. Of the 
non-QOF studies, follow-up times for quit rates were reasonable at between 6 and 12 months, 
with the exception of the seven day quit rates reported by Roski et al.206 As previously 
mentioned most of the observational studies I identified did not take account of secular 
changes in smoking during the intervention period.  
 
Of the 19 included studies, 11 examined the impact of the UK’s QOF. Their findings may not 
be generalisable to other countries as the size of the incentive is large, supported by prompts 
from the electronic medical records (EMRs),132 210 and is backed up with access to a 
comprehensive NHS smoking cessation service. The non-QOF studies identified in my 
review examined financial incentives that were mainly aimed at doctors. Therefore, the 
generalisability of most of these studies to clinicians other than doctors may be limited. 
However, those examining QOF would include work performed by practice nurses. 
 
The financial incentives examined differed in amount and in this review I was not able to 
identify an optimal amount. If health practitioners were offered very large amounts for each 
smoker who stopped then the intervention would likely be successful but would not be 
financially practical. In addition, the results from Salize et al192 suggest that subsidised 
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smoking cessation medication may have more of an effect that a financial incentive. This was 
the only study that also examined the cost effectiveness of financial incentives and found that 
GP training and remuneration per abstinent patient was not effective compared to usual 
treatment. However, GP training plus cost-free smoking cessation medication and a 
combination of GP training, free medication and remuneration were both more cost effective 
interventions compared with usual treatment.  
 
These findings fit with those from other systematic reviews211-213 that have found multi-
component interventions more effective than single-component interventions in helping 
primary care doctors to deliver prevention services, including smoking cessation.214 
Therefore, financial incentives may have more impact when combined with other 
interventions, such as clinician education and subsidised smoking cessation prescriptions.  
 
Financial incentive schemes can have unintended outcomes as described in Chapter 3, such 
as gaming,215 adverse patient selection,216 poor performance for unrewarded activities217 and 
taking away doctors’ internal motivation.218 The studies identified in this review did not 
examine these. Also, unless quit rates are also rewarded, such schemes may not encourage 
practitioners to be effective in providing smoking cessation advice. Recording that smoking 
cessation advice has been given is no indication of the quality of advice given, and having 
someone stop smoking is obviously more valuable than simply recording smoking status. 
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Conclusions 
Financial incentives can be effective in improving the recording of smoking status, recording 
of smoking cessation advice and referral to smoking cessation services. We know that doctor 
advice to smokers is effective in reducing smoking rates102 so any intervention which 
increases such advice is important. However, few studies evaluated the impact of financial 
incentives on quit rates or inequalities and for these there were mixed results. Overall, these 
results are encouraging but the area does require more comparative studies. As several areas 
of the UK are currently developing local versions of the QOF219 in which prevention 
activities such as smoking cessation are more strongly incentivised, this gives a further 
opportunity to examine the effectiveness of financial incentives for smoking cessation work 
in primary care, in particular the effects on healthcare inequalities. 
 
 137 
 
Chapter 6: Effect of financial incentives on ethnic 
disparities in smoking cessation interventions for patients 
from different disease groups in primary care: cross-
sectional study using data from Wandsworth, London, UK 
 
As stated in Chapter 4, the null hypothesis for this research is that financial incentives do not 
the provision of smoking cessation activities in primary care, or smoking prevalence, in 
people with or without long-term conditions, regardless of demographic group. The 
alternative hypothesis is that financial incentives do affect these activities and may therefore 
influence inequalities in smoking cessation provision and outcomes. 
Main research question 
What are the effects of financial incentives on smoking cessation activities undertaken in 
healthcare, and do they affect inequalities in the provision of smoking cessation activities in 
primary care? 
Objectives 
• To examine the effects of a financial incentive scheme (QOF) on smoking cessation 
activities (the proportion of patients whose smoking status is recorded and who then 
receive smoking cessation advice, or referral to other smoking cessation services) 
provided to patients with and without smoking-related long-term conditions in general 
practices, and the effect on smoking prevalence in these patients, using data from 
general practices in Wandsworth, London, UK 
• To examine the effects of QOF on inequalities in the provision of smoking cessation 
activities to different groups (defined by age, gender, ethnicity and socio-economic 
status and, for disease group). 
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Background 
As previously noted, smoking cessation interventions by healthcare professionals are 
effective and can reduce health inequalities related to tobacco use.92 102 However, smoking 
cessation interventions tend to be underprovided in healthcare.184 Practitioners consider 
disease prevention activities to be important185 but among several reasons healthcare 
practitioners give for their reluctance to give smoking cessation advice during routine 
appointments is a concern about lack of time. This may be due to insufficient financial 
reward for taking on this work.114  
Pay-for-performance schemes are becoming more widespread in healthcare, particularly in 
the USA186 187 and the UK.142 188 They aim to improve the quality of healthcare by financially 
rewarding practitioners for achieving performance targets and have been incorporated into 
many quality improvement programmes. Some financial incentive schemes such as the UK’s 
Quality and Outcomes Framework (QOF) reward smoking cessation work mainly for 
secondary prevention for smoking-related chronic diseases.  
Findings from my systematic review suggested that such schemes may improve recording of 
smoking status, advice and referral, but there has been little research in the UK into their 
impact on disparities in the delivery of smoking cessation interventions or tobacco use. I 
carried out a cross-sectional study using data from Wandsworth, London to examine this 
question.  
I wrote up this study as first author. Co-authors commented on the first draft and it was 
published in a peer-reviewed journal (Journal of Public Health) in 2012 (See Appendix C). 
 139 
 
 
Methods 
Setting and patients 
The London Borough of Wandsworth, situated in South West London, is the largest inner 
London borough with a population of approximately 290,000 (See Figure 26). The 
population is younger than average for London as a whole, as shown in Figure 27, and is 
ethnically diverse, with around 22% of the population from Black and Minority Ethnic 
groups (Greater London Authority 2008 Ethnic Group population predictions), compared 
with around 11% for the UK as a whole.220 
Figure 26: Map of Greater London 
 
Source: www.ons.gov.uk © Crown copyright 
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Figure 27: Population pyramid for Wandsworth
 
Source: © Greater London Authority 2008 
Deprivation 
Wandsworth has pockets of extreme deprivation, but overall is rated as less deprived than 
England as a whole, with around 11% of people in this area living in the 20% most deprived 
areas in England, compared with an average for England of 20%. The map in Figure 28 
shows the range of deprivation levels in Wandsworth based on national IMD quintiles.221  
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Figure 28: Deprivation in Wandsworth compared with England 2010 
 
Source: APHO and Department of Health. © Crown Copyright 2012 www.healthprofiles.info   
 
Smoking cessation services in Wandsworth 
Smoking levels in Wandsworth have fallen over the last few years from around 24.2% of 
adults in 2007 (APHO estimate, modeled from Health Survey for England data), the year of 
this study, lower than the England average of 26.0% for the same year. By 2011, using data 
from the Integrated Household Survey the London Health Observatory estimated that 16.2% 
of adults (and 4.2% of pregnant women) in Wandsworth smoked compared with 18.9% of 
adults (and 13.2% of pregnant women) in England as a whole.222 Smoking attributable 
mortality and hospital admissions in Wandsworth are similar to the average for England 
(Figure 29), although mortality rates from COPD and registrations for lung cancer are higher. 
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Figure 29: Smoking profile for Wandsworth* 
 
Source: ©London Health Observatory 2012 http://www.tobaccoprofiles.info/222  
*Directly standardised rates per 100,000 
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NHS stop smoking services available in Wandsworth (in addition to advice and prescribed 
medication provided by general practices) include one-to-one support with over 160 advisors 
throughout the borough, based at six drop-in community clinics and at around 55 pharmacies, 
and a freephone number for advice. Smokers can access planned programmes of up to 12 free 
weekly sessions of behavioural support and discounted NRT products, with other tobacco-
dependence medication such as Bupropion available on prescription from GPs. 
(http://www.smokefreewandsworth.nhs.uk/default.asp). 
 
Study design 
I conducted a cross-sectional study using an anonymised extract of data from 29 of the 34 
general practices in Wandsworth containing the medical records of all adult patients (aged 16 
years and over) registered on 31 December 2007. I excluded those patients who registered in 
the last three months of 2007, as suggested in QOF business rules, or who were registered at 
a practice for less than three months in total, as practices might not have had the opportunity 
to ascertain smoking status for newly registered patients or to provide appropriate advice to 
those who were smokers.  All general practices in Wandsworth were using electronic medical 
records at the time of this study, reflecting the high use of electronic medical records in UK 
primary care.132 Missing data for the study variables were minimal. One person had 
indeterminate gender, 24 people were missing a gender and 136 people were missing an age, 
so these subjects were dropped from the study. There were no data available on exception 
reporting in the dataset. 
I divided the patients into four disease categories depending on the presence of relevant Read 
diagnosis codes223 dated prior to or during the study year: 
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• Cardiovascular disease, or having a long-term condition predisposing to 
cardiovascular disease (coronary heart disease, hypertension, heart failure, atrial 
fibrillation, stroke, transient ischaemic attack, diabetes, chronic renal failure) 
• Respiratory disease (asthma, chronic obstructive pulmonary disease) 
• Depression 
• None (having none of the above specified conditions). 
I chose the first two disease groups because smoking cessation activity for these 
conditions received greater remuneration in 2007 than for others (see Chapter 3). The 
depression group was chosen due to the known association between depression and 
smoking224 and as this group of patients would most likely require frequent contacts with 
primary care, giving extended opportunities for smoking cessation advice.  To avoid 
double counting between disease groups, I categorised patients according to the following 
hierarchy; (1) cardiovascular disease (2) respiratory disease excluding those with 
cardiovascular disease (3) depression excluding those with cardiovascular or respiratory 
disease (4) none – those patients not included in 1, 2 or 3.  
Study variables 
Binary variables for patients in each of the different disease categories were used to generate 
the following outcome measures:  
1. The proportion of patients with their smoking status ascertained in 2007  
2. The proportion of all patients coded as current smokers in 2007 
3. The proportion of smokers who were offered cessation advice or referral to smoking 
cessation services in 2007  
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I used the business rules for QOF to determine whether smoking status was ascertained in 
2007. Patients with a smoker code, ex-smokers with fewer than three consecutive ex-smoker 
codes, and never-smokers under the age of 25 need to be asked their smoking status every 15 
months if they have a smoking-related long-term condition (cardiovascular disease or 
respiratory disease as defined above) and every 27 months if they have any other or no long-
term conditions. The business rules therefore allow practice staff to permanently code (as 
having been asked their smoking status) all ex-smokers with three consecutive non-smoker 
codes and all never-smokers over 25 years.  
Ethnicity was derived from the 2001 Census Ethnic Categories. I collapsed these to give nine 
categories including ‘not-stated’. I included patients whose ethnicity was missing in the ‘not 
stated’ group because missing ethnicity is considered data missing not at random (MNAR) 
and other methods of dealing with these data such as imputation are inappropriate for 
anonymised data225 226 Excluding these patients from the analysis may have introduced bias. 
Age was recorded as a continuous variable. Patients were assigned a deprivation score based 
on individual general practice post-code using the Index of Multiple Deprivation, IMD,227, a 
validated proxy measure.52  
Statistical analysis 
I analysed the data with STATA version 11. Data analysis was conducted separately for men 
and women due to the known differences in smoking prevalence by gender within ethnic 
minority groups in the UK.228 I computed percentages of patients with smoking status 
ascertained, whether they were current smokers and whether smokers had been offered 
cessation advice, giving results for these outcomes by ethnic group within each disease 
category.  
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I then undertook individual bivariate analyses for these outcomes by age, ethnicity, IMD, and 
practice size variables, and also tested for interactions between gender and disease, and 
disease and ethnicity. All results were statistically significant so I included all as predictor 
variables in the multiple logistic regression model, adjusting for practice clustering (to 
account for the fact that patients may be more similar to each other, for example, patients 
from some ethnic groups may be more likely to be registered in certain practices than others).  
Results 
In 2007, 172,787 adult patients were registered at participating general practices in 
Wandsworth. There were 21,826 patients with cardiovascular disease (10,517 men and 
11,309 women); 12,798 with respiratory disease (6,129 men and 6,669 women); 12,312 with 
depression (4,420 men and 7,892 women); and 125,749 in the group with none of the 
diseases of interest (66,297 men and 59,452 women). Ethnicity coding was present in 92% 
patients with CVD, 82% with respiratory conditions, 80% with depression and 30% in the 
group without these chronic diseases. The numbers of patients in the different disease groups 
subdivided by ethnic group and gender are given in Table 3.  
The proportion of patients in the different disease groups, subdivided by ethnicity and gender, 
whose smoking status was ascertained, who were smokers, and who received smoking 
cessation advice are given in Tables 4-6. Key results from the multiple logistic regression 
analyses of smoking outcomes by disease group are reported below, stratified by gender, and 
adjusted for age, deprivation, practice size, and for clustering at the general practice level.
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Table 3: Descriptive statistics for disease groups in Wandsworth by ethnicity and gender in 2007  
 CVD Respiratory Depression None1 Total by ethnic group 
 Men Women Men Women Men Women Men Women Men Women All 
 N 
(%) 
N 
(%) 
N 
(%) 
N 
(%) 
N 
(%) 
N 
(%) 
N 
(%) 
N 
(%) 
N 
 
N 
 
N 
 
White British 4622 
(43.95) 
 
4668 
(41.28) 
2818 
(45.98) 
3324 
(49.84) 
2019 
(44.65) 
3706 
(46.96) 
18988 
(28.64) 
20648 
(34.73) 
28447 
(32.56) 
32346 
(37.91) 
 
60793 
(35.18) 
White Other 1124 
(10.69) 
1189 
(10.51) 
 
645 
(10.52) 
894 
(13.41) 
483 
(10.68) 
1094 
(13.86) 
9260 
(13.97) 
12679 
(21.33) 
11512 
(13.16) 
 
15856 
(18.58) 
 
27368 
(15.84) 
Black African 858 
(8.16) 
 
966 
(8.54) 
216 
(3.52) 
223 
(3.34) 
144 
(3.18) 
307 
(3.89) 
3728 
(5.62) 
3635 
(6.11) 
4946 
(5.65) 
 
5131 
(6.01) 
 
10077 
(5.83) 
Black 
Caribbean 
953 
(9.06) 
 
1485 
(13.13) 
281 
(4.59) 
419 
(6.28) 
281 
(6.21) 
424 
(5.37) 
2102 
(3.17) 
2155 
(3.62) 
3617 
(4.14) 
4483 
(5.25) 
8100 
(4.69) 
Indian 633 
(6.02) 
 
629 
(5.56) 
151 
(2.46) 
138 
(2.07) 
44 
(0.97) 
107 
(1.36) 
1814 
(2.74) 
1628 
(2.74) 
2642 
(3.02) 
 
2502 
(2.93) 
 
5144 
(2.98) 
Pakistani 466 
(4.43) 
 
345 
(3.05) 
125 
(2.04) 
115 
(1.72) 
83 
(1.84) 
114 
(1.44) 
1982 
(2.99) 
1205 
(2.03) 
2656 
(3.04) 
 
1779 
(2.09) 
 
4435 
(2.57) 
Bangladeshi 80 
(0.76) 
 
59 
(0.52) 
23 
(0.38) 
21 
(0.31) 
9 
(0.20) 
27 
(0.34) 
242 
(0.37) 
192 
(0.32) 
354 
(0.40) 
 
299 
(0.35) 
 
653 
(0.38) 
Chinese 61 
(0.58) 
61 
(0.54) 
31 
(0.51) 
52 
(0.78) 
10 
(0.22) 
30 
(0.38) 
396 
(0.60) 
501 
(0.84) 
498 
(0.57) 
 
644 
(0.75) 
 
1142 
(0.66) 
Mixed 
Ethnicity 
806 
(7.66) 
 
921 
(23.22) 
1423 
(23.22) 
927 
(13.90) 
1091 
(24.13) 
1421 
(18.01) 
23341 
(35.21) 
12174 
(20.48) 
26661 
(30.48) 
 
15443 
(17.10) 
 
42104 
(24.37) 
Ethnicity not 
stated 
914 
(8.69) 
 
986 
(8.72) 
416 
(6.79) 
556 
(8.34) 
358 
(7.92) 
662 
(8.39) 
4444 
(6.70) 
4635 
(7.80) 
6132 
(7.01) 
 
6839 
(8.02) 
 
12971 
(7.50) 
Total by 
disease group 
 
10517 
(100) 
11309 
(100) 
6129 
(100) 
6669 
(100) 
4522 
(100) 
7892 
(100) 
66297 
(100) 
59452 
(100) 
87465 
(100) 
85322 
(100) 
172787 
(100) 
1 = Not diagnosed with CVD, respiratory disease or depression; N = number of patients, % = the proportion of patients, with CVD, respiratory disease, depression or other 
conditions for each ethnic group by gender 
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Table 4: Proportion of patients in Wandsworth with smoking status ascertained in 2007, by disease group, ethnicity and gender 
 CVD Respiratory disease Depression None1 
 Men Women Men Women Men Women Men Women 
 % 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
White British 85.74 
1 
88.45 
1 
67.16 
1 
78.91 
1 
49.75 
1 
63.25 
1 
52.37 
1 
67.61 
1 
White Other 86.45 
1.07 (0.91 to 1.28) 
 
88.09 
0.98 (0.78 to 1.25) 
70.37 
1.17 (0.86 to 1.57) 
75.22 
0.84 (0.66 to 1.06) 
46.34 
0.91 (0.62 to 1.32) 
65.52 
1.12 (0.88 to 1.43) 
49.64 
1.01 (0.86 to 1.18) 
61.62** 
0.82 (0.73 to 0.92) 
Black African 92.10** 
2.31 (1.48 to 3.61) 
 
98.16** 
8.57 (5.62 to 13.05) 
70.30 
1.26 (0.78 to 2.02) 
79.17 
1.04 (0.66 to 1.65) 
62.26** 
1.92 (1.23 to 3.00) 
77.69** 
2.09 (1.27 to 3.45) 
59.37** 
1.38 (1.13 to 1.68) 
73.21** 
1.32 (1.06 to 1.65) 
Black 
Caribbean 
88.79 
1.27 (0.96 to 1.68) 
 
94.63** 
2.48 (1.55 to 3.96) 
53.50** 
0.59 (0.44 to 0.79) 
73.36* 
0.75 (0.57 to 0.99) 
39.13 
0.69 (0.43 to 1.10) 
67.82 
1.22 (0.92 to 1.63) 
44.14** 
0.69 (0.54 to 0.88) 
66.74 
0.92 (0.79 to 1.06) 
Indian 94.08** 
2.93 (1.53 to 5.60) 
 
99.03** 
15.98 (5.49 to 46.51) 
64.00 
0.74 (0.44 to 1.25) 
92.41** 
2.72 (1.36 to 5.46) 
58.82 
1.44 (0.57 to 3.64) 
80.00** 
2.35 (1.35 to 4.11) 
55.18 
1.09 (0.79 to 1.49) 
78.59** 
1.72 (1.30 to 2.28) 
Pakistani 93.66 ** 
2.84 (1.93 to 4.16) 
 
97.50** 
9.14 (2.52 to 33.14) 
69.09 
1.08 (0.57 to 2.05) 
91.80 
2.78 (0.98 to 7.86) 
73.53* 
2.77 (1.27 to 6.02) 
77.08* 
2.06 (1.10 to 3.89) 
51.84 
1.08 (0.75 to 1.57) 
73.42 
1.39 (0.95 to 2.02) 
Bangladeshi 93.94* 
2.87 (1.06 to 7.82) 
 
97.30 
6.57 (0.83 to 54.67) 
90.91 
5.68 (0.90 to 35.90) 
100‡ 33.33 
0.73 (0.06 to 8.53) 
80.00 
2.43 (0.94 to 6.31) 
50.70 
1.02 (0.63 to 1.65) 
69.23 
1.09 (0.55 to 2.15) 
Chinese 97.22 
5.47 (0.72 to 41.61) 
 
97.4 
5.82 (0.79 to 42.71) 
62.50 
0.71 (0.25 to 2.03) 
69.23 
0.69 (0.33 to 1.44) 
100† 84.62 
3.28 (0.47 to 22.80) 
56.20 
1.29 (0.90 to 1.84) 
75.42 
1.48 (0.95 to 2.31) 
Mixed 
Ethnicity 
89.07* 
1.52 (1.06 to 2.17) 
 
94.85** 
2.79 (1.56 to 5.00) 
61.03 
0.84 (0.45 to 0.92) 
73.50 
0.74 (0.54 to 1.01) 
52.03 
1.12 (0.82 to 1.53) 
64.29 
1.06 (0.75 to 1.51) 
52.05 
1.04 (0.80 to 1.34) 
68.67 
1.07 (0.89 to 1.28) 
Ethnicity not 
stated 
75.78** 
0.57 (0.43 to 0.75) 
85.20 
0.79 (0.49 to 1.28) 
56.83* 
0.64 (0.45 to 0.92) 
72.76 
0.71 (0.48 to 1.06) 
42.38 
0.72 (0.43 to 1.18) 
57.11 
0.77 (0.58 to 1.03) 
49.00 
0.81 (0.50 to 1.32) 
61.52** 
0.72 (0.59 to 0.87) 
All 
 
87.46 91.38 64.87 77.53 49.12 64.29 51.35 66.27 
1 = Not diagnosed with CVD, respiratory disease or depression; AOR = adjusted odds ratio with white British as reference group (adjusted for age, deprivation, practice size, 
and for clustering at the general practice level); CI = 95% confidence intervals; Significance in logistic regression analysis: *= p<0.05; ** = p<0.01;‡ = not included in the 
analysis due to small numbers
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Table 5: Wandsworth smoking prevalence in 2007, by disease group, ethnicity and gendera 
 CVD Respiratory disease Depression None1 
 Men Women Men Women Men Women Men Women 
 % 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
White British 
 
28.29 
1 
 
23.07 
1 
 
30.44 
1 
 
26.62 
1 
 
48.13 
1 
40.30 
1 
 
30.70 
1 
 
21.08 
1 
White Other 
 
23.58** 
0.75 (0.63 to 0.90) 
18.40** 
0.73 (0.59 to 0.89) 
28.11 
0.91 (0.70 to 1.18) 
20.13** 
0.67 (0.51 to 0.87) 
49.03 
1.04 (0.75 to 1.45) 
 
31.57** 
0.67 (0.55 to 0.82) 
33.58 
1.03 (0.94 to 1.13) 
23.37 
1.02 (0.89 to 1.16) 
Black African 
 
11.43** 
0.28 (0.19 to 0.41) 
2.44** 
0.06 (0.03 to 0.10) 
17.98** 
0.49 (0.31 to 0.78) 
10.57** 
0.31 (0.18 to 0.51) 
41.30 
0.72 (0.44 to 1.20) 
22.55** 
0.40 (0.23 to 0.69) 
20.27** 
0.51 (0.38 to 0.67) 
 
6.42** 
0.21 (0.15 to 0.29) 
 
Black 
Caribbean 
 
25.69 
0.90 (0.73 to 1.10) 
12.03** 
0.38 (0.31 to 0.48) 
37.14 
1.31 (0.95 to 1.82) 
25.20 
0.85 (0.63 to 1.16) 
61.97* 
1.69 (1.12 to 2.54) 
35.94 
0.78 (0.51 to 1.18) 
48.09** 
1.50 (1.29 to 1.74) 
26.43 
0.89 (0.78 to 1.02) 
Indian 
 
17.05** 
0.54 (0.39 to 0.75) 
1.51** 
0.05 (0.02 to 0.12) 
18.33 
0.54 (0.26 to 1.13) 
 
10.39** 
0.38 (0.19 to 0.74) 
42.86 
0.86 (0.35 to 2.11) 
13.16** 
0.23 (0.10 to 0.52) 
25.05** 
0.64 (0.52 to 0.78) 
6.21** 
0.21 (0.15 to 0.30) 
Pakistani 
 
14.16** 
0.38 (0.28 to 0.53) 
 
0.92** 
0.03 (0.01 to 0.11) 
27.12 
0.88 (0.47 to 1.66) 
4.76** 
0.14 (0.05 to 0.40) 
47.06 
0.98 (0.49 to 1.97) 
3.03** 
0.05 (0.01 to 0.36) 
33.27 
0.91 (0.78 to 1.07) 
4.80** 
0.15 (0.10 to 0.23) 
Bangladeshi 
 
13.64** 
0.36 (0.21 to 0.63) 
 
7.89** 
0.21 (0.07 to 0.64) 
25.00 
0.73 (0.16 to 3.39) 
0.00† 50.00 
1.18 (0.21 to 6.63) 
8.33 
0.13 (0.02 to 1.01) 
36.00 
0.86 (0.62 to 1.19) 
4.92** 
0.19 (0.08 to 0.44) 
Chinese 
 
18.18 
0.60 (0.27 to 1.34) 
 
5.41** 
0.15 (0.04 to 0.52) 
9.09 
0.23 (0.02 to 2.17) 
11.54 
0.35 (0.11 to 1.10) 
0.00† 45.45 
1.11 (0.13 to 2.85) 
20.18** 
0.54 (0.37 to 0.77) 
9.90** 
0.33 (0.23 to 0.49) 
Mixed 
Ethnicity 
23.95** 
0.74 (0.60 to 0.90) 
 
10.58** 
0.32 (0.24 to 0.43) 
27.78 
0.87 (0.61 to 1.23) 
22.6 
0.78 (0.58 to 1.07) 
51.24 
1.06 (0.72 to 1.55) 
42.20 
1.06 (0.83 to 1.35) 
36.80 
1.10 (0.97 to 1.24) 
21.04* 
0.84 (0.72 to 0.98) 
Ethnicity not 
stated 
30.70 
1.05 (0.80 to 1.38) 
21.48 
(0.79 (0.55 to 1.13) 
32.24 
1.07 (0.80 to 1.44) 
22.45 
1.01 (0.76 to 1.33) 
54.42 
1.32 (0.91 to 1.92) 
45.81* 
1.28 (1.02 to 1.60) 
40.35 
1.07 (0.76 to 1.49) 
26.82 
1.13 (0.93 to 1.37) 
All 
 
24.43 16.20 29.53 24.01 49.63 38.25 33.21 20.98 
a = Not diagnosed with CVD, respiratory disease or depression 2 = of patients with a smoking code, the proportion recorded as smokers (for denominators see Table 1); AOR 
= adjusted odds ratio with white British as reference group (adjusted for age, deprivation, practice size, and for clustering at the general practice level); CI = 95% confidence 
intervals; Significance in logistic regression analysis: *= p<0.05; ** = p<0.01 
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Table 6: Smokers in Wandsworth offered smoking cessation advice or referral in 2007, by disease group, ethnicity and gender   
 CVD Respiratory disease Depression None1 
 Men Women Men Women Men Women Men Women 
 % 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
% 
AOR (CI) 
White British 
 
92.37 
1 
94.80 
1 
89.00 
1 
89.82 
1 
81.45 
1 
80.11 
1 
74.26 
1 
76.93 
1 
White Other 
 
90.26 
0.79 (0.42 to 1.49) 
 
90.48** 
0.50 (0.31 to 0.81) 
94.28 
2.04 (0.75 to 5.50) 
91.58 
1.22 (0.57 to 2.65) 
73.68 
0.64 (0.30 to 1.36) 
75.78 
0.80 (0.52 to 1.23) 
73.21 
0.88 (0.75 to 1.02) 
76.61 
1.05 (0.83 to 1.33) 
Black African 
 
88.89 
0.76 (0.30 to 1.90) 
 
92.86 
0.77 (0.12 to 5.00) 
93.75 
2.07 (0.27 to 15.69) 
84.62 
0.70 (0.12 to 4.22) 
78.95 
0.93 (0.28 to 3.15) 
65.22 
0.50 (0.18 to 1.40) 
 
76.24 
1.16 (0.78 to 1.73) 
79.17 
0.82 (0.58 to 1.16) 
Black 
Caribbean 
 
94.32 
1.41 (0.78 to 2.56) 
 
95.20 
1.09 (0.34 to 3.54) 
92.31 
1.36 (0.42 to 4.45) 
90.48 
1.11 (0.49 to 2.55) 
59.09** 
0.34 (0.18 to 0.66) 
78.21 
0.95 (0.60 to 1.51) 
71.02 
1.00 (0.73 to 1.36) 
75.77 
1.01 (0.78 to 1.30) 
Indian 
 
90.67 
0.87 (0.43 to 1.76) 
 
100‡ 100‡ 75.00 
0.38 (0.07 to 1.85) 
83.33 
1.06 (0.11 to 9.61) 
80.00 
1.08 (0.10 to 11.13) 
81.58* 
1.24 (0.84 to 1.82) 
67.74 
0.88 (0.45 to 1.70) 
Pakistani 
 
89.36 
0.69 (0.29 to 1.63) 
 
100‡ 100† 100‡ 87.50 
1.65 (0.43 to 6.34) 
100‡ 79.77 
1.15 (0.64 to 2.08) 
66.67 
0.83 (0.37 to 1.86) 
Bangladeshi 
 
100† 100‡ 66.7 
0.13 (0.01 to 1.11) 
100‡ 50.00 
0.28 (0.01 to 5.57) 
100‡ 77.78 
1.67 (0.94 to 2.96) 
100‡ 
 
Chinese 87.50 
0.45 (0.08 to 2.62) 
 
100‡ 100‡ 100† Ω† 80.00 
1.19 (0.08 to 17.88) 
81.82 
1.52 (0.68 to 3.40) 
63.16 
0.77 (0.38 to 1.57) 
Mixed 
Ethnicity 
93.96 
1.30 (0.59 to 2.85) 
 
92.54 
0.68 (0.35 to 1.35) 
83.64 
0.69 (0.34 to 1.08) 
89.39 
1.01 (0.44 to 2.28) 
88.71 
1.85 (0.69 to 5.00) 
76.47 
0.92 (0.56 to 1.52) 
73.58 
1.06 (0.88 to 1.27) 
73.74 
0.91 (0.75 to 1.10) 
Ethnicity not 
stated 
96.33 
2.41 (0.66 to 8.84) 
 
90.80 
0.57 (0.16 to 2.07) 
82.65 
0.62 (0.35 to 1.08) 
86.27 
0.70 (0.39 to 1.27) 
82.05 
1.05 (0.52 to 2.21) 
89.78** 
2.14 (1.37 to 3.35) 
68.49 
0.76 (0.43 to 1.37) 
76.78 
1.02 (0.68 to 1.52) 
All 
 
92.45 93.92 88.86 89.49 80.03 80.28 73.21 76.40 
1 = Not diagnosed with CVD, respiratory disease or depression; AOR = adjusted odds ratio with white British as reference group (adjusted for age, deprivation, practice size, 
and for clustering at the general practice level); CI = 95% confidence intervals; Significance in logistic regression analysis: *= p<0.05; ** = p<0.01; ‡ = not included in the 
analysis due to small numbers 
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i) Smoking status ascertained 
Eighty nine percent of patients in the cardiovascular disease (CVD) group had their smoking 
status ascertained in 2007 while patients in the other three disease groups were less likely to 
have their smoking status ascertained compared to patients in the CVD group (72% of 
patients with respiratory disease, adjusted odds ratio (AOR) 0.53, 95% confidence intervals 
(CI) 0.42 to 0.67; 60% of patients with depression, AOR 0.25, CI 0.19 to 0.33; 60% of 
patients with none of these conditions, AOR 0.30, CI  0.22 to 0.41). Men were less likely to 
have their smoking status recorded than women across all the disease groups (62% versus 
73%, AOR 0.25, CI 0.55 to 0.61).  
For CVD, white British patients were less likely to be asked about smoking than patients 
from ethnic minority groups, with the exception of those from the white Other ethnic group, 
as shown in Table 4. For respiratory disease, there was less variation, but black Caribbean 
patients with respiratory disease were less likely to be asked about smoking than white 
British patients (63% versus 73%, AOR 0.68, CI 0.56 to 0.84). Only 57% of men with 
unstated ethnicity with respiratory disease were asked about smoking compared to 67% of 
white British men while Indian women were more likely to have their smoking status 
recorded then white British women (92% versus 79%).  
For depression, 70% of black African patients and 75% of Pakistani patients were asked 
about smoking compared with 57% of white British patients (AOR 2.02, CI 1.41 to 2.90; 
AOR 2.4, CI 1.37 to 4.21, respectively). Indian women were also more likely to be asked 
about smoking than white British women (80% versus 63%).  
For patients with none of the diseases of interest, black African patients were more likely to 
be asked about smoking than white British patients (66% versus 60%, AOR 1.36, CI 1.13 to 
1.63) as were Indian women compared with white British women (79% versus 68%). 
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However, black Caribbean men were less likely to be asked than white British men (44% 
versus 52%) as were white Other women and women with unstated ethnicity compared with 
white British women (both at 62% versus 68%). 
ii) Smoking prevalence 
The overall smoking prevalence was 26.5% (31% for men and 22% for women). Compared 
to patients with CVD, patients without CVD were more likely to smoke, and this was most 
striking for people with depression (42% of depressed patients smoked compared with 21% 
of those with CVD, AOR 2.58, CI 2.26 to 2.93). Men were more likely to smoke than women 
in all the disease groups and across almost all ethnic groups. 
Twenty eight percent of white British men with CVD were smokers and 23% of white British 
women (Table 3). Men and women with CVD in all ethnic groups except those with unstated 
ethnicity were less likely to smoke than white British patients (smoking prevalence ranged 
from 0.92% for Pakistani women to 26% for black Caribbean men). 
For respiratory disease, 30% of white British men and 26% of white British women were 
smokers. There was much less variation with ethnicity than with CVD for men, with black 
African men being the only group less likely than white British men to smoke (18% versus 
30%). Women from white Other, black African, Indian and Pakistani ethnic groups were less 
likely to smoke than white British females (20%, 11%, 10% and 5% respectively, compared 
to 27% of white British women with respiratory disease). 
The prevalence of smoking in patients with depression was extremely high at 48% for white 
males and 40% for white females. Males in all ethnic groups had smoking rates of over 40%, 
but black Caribbean men were even more likely to smoke than white British males (62% 
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versus 48%). For women with depression, only those with unstated ethnicity had higher 
smoking rates than white British women (46% versus 40%). 
In the group of patients with none of the conditions of interest smoking prevalence was 31% 
for white British men and 21% for white British women. There was considerable variation 
with ethnicity in this group, but black Caribbean men were more likely to smoke than white 
British men (48% versus 31%). Black African, Indian and Chinese patients and Pakistani 
men and women were less likely to smoke than white British patients whilst Bangladeshi and 
mixed ethnicity women were less likely to smoke than white British women in this group.  
iii) Smoking cessation advice or referral 
Smokers with depression or none of the conditions of interest were far less likely to receive 
smoking cessation advice than those in the CVD group or those with respiratory diseases 
(80% of patients with depression compared to 93% of patients with CVD and 89% with 
respiratory disease (AOR for depression compared with the CVD group was 0.34, CI 0.22 to 
0.51). Only 75% of patients with none of the conditions had smoking advice (AOR 0.27, CI 
0.17 to 0.40). Overall, rates of smoking cessation advice were similar for men and women.  
There was very little variation with ethnicity for smoking cessation advice or referral (Table 
4). The exceptions were white Other women with CVD, who were less likely to receive stop 
smoking advice compared with white British women (90% versus 95%). Black Caribbean 
men with depression were also much less likely to receive such advice compared with white 
British men (59% versus 81%) despite being more likely to smoke, as previously noted. 
However, women with depression whose ethnicity was unstated were more likely to receive 
advice compared to white British women (90% versus 80%), and Indian men from the group 
with none of the diseases were more likely to receive advice than white British men (82% 
versus 74%). 
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Key points 
A large percentage of patients with CVD had their smoking status ascertained and, if 
smokers, received smoking cessation advice. Although patients with respiratory disease were 
less likely to have their smoking status ascertained than those with CVD, smokers in both 
these disease groups received similar levels of advice. The rates of ascertainment and advice 
were considerably lower among patients with depression and those without the smoking-
related long-term conditions for which smoking cessation is maximally rewarded by QOF, 
reflecting QOF’s focus on secondary prevention in the other two disease groups  
Smoking prevalence overall was higher than the national average of 24% for men and 21% 
for women in 2007 (Health Survey for England, 2007) partly reflecting the younger 
population in Wandsworth but this finding raises concerns particularly for high risk groups of 
patients with CVD or respiratory disease. There were particularly high rates of smoking seen 
in patients with depression (particularly black Caribbean men, white British patients and 
those with unrecorded ethnicity).  
There was encouragingly little variation between ethnic groups in the provision of smoking 
cessation advice or referral, with the notable exception of black Caribbean men with 
depression, who were much less likely to receive such advice than white British men.    
Strengths and weaknesses of the study  
My study used data from a large number of patients registered at general practices in an 
ethnically diverse area of South London with relatively complete ethnicity coding. My 
findings may be generalisable to other health systems with universal coverage that utilise 
financial incentives for prevention activities.  All practices in the study used electronic 
medical records to record clinical information. While this permitted me to examine the 
delivery of cessation interventions in an extended number of ethnic categories using the data 
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collected by primary care teams, the numbers of patients were too small in a few groups to 
produce meaningful results.  
I included patients without an ethnic group category into a group where ethnicity was ‘not 
stated’ in order to avoid bias of multiple imputation as described in the methods section. 
However, this group would have included people from all the other ethnic groups and may 
have introduced bias as well. I chose to keep the group in as I considered that people who do 
not have their ethnicity recorded may behave differently to those who do, regardless of ethnic 
group. A sensitivity analysis conducted after excluding the ‘not-stated’ group could also be 
used to address this problem.  
In addition, the analysis used required multiple comparisons across 10 ethnic groups. I did 
not undertake the analysis using a Bonferonni adjustment for this, as other studies identified 
in my systematic review using similar methodology did not. Ordinarily, in tests of 
significance, α is set at 0.05, giving a 1 in 20 chance of a significant difference in outcomes 
between groups occurring by chance alone, leading to the null hypothesis being rejected 
inappropriately, called a Type I error. The Bonferonni approach adjusts for the increase in the 
chance of a Type I error caused by multiple comparisons by dividing α by the number of 
tests. This would mean for my study reporting only a p value below 0.005 (0.05/10). Other 
authors such as Perneger dispute the use of Bonferonni in epidemiological studies testing 
prior hypotheses, suggesting they are too conservative and they increase the risk of Type II 
errors, whereby the null hypothesis is rejected in error due to inadequate sample sizes.229 As 
most of my results were below p<0.001, I feel reasonably confident that the results are sound, 
although perhaps the results which were significant at the 0.05 level should be interpreted 
more cautiously. 
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My studies results were based on outcomes recorded in the medical record over the past 12 
months rather than in the past 15 months as suggested by QOF for smoking-related long-term 
conditions. This is because I had incomplete data on the date that ascertainment occurred. 
However, in practice most patients with chronic diseases are seen at least annually in primary 
care, and asking about smoking status for smokers and recent ex-smokers is built into the 
templates for most primary care IT systems. My findings are similar to previous research 
looking at the proportion of patients with smoking status ascertained every 15 months.180  
The QOF requirement for patients without smoking-related conditions in 2007 was for 
recording of smoking status every 27 months and there was no incentive at the time for 
giving advice to smokers in this group. By comparing the proportion of patients with and 
without smoking-related conditions using the same time frame shows there was relatively 
little spill over to primary prevention of the improvements in primary care achievements of 
smoking indicators seen for secondary prevention. 
I found that smoking prevalence overall at 26.5% similar to the national average of 26.0% in 
2007 but higher than the APHO estimates for Wandsworth for this year (24.2%). This partly 
reflects the younger population in Wandsworth but also illustrates the limitations of APHO 
estimates, which use modeled data but are not age-standardised, and are inaccurate for small 
areas. General practice data may be more useful for estimating smoking prevalence, 
particularly for patients with long-term conditions, as practices are financially rewarded for 
providing evidence-based care and so have an incentive to accurately record smoking 
outcomes. A study by Szatkowsky et al in 2012 compared national smoking prevalence data 
(modelled using prevalence figures obtained from the General Household Survey) with THIN 
data and found close correspondence in prevalence rates, giving credence to the use of 
general practice data to monitor smoking prevalence.230 For patients without these conditions 
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however, who may attend infrequently, smoking status may not be up to date.231 In addition, 
smoking status recorded in general practice is self-reported and not verified by CO reading or 
urinary cotinine, so subject to reporting bias as some smokers may not feel comfortable 
discussing their smoking status with general practice staff or clinicians. 
The data on recording of advice given to smokers may have been subject to recording bias in 
that patients with conditions not incentivised by the version of QOF in 2007 might have 
received smoking cessation advice from healthcare practitioners but this advice may not have 
been coded. I was unable to determine the quality of advice given, as these data were not 
available. I acknowledge, it is likely to vary considerably with some practitioners giving, just 
enough advice, or sign-posting to NHS stop smoking services, in order to input the required 
Read code for the practice to meet QOF targets. Others may advise in a well-meaning way 
but not using evidence-based methods and others may provide an evidence-based brief 
intervention, taking into account the situation of the patient at the time. Qualitative research 
may be useful in answering this question. 
The group of patients without CVD, respiratory disease or depression would have included 
patients with schizophrenia or other psychoses, conditions which were due to be added to the 
list of smoking-related long-term conditions for which the recording of smoking status and 
advice were maximally rewarded by QOF after 2007. Practices may have started recording 
smoking outcomes for these patients during 2007 in preparation for the change, but this is 
unlikely to have a major bearing on my findings given the small number of patients involved.  
My sample includes patients who would have been exception reported when calculating QOF 
payments. However, this may provide a more complete picture of the delivery of cessation 
interventions in primary care.232 I was also unable to examine quit rates in this study, as these 
are not specifically coded in primary care. 
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My observational study cannot show that the high levels of cessation interventions were due 
to the financial incentives available through QOF. However, previous research suggests 
marked improvement in smoking and other outcome measures were associated with the 
introduction of QOF.233 234 Wandsworth has many NHS stop smoking services provided 
through clinics and pharmacies, of which as detailed in the background section. This may 
have made it easier for GPs to provide advice through signposting to the services. Smoke-free 
legislation was introduced into England from 1 July 2007, and this may have impacted on the 
results observed. This may also have affected ethnic groups differently,235 for example those 
groups for whom drinking alcohol is prohibited would be less likely to be influenced by the 
smoking ban being enforced in public bars.  
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Chapter 7: Effect of financial incentives on ethnic 
disparities in smoking cessation interventions in primary 
care: before-and-after study using data from Hammersmith 
& Fulham, London 
 
Hypothesis 
As stated in Chapter 4, the null hypothesis for this research is that financial incentives do not 
affect the provision of smoking cessation activities in primary care and therefore also do not 
affect smoking prevalence, regardless of demographic group. The alternative hypothesis is 
that financial incentives do affect these outcomes. 
Main research question 
What are the effects of financial incentives on smoking cessation activities undertaken in 
healthcare, and do they affect inequalities in the provision of smoking cessation activities in 
primary care? 
Aims 
In this study I plan to examine the effect of financial incentives for the provision of smoking 
cessation activities to people without smoking-related diseases (primary prevention). I also 
aim to look at smoking outcomes with respect to inequalities in provision for people from 
different demographic groups based on age, gender, ethnicity and socio-economic status. 
Objectives 
To examine the effects of a local financial incentive scheme (QOF+) on smoking cessation 
activities, smoking prevalence, and inequalities in the provision of smoking cessation 
activities to different groups (defined by age, gender, ethnicity and socio-economic status) for 
adult patients without smoking-related long-term conditions using data from general practices 
in Hammersmith & Fulham, London, UK. 
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Background 
As previously noted, pay-for-performance schemes are becoming more widespread in 
healthcare, particularly in the USA186 187 and the UK.142 188 They aim to improve the quality 
of healthcare by financially rewarding practitioners for achieving performance targets and 
have been incorporated into many quality improvement programmes. Some financial 
incentive schemes such as the UK’s Quality and Outcomes scheme (QOF) reward smoking 
cessation work mainly for secondary prevention for smoking-related chronic diseases.  
 
The Wandsworth smoking study (Chapter 6) compared achievement of indicators for patients 
with smoking-related diseases already incentivised by QOF against achievement for patients 
without this incentive. This found much lower levels of achievement associated with the 
unincentivised patient groups. There was also evidence of inequalities in the delivery of 
smoking cessation activity, particularly for Black Caribbean men with depression. For the 
Hammersmith & Fulham study I was interested in examining the effect of additional 
incentives for patients without smoking-related diseases (primary prevention).  
 
Following up on the Wandsworth study, I was interested in examining the impact of financial 
incentives on primary prevention smoking activities in primary care, and on disparities 
smoking cessation. I carried out a before-and-after study to examine these questions using 
data from Hammersmith & Fulham, London, which introduced a local version of QOF, called 
QOF+, in which smoking prevention was incentivised for all patients, with a sub-analysis for 
pregnant women, reported in Chapter 8. 
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Methods 
 
Setting and patients 
The London Borough of Hammersmith & Fulham is situated in North West London and has a 
population of approximately 182,500 (see Figure 30, borough 1). The population is younger 
than average for London as a whole, as shown in Figure 31, and is ethnically diverse, with 
around 22% of the population from Black and Minority Ethnic groups (Greater London 
Authority 2008 Ethnic Group population predictions), compared with around 11% for the UK 
as a whole.220 
Figure 30: Map of Greater London 
 
Source: www.ons.gov.uk © Crown copyright
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Figure 31: Population pyramid for Hammersmith & Fulham 
 
Source: © Greater London Authority 2008 
 
Deprivation 
Large parts of Hammersmith & Fulham are extremely deprived, and overall the borough is 
rated as more deprived than England as a whole, with around 27% of its population living in 
the 20% most deprived areas in England, compared with an average for England of 20%. The 
map in Figure 32 shows the range of deprivation levels in Hammersmith & Fulham based on 
national IMD quintiles.221 
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Figure 32: Deprivation in Hammersmith & Fulham compared with England 2010 
 
Source: APHO and Department of Health. © Crown Copyright 2012 222 
 
 
Smoking cessation services in Hammersmith & Fulham 
Smoking levels in Hammersmith & Fulham are estimated to have stayed the same over the 
last two years according to the London Health Observatory using data from the Integrated 
Household Survey. In 2008, the baseline year for this study, 24.2% of adults and 6.3% of 
pregnant women in the borough smoked. The rates for adult smokers were similar to that of 
England for adults that year (24.1%) but better than the average for women smoking while 
pregnant in England (14.7%). By 2011 the rate of smoking in adults had dropped to 20.7% of 
adults, similar to that of England (20.0%). Smoking rates also dropped in pregnant women 
(4.2% vs 13.2% of pregnant women in England as a whole).221 Smoking-attributable 
mortality and hospital admissions are much higher than the average for England (Figure 33). 
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Figure 33: Smoking profile for Hammersmith & Fulham* 
 
Source: ©London Health Observatory 2012 http://www.tobaccoprofiles.info/222 
*Directly standardised rates per 100,000 
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NHS stop smoking services available in Hammersmith & Fulham (other than advice and 
prescribed medication provided by general practices) include one-to-one support with trained 
advisors throughout the borough, based at seven drop-in community clinics and at around 28 
pharmacies, and a free phone number for advice. Smokers can access planned programmes of 
six free weekly sessions of behavioural support and prescriptions for NRT or tobacco-
dependence medication such as Bupropion (http://www.kick-it.org.uk/). 
This high rates of smoking in the Borough at the time, with associated burden of ill-health 
and mortality, led Hammersmith & Fulham to prioritise smoking cessation activity in primary 
care through a local version of the UK’s financial incentive scheme (the Quality and 
Outcomes Framework, QOF), named QOF+.236 The scheme was introduced on 1 July 2008 
and was in place until 31 March 2011. QOF+ extended financial incentives for smoking 
cessation work to all patients for recording smoking status and providing smoking cessation 
advice or referral. It also introduced specific financial incentives for the recording of smoking 
status for pregnant women at the time of booking for antenatal care, and for the provision of 
smoking cessation advice or referral at the booking appointment for pregnant women who 
were smokers.  
In addition to smoking cessation work it also rewarded the achievement of targets for other 
prevention work such as vascular risk screening for adults aged 40-74 years and alcohol 
screening and brief intervention. For a list of the QOF+ smoking indicators see Figure 34.  
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Figure 34: Smoking indicators in QOF+ 
 
Currently national QOF rewards smoking cessation mainly for smoking-related chronic 
diseases as previously discussed, with far fewer points available for primary prevention. 
QOF+ provided additional payments for the achievement of smoking indicators aimed at all 
adults registered at participating general practices in the borough. The indicators were for 
recording of smoking status and providing smoking cessation advice to smokers or referral to 
smoking cessation services. 
Study design 
I carried out a before-and-after study using anonymised data extracted from 30 general 
practices in Hammersmith & Fulham. All the general practices had electronic medical 
records (EMR).132 The data contained the medical records of adults (aged over 16 years) 
registered between 1 July 2008 and 31 March 2011.  
Patients included in this study were those aged 15 years or over without smoking-related 
chronic diseases or mental health conditions for whom smoking cessation activities are 
already incentivised by National QOF.  
I therefore excluded patients with Read diagnosis codes223 for CHD, stroke or  
TIA, hypertension, diabetes, COPD, asthma, schizophrenia, bipolar affective disorder or 
other psychoses dated before or during the study. Patients with peripheral vascular disease 
were not excluded as this group was added to the smoking indicators after the study period. 
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Patients with CKD (US National Kidney Foundation: Stage 3 to 5) were not specifically 
excluded as the majority of these patients are also on registers for hypertension, CHD or 
diabetes.237 Data from two practices were excluded due to inaccurate recording of dates 
across all fields (dates for all registrations, deregistrations and dates of recording smoking 
indicators and diagnoses was missing or a default date of 1 January 1900). I excluded two 
patients with indeterminate gender and 1050 patients missing a date of registration. 
I used a complete case cohort study design using anonymised data from patients who were 
registered at 28 participating practices in Hammersmith & Fulham. Patients were included in 
the study if they were registered at the practices throughout the 27 months prior to the 
introduction of QOF+ on 1 July 2008 and if they remained registered for the whole QOF+ 
follow up period (1 July 2008 to 31 March 2011). Although two further practices enrolled for 
QOF+ after 1 July 2008, their patients were not eligible for inclusion in the cohort as they 
were not contributing data to the pre-QOF+ period. The reason for choosing 27 months for 
the pre-QOF+ period was because this is the period in which smoking status should be 
ascertained under National QOF business rules.  
I also carried out a sensitivity analysis with an open cohort design to see if there were 
differences in outcomes as a result of new patient checks. Patients were included in the open 
cohort if they were registered at participating practices on 1 July 2008 (for the baseline 
analysis), excluding those who registered in the three months prior to this date. I excluded 
these patients as practices might not have had sufficient time to ask these patients about 
smoking or provide brief advice (as stated in National QOF business rules) and so might have 
distorted the results for the pre-QOF+ period. Patients were included in the cohort for the 
follow up period if they were registered for at least three months during this time.  
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The reason for describing this as an open cohort is that the patients could enter or leave the 
cohort throughout the study period and contribute data as long as they were registered for at 
least three months. The reason for choosing three months as the minimum time a patient 
could be registered is that general practices do not have to include patients registered for less 
than three months in the denominator for smoking outcomes under National QOF business 
rules. 
Study variables 
The following binary outcome measures were extracted from the data:  
• Percentage of registered patients (> 15 years) with smoking status recorded at 
baseline (within 27 months before 1 July 2008) and after the introduction of QOF+ (1 
July 2008 to 31 March 2011, 33 months); 
• Percentage of those patients with a smoking status recorded whose last smoking code 
was that of smoker before and after the introduction of QOF+; 
• Percentage of smokers given smoking cessation advice before and after the 
introduction of QOF+. 
I used the QOF business rules to examine the ascertainment of smoking status, as I did for the 
Wandsworth study. I identified those ex-smokers who had three consecutive ex-smoker 
codes, and those never-smokers under the age of 25 years who had three consecutive never-
smoker codes, and coded these patients as having had their smoking status recorded. 
Similarly all never-smokers over the age of 25 years were recorded as having their smoking 
status recorded. I then determined the additional proportion of the remaining patients who 
had their smoking status recorded (of current smokers; ex-smokers with fewer than three ex-
smoker codes; and never-smokers under the age of 25 years with fewer than three never-
smoker codes).  
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I used the last smoking Read code recorded on the EMR of each patient to calculate the 
prevalence of smoking before and after the introduction of QOF+. I did not exclude patients 
whose smoking status was not ascertained within the study period as this might artificially 
reduce smoking prevalence, as smokers without smoking-related chronic diseases might not 
visit their GP regularly. I therefore included all patients with a smoking code ever recorded 
for this outcome. I used smoking advice and referral Read codes to determine the proportion 
of smokers offered advice or referral. 
I tested for interactions between gender and smoking and as the results were statistically 
significant I examined outcomes separately for men and women. Predictor variables for the 
multiple logistic regression analysis of smoking outcomes were age, ethnicity and 
deprivation. Age was categorised into four groups: under-30 years, 30-49 years; 50-69 years; 
over-70 years.  Ethnicity was derived from the 2001 Census Ethnic Categories. In order to 
maximize statistical power I collapsed these to give five categories: White; Black; South 
Asian; Mixed; Other; and a ‘not-stated’ category for those patients whose ethnicity was not 
given.  
Hammersmith & Fulham Primary Care Trust staff assigned patients a deprivation score 
(Index of Multiple Deprivation, IMD238) based on their post-code before the data were 
anonymised and extracted to a research database held at the Department of Primary Care & 
Public Health, Imperial College London. London Queen Square Research Ethics Committee 
granted ethics approval for the use of the data for research.  
Statistical analysis 
I calculated the proportions of patients with the smoking outcomes at baseline and during the 
study period. I then examined differences in these outcomes by gender, age group, ethnic 
group, deprivation, and practice size.  
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Bivariate analyses for these outcomes by age group, ethnicity, IMD were all statistically 
significant (not reported) but practice size was not. I therefore included all the predictor 
variables except practice size in a multiple logistic regression model for each study design 
adjusting for practice clustering at the general practice level. I also conducted a within-group 
analysis, adjusted for the other main variables, to determine whether QOF+ had influenced 
outcomes for some groups more or less than for others. I analysed the data with STATA 
version 11. 
Results 
1. Smoking status ascertained 
During the study period there were 41,239 patients eligible for inclusion in the study (18,716 
men and 22,523 women). Prior to the introduction of QOF+ ethnicity data were available for 
46.7% of patients, 62.3% of all patients had their smoking status ascertained (55.5% of men 
and 67.9% of women), and only two patients were exception reported for smoking indicators 
in the pre-QOF+ period.  
From 1 July 2008 to 31 March 2011 (after the introduction of QOF+) ethnicity data were 
available for 69.6% of patients, the proportion of the total who had smoking status 
ascertained had increased to 75.8% (64.2% of men and 75.8% of women), a significant 
increase (AOR for men 1.37, CI 1.18 to 1.60, p<0.001; AOR for women 1.35, CI 1.17 to 
1.56, p<0.001), and all groups benefitted from an increase. After the introduction of QOF+ 
140 patients were exception reported for smoking indicators. The proportions of patients with 
smoking ascertained before and after the introduction of QOF+, subdivided by ethnic group 
and gender, are shown in Table 7. 
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Prior to QOF+ patients aged under-30 years were less likely to have smoking status 
ascertained than patients aged 30 to 49 years (47.5% vs 59.3% for men under-30 years, AOR 
0.73, CI 0.57 to 0.95, p<0.001; 58.0% vs 70.4% for women under-30 years, AOR 0.52, CI 
0.42 to 0.66, p<0.001). However men and women aged over-70 years were more likely to 
have their status recorded than those aged 30 to 49 years (73.0% vs 59.3% for men over 70 
years, AOR 2.17, CI 1.71 to 2.74, p<0.001; and 78.9% vs 70.4% for women over 70 years, 
AOR 1.55, CI 1.26 to 1.92, p<0.001). South Asian men and men with mixed ethnicity were 
more likely to have smoking status recorded compared with White men (74.7% for South 
Asian men vs 64.6%, for White men, AOR 1.71, CI 1.27 to 2.31, p<0.001; 76.5% for men 
with Mixed ethnicity, AOR 1.87, CI 1.16 to 3.03, p<0.001). Women from Black, South Asian 
and Other ethnic groups were more likely to have their status recorded compared with White 
women. For example, 87.1% of South Asian women had their status recorded compared with 
71.6% of White women (AOR 2.81, CI 1.75 to 4.53, p<0.001). Patients with no stated 
ethnicity were much less likely to be asked.  There was no difference between the three 
deprivation categories in the chance of either men or women being asked about smoking in 
this cohort. 
After QOF+ the youngest group of men were no longer less likely to be asked about smoking, 
although women under-30 years were still less likely to be asked than women aged 30 to 49 
years (70.0% vs 76.2%, AOR 0.68, CI 0.58 to 0.80, p<0.001). Patients over-70 years were 
still more likely to be asked (75.5% vs 67.5% for men over-70 years, AOR 1.68, CI 1.29 to 
2.18, p<0.001; 85.9% vs 76.2% for women over-70 years, AOR 1.79, CI 1.42 to 2.24, 
p<0.001).  
Black men and South Asian men were more likely than White men to have their status 
recorded after the introduction of QOF+ (72.2% of Black men vs 69.8% of White men, AOR 
 172 
 
1.22, CI 1.07 to 1.39, p<0.01; 81.2% of South Asian men, AOR 1.99, CI 1.42 to 2.79, 
p<0.001). Women from all the ethnic groups except those with ethnicity not stated were more 
likely to have smoking status recorded than White women. For example, 84.8% of Black 
women had their status recorded compared with 76.7% of White women (AOR 1.93, CI 1.65 
to 2.29, p<0.001). Men and women with ethnicity not stated were still less likely to be asked 
than White patients. After QOF+ the middle and most deprived patients were less likely to be 
asked than those from more affluent areas (both genders). 
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Table 7: Patient characteristics associated with being asked about smoking in 
Hammersmith & Fulham, before and after the introduction of QOF+1 
    Pre-QOF+ Post-QOF+ 
    Men Women Men Women 
    
N       
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
Age group <30 
4869 
(47.53) 
0.73*   
(0.57-0.95) 
5532 
(58.04) 
0.52*** 
(0.42-0.66) 
3913 
(56.99) 
0.87     
(0.68-1.11) 
3943 
(69.95) 
0.68*** 
(0.58-0.80) 
  30 to 49$ 
8898 
(59.25) 
1 11547 
(70.43) 
1 8646 
(67.49) 
1 11957 
(76.16) 
1 
  50 to 69 
4386 
(54.61) 
1.13     
(0.95-1.34) 
4649 
(71.46) 
0.91     
(0.81-1.02) 
5389 
(62.68) 
1.23     
(1.00-1.50) 
5524 
(77.37) 
0.92     
(0.82-1.03) 
  70+ 
563 
(73.00) 
2.17*** 
(1.71-2.74) 
795 
(78.87) 
1.55*** 
(1.26-1.92) 
768 
(75.52) 
1.68*** 
(1.29-2.18) 
1099 
(85.90) 
1.79*** 
(1.42-2.24) 
Ethnic 
group White$ 
5508 
(64.56) 
1 1967 
(71.56) 
1 8312 
(69.80) 
1 11558 
(76.67) 
1 
  Black 
829 
(67.67) 
1.21     
(0.97-1.51) 
1196 
(77.59) 
1.53*** 
(1.28-1.83) 
1177 
(72.22) 
1.22**    
(1.07-1.39) 
1777 
(84.81) 
1.93*** 
(1.65-2.26) 
  
South 
Asian 
483 
(74.74) 
1.71*** 
(1.27-2.31) 
675 
(87.11) 
2.81*** 
(1.75-4.53) 
680 
(81.18) 
1.99*** 
(1.42-2.79) 
905 
(93.26) 
4.56*** 
(2.74-7.58) 
  Mixed 
153 
(76.47) 
1.87*    
(1.16-3.03) 
243 
(75.72) 
1.47     
(0.93-2.31) 
293 
(72.35) 
1.22     
(0.87-1.71) 
426 
(82.63) 
1.71**   
(1.26-2.33) 
  Other 
911 
(68.17) 
1.21     
(0.99-1.47) 
1302 
(77.50) 
1.44*** 
(1.22-1.69) 
1629 
(68.26) 
0.95     
(0.75-1.21) 
1941 
(80.68) 
1.35*   
(1.01-1.80) 
  Not stated 
10832 
(47.78) 
0.52*** 
(0.43-0.64) 
11,140 
(61.79) 
0.65*** 
(0.53-0.79) 
6625 
(52.75) 
0.51*** 
(0.41-0.64) 
5916 
(66.78) 
0.65*** 
(0.52-0.80) 
Deprivation 
level† Least$ 
5890 
(56.60) 
1 7409 
(68.62) 
1 5858 
(66.51) 
1 7384 
(77.78) 
1 
  Middle 
5959 
(53.97) 
0.91     
(0.81-1.02) 
7,175 
(68.36) 
1.01     
(0.90-1.13) 
6143 
(63.47) 
0.89*     
(0.79-0.99) 
7408 
(75.59) 
0.88*** 
(0.83-0.94) 
  Most 
6613 
(56.06) 
0.99     
(0.84-1.17) 
7703 
(66.62) 
0.92     
(0.80-1.06) 
6461 
(62.90) 
0.86*   
(0.74-0.99) 
7495 
(74.14) 
0.77*** 
(0.68-0.88) 
Number (%) with 
smoking status recorded 
10392 
(55.52)  
15293 
(67.90)  
12023 
(64.24)  
17082 
(75.84)  
Total N 18716 
 
22523 
 
18,716 
 
22523 
 
1 = Patients in Hammersmith & Fulham without diseases specifically incentivised for smoking cessation activities under 
national QOF;        N = denominator (number of registered adult patients); % = percentage of patients with smoking status 
ascertained; AOR = Adjusted Odds Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence 
Interval;   $ = Reference group; † = missing IMD (490 pre/post QOF+); * = p<0.05; ** = p<0.01; *** = p<0.001
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2. Smoking prevalence  
Smoking prevalence at baseline was 20.0% (25.0% of men and 16.1% of women). After the 
introduction of QOF+ smoking prevalence fell to 16.2% (20.8% of men and 12.5% of 
women). Compared with the pre-QOF+ period, the AOR for smoking prevalence was 0.79 
for men (CI 0.75 to 0.83, p<0.001) and 0.77 for women (CI 0.72 to 0.82, p<0.001). Smoking 
prevalence, stratified by gender before and after the introduction of QOF+, is given in Table 
8. 
Pre-QOF+ smoking rates for men were lower among patients aged under-30 years and in 
those aged over-70 years compared with those aged 30 to 49 years (20.2% of men under-30 
years vs 27.5% of men aged 30 to 49, AOR 0.68, CI 0.55 to 0.83, p<0.001; 11.7% of men 
over-70 years, AOR 0.36, CI 0.27 to 0.53, p<0.001). Women aged over-70 years were the 
only age group in this cohort less likely to smoke than women aged 30 to 49 years (6.9% vs 
16.7%, AOR 0.38, CI 0.26 to 0.56, p<0.001).  
Smoking rates were lower in Black, South Asian and Other men compared with White men 
(21.8% of Black men smoked vs 25.5% of White men, AOR 0.73, CI 0.57 to 0.94, p<0.05; 
15.27% of South Asian men smoked, AOR 0.49, CI 0.36 to 0.69, p<0.001; 20.9% of Other 
men smoked, AOR 0.75, CI 0.62 to 0.89, p<0.001). Women from Black, South Asian and 
Other groups were also less likely to smoke than White women, with the South Asian women 
being least likely to smoke of all groups (3.3% vs 18% of White women, AOR 0.15, CI 0.07 
to 0.31, p<0.001).  
Smoking rates were higher in the middle and most deprived groups compared with those 
from the most affluent areas. For example, 28.6% of men in the most deprived areas smoked 
compared with 20.3% of men in the least deprived areas (AOR 1.42, CI 1.42 to 1.99, 
p<0.001). 
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After QOF+, smoking rates reduced in all age groups, and remained significantly lower in 
men aged under-30 years and in men and women aged over-70 years compared with those 
aged 30 to 49 years.  
Smoking rates dropped among White men such that they were now not significantly greater 
than those for Black men and men with Mixed ethnicity now were more likely to smoke than 
White men (28.1% vs 21.3%, AOR 1.34, CI 1.07 to 1.66, p<0.05). South Asian men and men 
with Other ethnicity continued to have lower rates of smoking than White men (13.2% for 
South Asian men vs 21.3% for White men, AOR 0.52, CI 0.39 to 0.71, p<0.001; 18.1% for 
Other men, AOR 0.73, CI 0.39 to 0.93, p<0.001). Smoking rates among Black, South Asian 
and Other women remained lower than those of White women. For example, only 2.1% of 
South Asian women smoked compared with 14.6% of White women (AOR 0.13, CI 0.06 to 
0.24, p<0.005). Smoking rates remained higher among the middle and most deprived groups 
compared with those from the most affluent areas following the introduction of QOF+. 
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Table 8: Patient characteristics associated with having a latest smoking code of ‘current 
smoker’ pre/post QOF+ in Hammersmith & Fulham 
    Pre-QOF+ Post-QOF+ 
    Men Women Men Women 
    
N       
(%) 
AOR       
(CI) 
N       
(%) 
AOR       
(CI) 
N       
(%) 
AOR       
(CI) 
N       
(%) 
AOR       
(CI) 
Age group <30 
3899 
(20.18) 
0.68*** 
(0.55-0.83 
1923 
(16.51) 
1.06     
(0.92-1.23) 
3531 
(17.08) 
0.65*** 
(0.54-0.78) 
3781 
(11.16) 
0.88     
(0.73-1.08) 
  30 to 49$ 
8091 
(27.52) 
1 10960 
(16.67) 
1 8357 
(21.79) 
1 11735 
(13.41) 
1 
  50 to 69 
3657 
(26.39) 
1.07     
(0.97-1.18) 
4373 
(15.73) 
1.09     
(0.99-1.21) 
4781 
(22.97) 
0.94     
(0.88-1.01) 
5364 
(12.62) 
1.08     
(0.98-1.21) 
  70+ 
515 
(11.65) 
0.38*** 
(0.27-0.53) 
754 
(6.90) 
0.38*** 
(0.26-0.56) 
728 
(13.19) 
0.52*** 
(0.43-0.62) 
1071 
(7.00) 
0.50*** 
(0.36-0.69) 
Ethnic 
group White$ 
5373 
(25.54) 
1 7822 
(17.97) 
1 8243 
(21.33) 
1 11525 
(14.56) 
1 
  Black 
810 
(21.85) 
0.73*    
(0.57-0.94) 
1175 
(9.28) 
0.41*** 
(0.31-0.54) 
1165 
(22.15) 
0.96     
(0.79-1.15) 
4775 
(8.51) 
0.48*** 
(0.38-0.61) 
  
South 
Asian 
478 
(15.27) 
0.49*** 
(0.36-0.69) 
663 
(3.32) 
0.15*** 
(0.07-0.31) 
677 
(13.15) 
0.52*** 
(0.39-0.71) 
903 
(2.10) 
0.12*** 
(0.06-0.24) 
  Mixed 
152 
(30.26) 
1.17     
(0.82-1.68) 
240 
(19.58) 
0.95     
(0.60-1.52) 
292 
(28.08) 
1.34*     
(1.07-1.66) 
425 
(12.00) 
0.69     
(0.46-1.03) 
  Other 
885 
(20.90) 
0.75**   
(0.62-0.89) 
1277 
(9.55) 
0.46*** 
(0.36-0.60) 
1504 
(18.09) 
0.82**   
(0.73-0.93) 
1880 
(6.81) 
0.41*** 
(0.33-0.52) 
  Not stated 
8464 
(25.83) 
1.01     
(0.85-1.21) 
9833 
(17.02) 
0.93     
(0.78-1.11) 
5516 
(21.01) 
1.00     
(0.84-1.17) 
5443 
(13.25) 
0.88     
(0.78-1.01) 
Deprivation   
level† Least$ 
5006 
(20.38) 
1 6846 
(13.94) 
1 5384 
(16.51) 
1 7161 
(10.29) 
1 
  Middle 
5140 
(25.49) 
1.38**    
(1.14-1.66) 
6713 
(16.52) 
1.25*** 
(1.13-1.38) 
5702 
(20.66) 
1.35*** 
(1.15-1.60) 
7241 
(13.19) 
1.38*** 
(1.25-1.52) 
  Most 
5,16 
(28.58) 
1.68*** 
(1.42-1.99) 
7235 
(17.83) 
1.45*** 
(1.27-1.64) 
6096 
(24.62) 
1.74*** 
(1.48-2.03) 
7328 
(14.14) 
1.60*** 
(1.42-1.81) 
Number (%) of smokers 
4039 
(24.99) 
 3380 
(16.09) 
 3618 
(20.80) 
 2748 
(12.52) 
 
Total N   16162  32320  17,397  21951  
N = denominator (number of patients with a smoking code); % = percentage of smokers; AOR = Adjusted Odds Ratio (adjusted 
for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence Interval; $ = Reference group; † = missing IMD 
(416 pre-QOF+; 436 post-QOF+); * = p<0.05; ** = p<0.01; *** = p<0.001 
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3. Smoking advice 
Before the introduction of QOF+, 35.4% of smokers in the complete case cohort were given 
advice (32.7% of men and 35.4% of women). After the introduction of QOF+ this proportion 
increased to 54.0% (54.0% of men and 54.1% of women). The AOR for men being given 
advice after the introduction of QOF+ compared with the prior period was 2.29 (CI 1.45 to 
3.61, p<0.001) and 2.09 for women (CI 1.38 to 3.17, p<0.01. The proportions of smokers 
receiving advice pre/post-QOF+, stratified by gender, are given in Table 9. 
Prior to QOF+, there was little variation in the chance of smokers getting advice. Men aged 
over-70 years were somewhat more likely to receive advice compared with men aged 30 to 
49 years (46.7% vs 34.56%, AOR 1.69, CI 1.06 to 2.69, p<0.05). Men with Mixed ethnicity 
were statistically more likely to receive smoking cessation advice than White men (58.7% vs 
36.0%, AOR 2.60, CI 1.64 to 4.12, p<0.001), but men whose ethnicity was not stated were 
less likely (29.1% vs 36.0%, AOR 0.72, CI 0.56 to 0.93, p<0.05). There were no statistically 
significant differences in rates of smoking advice among the different demographic groups 
for women, or for either gender for different deprivation areas.  
After the introduction of QOF+ smoking cessation advice to smokers was still provided 
relatively equitably. There were now no statistically significant differences in rates of advice 
for different age groups for men, but women aged under-30 years were more likely to receive 
advice than those aged 30 to 49 years (63.7% vs 52.9%, AOR 1.73, CI 1.29 to 2.30, 
p<0.001). There remained no significant difference in rates of advice to patients from 
different ethnic groups of those living in areas with different levels of deprivation. 
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Table 9: Patient characteristics associated with smokers receiving cessation advice or 
referral pre/post QOF+ in Hammersmith & Fulham 
    Pre-QOF+ Post-QOF+ 
    Men Women Men Women 
    
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N           
(%) 
AOR       
(CI) 
Age group <30 
787 
(34.56) 
1.08     
(0.79-1.48) 
813 
(36.65) 
0.93     
(0.68-1.28) 
603 
(54.23) 
1.01     
(0.79-1.28) 
422 
(63.74) 
1.73*** 
(1.29-2.30) 
  30 to 49$ 
2,227 
(31.43) 
1 1827 
(33.94) 
1 1821 
(52.61) 
1 1,574 
(52.86) 
1 
  50 to 69 
965 
(33.16) 
0.91     
(0.79-1.04) 
688 
(37.50) 
0.83     
(0.68-1.00) 
1098 
(55.65) 
0.93     
(0.76-1.13) 
677 
(50.96) 
1.09     
(0.86-1.38) 
  70+ 
60   
(46.67) 
1.69*    
(1.06-2.69) 
52   
(40.38) 
1.18     
(0.58-2.40) 
96   
(58.33) 
1.06     
(0.70-1.59) 
75   
(54.67) 
1.17     
(0.62-2.23) 
Ethnic 
group White$ 
1372 
(36.01) 
1 1406 
(36.77) 
1 1758 
(55.75) 
1 1678 
(55.01) 
1 
  Black 
177 
(40.11) 
1.19     
(0.83-1.71) 
109 
(45.87) 
1.47     
(1.00-2.18) 
258 
(58.53) 
1.09     
(0.79-1.51) 
151 
(55.63) 
0.94     
(0.71-1.26) 
  
South 
Asian 
73   
(42.47) 
1.18     
(0.57-2.47) 
22   
(40.91) 
1.21     
(0.49-2.95) 
89   
(46.07) 
0.70     
(0.46-1.06) 
19   
(57.89) 
1.02     
(0.34-3.13) 
  Mixed 
46   
(58.70) 
2.60*** 
(1.64-4.12) 
47   
(53.19) 
2.02     
(0.87-4.69) 
82   
(65.85) 
1.50     
(0.72-3.13) 
51   
(64.71) 
1.39     
(0.71-2.71) 
  Other 
185 
(32.97) 
0.89     
(0.63-1.26) 
122 
(31.97) 
0.80     
(0.52-1.24) 
272 
(56.62) 
1.03     
(0.74-1.43) 
128 
(58.59) 
1.11     
(0.75-1.63) 
  Not stated 
2186 
(29.09) 
0.72*    
(0.56-0.93) 
1674 
(33.27) 
0.84     
(0.68-1.04) 
1159 
(49.35) 
0.78     
(0.61-1.00) 
721 
(50.07) 
0.79     
(0.62-1.01) 
Deprivation   
level† Least$ 
1020 
(31.37) 
1 954 
(32.91) 
1 889 
(52.42) 
1 737 
(52.92) 
1 
  Middle 
1310 
(32.82) 
1.07     
(0.87-1.32) 
1109 
(399.00) 
1.14     
(0.89-1.46) 
1178 
(54.41) 
1.09     
(0.86-1.37) 
955 
(56.13) 
1.13     
(0.87-1.46) 
  Most 
1662 
(32.85) 
1.05     
(0.81-1.36) 
1290 
(479.00) 
1.18     
(0.84-1.65) 
1501 
(55.10) 
1.10     
(0.81-1.48) 
1036 
(53.67) 
1.01          
(0.73-1.38) 
Number (%) of smokers 
1320 
(32.68) 
 1197 
(35.41) 
 1952 
(53.95) 
 1487 
(54.11) 
 
Total N   4039  3380  3618  2748  
N = denominator (smokers); % = percentage of smokers receiving advice or referral; AOR = Adjusted Odds Ratio (adjusted for 
age group, ethnicity, IMD and practice clustering); CI = 95% Confidence Interval; $ = Reference group; † = missing IMD (74 
pre-QOF+; 70 post-QOF+); * = p<0.05; ** = p<0.01; ** = p<0.001 
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4. Differential effect of QOF+ in the complete case cohort on individual groups  
Table 10 shows the within-group comparisons for the effect QOF+ for men and women of 
different age groups, ethnic groups and deprivation levels, in each case adjusted for the other 
variables and for practice clustering. As there were statistically significant improvements for 
almost all age groups and ethnic groups, and for all levels of deprivation, in the following 
paragraphs I shall describe the groups who appeared to benefit the most and those who 
appeared not to benefit from QOF+.  
Smoking status 
The youngest age groups saw the biggest improvements in recording rates (for men aged 
under-30 years, AOR 2.54, CI 2.33 to 2.77, p<0.001; for women under-30 years, AOR 2.48, 
CI 2.28 to 2.71, p<0.001). South Asian patients saw a greater relative benefit (AOR for 
women 2.61, CI 1.87 to 3.64, p<0.001).  Men aged over-70 years were not significantly more 
likely to be asked about smoking after QOF+ than previously. Men with Mixed ethnicity 
were as likely to be asked about smoking after QOF+ as before. 
Smoking prevalence 
Women aged under-30 years and men aged 30 to 49 years saw the biggest improvements 
following the introduction of QOF+ (AOR for women under-30 0.64, CI 0.56 to 0.72, 
p<0.001; AOR for men aged 30 to 49 0.73, CI 0.58 to 0.79, p<0.001).  Patients aged over-70 
years were the only group not to have reduced their smoking rates significantly after the 
introduction of QOF+. Black and South Asian patients and men with Mixed or Other 
ethnicity had similar rates of smoking before and after the introduction of QOF+. 
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Smoking advice 
Women under-30 received the biggest improvement in smoking cessation advice levels 
(AOR 2.03, CI 2.38 to 3.88, p<0.001). Patients aged over-70 years were not significantly 
more likely to be given smoking cessation advice after the introduction of QOF+. South 
Asian patients and those with Mixed ethnicity also received similar levels of advice after 
QOF+ as before. Improvements for the different deprivation groups were similar.
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Table 10: Within-group analysis: effect of QOF+ on smoking outcomes in Hammersmith & Fulham1  
    Smoking status ascertained post QOF+ Smokers post QOF+ Smoking advice to smokers post QOF+ 
    Men Women Men Women Men Women 
    AOR CI AOR CI AOR CI AOR CI AOR CI AOR CI 
Age group <30 2.34*** 2.14-2.56 2.26*** 2.07-2.47 0.83** 0.74-0.93 0.66*** 0.58-0.75 2.22*** 1.78-2.77 2.95*** 2.30-3.79 
  30 to 49 1.21*** 1.14-1.29 1.16*** 1.10-1.24 0.76*** 0.71-0.82 0.80*** 0.74-0.86 2.38*** 2.09-2.72 2.11*** 1.83-2.43 
  50 to 69 1.07 0.98-1.16 1.16** 1.06-1.28 0.81*** 0.72-0.90 0.79*** 0.70-0.89 2.11*** 1.75-2.56 1.51*** 1.20-1.89 
  70+ 0.86 0.65-1.13 1.15 0.88-1.51 1.02 0.70-1.49 1.08 0.72-1.62 1.70 0.81-3.57 2.76* 1.13-6.71 
Ethnic group White 1.28*** 1.19-1.38 1.27*** 1.19-1.36 0.77*** 0.71-0.84 0.79*** 0.73-0.86 2.22*** 1.92-2.57 2.13*** 1.84-2.47 
  Black 1.49*** 1.23-1.81 1.84*** 1.52-2.23 0.99 0.79-1.23 0.93 0.71-1.21 2.03** 1.36-3.02 1.47 0.88-2.47 
  
South 
Asian 
1.72*** 1.30-2.29 2.50*** 1.77-3.52 0.82 0.58-1.15 0.65 0.35-1.22 1.30 0.67-2.51 2.13 0.52-8.72 
  Mixed 1.06 0.68-1.64 1.71** 1.16-2.51 0.88 0.56-1.39 0.59* 0.38-0.92 1.37 0.62-3.01 1.63 0.69-3.84 
  Other 1.23* 1.03-1.46) 1.31** 1.10-1.57 0.83 0.67-1.03 0.70** 0.54-0.90 2.54*** 1.71-3.77 3.18*** 1.87-5.40 
  Not stated 1.44*** 1.35-1.54 1.40*** 1.31-1.50 0.76*** 0.70-0.83 0.74*** 0.68-0.82 2.43*** 2.09-2.82 2.07*** 1.73-2.47 
Deprivation level Least 1.35*** 1.25-1.46 1.35*** 1.25-1.46 0.79*** 0.71-0.87 0.76*** 0.68-0.85 2.20*** 1.81-2.66 2.25*** 1.83-2.76 
  Middle 1.42*** 1.31-1.53 1.32*** 1.23-1.43 0.77*** 0.70-0.85 0.79*** 0.71-0.87 2.33*** 1.98-2.76 2.24*** 1.86-2.69 
  Most 1.35*** 1.26-1.46) 1.39*** 1.29-1.50 0.81*** 0.75-0.88 0.76*** 0.690.84 2.32*** 2.00-2.69 1.89*** 1.59-2.25 
1 = Adjusted odds ratios (AOR)(adjusted by age group, ethnicity, IMD and practice clustering) for outcome for each group post-QOF+ compared with pre-QOF+  
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Sensitivity analysis results 
1. Smoking status ascertained 
On 31 June 2008 there were 109,072 patients eligible for inclusion in the study registered at 
participating general practices in Hammersmith & Fulham (47,375 men and 61,697 women). 
From 1 July 2008 to 31 March 2011 (after the introduction of QOF+) the number of patients 
in the cohort increased to 151,511 (66,287 men and 85,224 women). Prior to the introduction 
of QOF+ ethnicity data were available for only 20.1% of patients in the open cohort 
compared with 74.0% after. Only two patients were exception reported for smoking 
indicators in the pre-QOF+ period, compared with 406 patients after the introduction of 
QOF+. For both time points these patients represent a very small proportion of the study 
sample. 
Before QOF+, 61.7% of patients had their smoking status ascertained (56.2% of men and 
65.9% of women). After the introduction of QOF+ the proportion of patients who had their 
smoking status recorded was 75.6% (70.1% of men and 79.9% of women), a significant 
increase compared with the pre-QOF+ period (AOR for men 1.32, CI 1.17 to 1.48, p<0.001; 
AOR for women 1.64, CI 1.45 to 1.85, p<0.001), and the only groups not to see an increase 
were patients with Other ethnicity and White women. The proportions of patients with 
smoking ascertained before and after the introduction of QO+, subdivided by ethnic group 
and gender, are shown in Table 11. 
Before QOF+ men aged 50 to 69 years and men over-70 years were less likely to have 
smoking status ascertained than men aged 30 to 49 years (40.5% vs 60.1% for men aged 50 
to 69 years, AOR 0.53, CI 0.45 to 0.61, p<0.001; 45.7% for men over-70 years, AOR 0.68, 
CI 0.51 to 0.91, p<0.01). Black men were less likely to have smoking status recorded 
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compared with White men (76.2% vs 79.8%, AOR 0.81, CI 0.68 to 0.96, p<0.05). South 
Asian and Other women were more likely to have their status recorded compared with White 
women (88.9% of South Asian women had their status recorded compared with 83.3% of 
White women, AOR 1.61, CI 1.31 to 1.96, p<0.001; 87.8% of Other women, AOR 1.46 to 
1.75, p<0.001). Patients with no stated ethnicity were much less likely to be asked.  There 
was no difference between the three deprivation categories in the chance of either men or 
women being asked about smoking in this cohort. 
After QOF+ men aged 50 to 69 years and over-70 years were still less likely to be asked 
about smoking than those aged 30 to 49 years despite a greater proportion being asked in 
each of the age groups. However women aged under-30 years were now more likely to be 
asked than women aged 30 to 49 years (82.3% vs 79.1%, AOR 1.12, CI 1.04 to 1.21, 
p<0.001).  
Black men were as likely as White men to be have their smoking status recorded after the 
introduction of QOF+ but South Asian men were now more likely than White men to have 
their status recorded (86.1% vs 78.4, AOR 1.75, CI 1.13 to 2.70, p<0.001). Women from all 
the ethnic groups except Not Stated were more likely to have smoking status recorded than 
White women. For example, 88.0% of Black women had their status recorded compared with 
82.8% of White women (AOR 1.63, CI 1.43 to 1.86, p<0.001). Men and women with 
unstated ethnicity were still less likely to be asked than White patients, although the 
proportions asked had improved considerably compared with the pre-QOF+ period. 
However, after QOF+ the most deprived patients were less likely to be asked than those from 
more affluent areas (both genders). 
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Table 11: Patient characteristics in the Hammersmith & Fulham open cohort associated 
with being asked about smoking, before and after the introduction of QOF+1 
    Pre-QOF+ Post-QOF+ 
    Men Women Men Women 
    
N       
(%) 
AOR       
(CI) N       (%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
Age group <30 
13734 
(60.12) 
0.88     
(0.73-1.06) 
21487 
(64.71) 
0.97     
(0.80-1.18) 
18963 
(74.18) 
0.97     
(0.89-1.05) 
30629 
(82.28) 
1.12**   
(1.04-1.21) 
  30 to 49 
21123 
(62.62) 
1 29459 
(65.39) 
1 33610 
(75.17) 
1 43002 
(79.12) 
1 
  50 to 69 
10812 
(40.48) 
0.53*** 
(0.45-0.61) 
8595 
(65.00) 
1.14     
(0.95-1.37) 
11992 
(50.94) 
0.47*** 
(0.41-0.55) 
9552 
(75.80) 
0.92     
(0.82-1.02) 
  70+ 
1706 
(45.72) 
0.68**    
(0.51-0.91) 
2156 
(58.40) 
0.98     
(0.78-1.23) 
1722 
(61.09) 
0.67**   
(0.50-0.89) 
2041 
(78.69) 
1.15     
(0.91-1.45) 
Ethnic 
group White 
15754 
(79.75) 
1 24637 
(83.33) 
1 35485 
(78.40) 
1 51680 
(82.78) 
1 
  Black 
1850 
(76.16) 
0.81*   
(0.68-0.96) 
2740 
(83.36) 
1.04     
(0.89-1.22) 
4072 
(77.82) 
1.00     
(0.92-1.09) 
5227 
(88.02) 
1.63*** 
(1.43-1.86) 
  
South 
Asian 
1194 
(79.56) 
0.99     
(0.83-1.17) 
1359 
(88.89) 
1.61*** 
(1.31-1.96) 
2922 
(86.11) 
1.75*    
(1.13-2.70) 
2559 
(92.50) 
2.64*** 
(1.75-4.00) 
  Mixed 
380 
(82.89) 
1.23     
(0.77-1.95) 
597 
(83.42) 
1.05     
(0.79-1.41) 
1001 
(77.72) 
0.98     
(0.83-1.15) 
1398 
(86.41) 
1.41*** 
(1.18-1.67) 
  Other 
2729 
(81.90) 
1.12     
(0.99-1.26) 
4080 
(87.82) 
1.46*** 
(1.22-1.75) 
7215 
(79.07) 
1.01     
(0.89-1.15) 
10124 
(87.20) 
1.45*** 
(1.20-1.75) 
  
Not 
stated 
25468 
(36.00) 
0.15*** 
(0.12-0.19) 
28284 
(44.39) 
0.16*** 
(0.12-0.22) 
15592 
(41.73) 
0.23*** 
(0.19-0.27) 
14196 
(58.10) 
0.30*** 
(0.26-0.35) 
Deprivation 
level† Least 
15336 
(57.63) 
1 21094 
(67.06) 
1 21585 
(71.28) 
1 29875 
(80.86) 
1 
  Middle 
15467 
(56.04) 
0.93     
(0.80-1.07) 
20085 
(66.91) 
1.03     
(0.87-1.23) 
21771 
(70.41) 
0.94     
(0.84-1.05) 
27915 
(80.12) 
0.94     
(0.86-1.02) 
  Most 
15080 
(55.49) 
0.89     
(0.73-1.08) 
18511 
(63.55) 
0.87     
(0.70-1.08) 
21858 
(62.21) 
0.85*    
(0.73-0.98) 
26176 
(78.62) 
0.80*** 
(0.71-0.89) 
Number (%) of 
smokers 
26641 
(56.23) 
 40657  
(65.90) 
 46,493 
(70.14) 
 68072 
(79.87) 
 
  
Total N 47375  61697  66287  85224  
 
1 = Patients in Hammersmith & Fulham without diseases specifically incentivised for smoking cessation activities under 
national QOF; N = denominator (number of registered adult patients); % = percentage of patients with smoking status 
ascertained; AOR = Adjusted Odds Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence 
Interval; $ = Reference group; † = missing IMD (3498 pre-QOF+; 1258 post-QOF+); * = p<0.05; ** = p<0.01; *** = p<0.001
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2. Smoking prevalence  
Smoking prevalence at baseline was 21.0% (25.8% of men and 17.6% of women). After the 
introduction of QOF+ smoking prevalence fell to 18.7% (23.7% of men and 15.1% of 
women). Compared with the pre-QOF+ period the AOR for smoking prevalence was 0.88 for 
men (CI 0.83 to 0.93, p<0.001) and 0.84 for women (CI 0.80 to 0.88, p<0.001). Smoking 
prevalence, stratified by gender before and after the introduction of QOF+, is given in Table 
12. 
Pre-QOF+ smoking rates for men were lower among patients aged under-30 years and in 
those aged over-70 years compared with those aged 30 to 49 years, as found with the other 
studies (23.4% of men under-30 years vs 27.3% of men aged 30 to 49, AOR 0.79, CI 0.71 to 
0.87, p<0.001; 14.5% of men over-70 years, AOR 0.44, CI 0.36 to 0.53, p<0.001). Women 
aged under-30 years were more likely to smoke than those aged 30 to 49 years (19.5% vs 
16.9%, AOR 1.16, CI 1.06 to 1.27, p<0.01). Women aged over-70 years were less likely to 
smoke than women aged 30 to 49 years (8.4% vs 19.5%, AOR 0.44, CI 0.36 to 0.52, 
p<0.001).  
Smoking rates were lower in Black and South Asian men compared with White men (24.7% 
of Black men smoked vs 23.1% of White men, AOR 0.81, CI 0.69 to 0.96, p<0.05; 18.6% of 
South Asian men smoked, AOR 0.61, CI 0.46 to 0.80, p<0.001). Women from Black, South 
Asian and Other groups were also less likely to smoke than White women, with the South 
Asian women being least likely to smoke of all groups (3.81% vs 19.8% of White women, 
AOR 0.16, CI 0.09 to 0.27, p<0.001).  
Smoking rates were again higher in the middle and most deprived groups compared with 
those from the most affluent areas.  
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After QOF+, smoking rates remained significantly lower in men aged under-30 years but 
rates in men aged 50 to 69 years were now higher than those aged 30 to 49 years (25.9% vs 
22.5%, AOR 1.09, CI 1.02 to 1.17. Smoking rates remained higher in women aged under-30 
years compared with women aged 30 to 49 years (16.9% vs 14.6%, AOR 1.17, CI 1.08 to 
1.26, p<0.001). Smoking prevalence remained lower in men and women aged over-70 years 
compared with those aged 30 to 49 years. 
Black men were no more likely to smoke than White men after the introduction of QOF+ and 
men with Mixed ethnicity were now more likely to smoke than White men (28.7% vs 24.1%, 
AOR 1.14, CI 1.01 to 1.29, p<0.05). South Asian men continued to have lower rates of 
smoking than White men (17.5% vs 24.1%, AOR 0.61, CI 0.43 to 0.88, p<0.01). Smoking 
rates among Black, South Asian and Other women remained lower than those of White 
women. For example, 8.5% of Black women smoked compared with 17.2% of White women 
(AOR 0.40, CI 0.34 to 0.48, p<0.005). Smoking rates again remained higher among those 
from the middle and most deprived areas compared with those from the most affluent areas 
following the introduction of QOF+. 
3. Smoking advice 
Before the introduction of QOF+, 37.4% of smokers in the open cohort were given advice 
(36.2% of men and 38.7% of women). After the introduction of QOF+ this proportion 
increased to 59.9% (59.9% for both men and women). The AOR for men being given advice 
after the introduction of QOF+ compared with the prior period was 2.33 (CI 1.30 to 4.14, 
p<0.01) and 2.13 for women (CI 1.28 to 3.54, p<0.01. The proportions of smokers receiving 
advice pre/post-QOF+, stratified by gender, are given in Table 13. 
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Table 12: Patient characteristics in the Hammersmith & Fulham open cohort associated 
with having a latest smoking code of ‘current smoker’ pre/post QOF+  
    Pre-QOF+ Post-QOF+ 
    Men Women Men Women 
    
N       
(%) 
AOR       
(CI) 
N       
(%) 
AOR       
(CI) 
N       
(%) 
AOR       
(CI) 
N       
(%) 
AOR       
(CI) 
Age group <30 
10611 
(23.39) 
0.79*** 
(0.71-0.87) 
17494 
(19.51) 
1.16** (1.06-
1.27) 
17710 
(22.48) 
0.90*   
(0.83-0.98) 
29692 
(16.86) 
1.17*** 
(1.08-1.26) 
  30 to 49 
17393 
(27.25) 
1 23977 
(16.91) 
1 32460 
(24.06) 
1 41587 
(14.55) 
1 
  50 to 69 
6400 
(27.70) 
1.02     
(0.93-1.12) 
7215 
(16.87) 
0.99     
(0.91-1.07) 
8666 
(25.86) 
1.09*   
(1.02-1.17) 
8971 
(13.60) 
0.92     
(0.83-1.02) 
  70+ 
989 
(14.46) 
0.44*** 
(0.36-0.53) 
1516 
(8.38) 
0.44*** 
(0.36-0.52) 
1324 
(14.80) 
0.54*** 
(0.46-0.63) 
1848 
(7.90) 
0.47*** 
(0.40-0.57) 
Ethnic group White 
15397 
(23.12) 
1 24189 
(19.81) 
1 34989 
(24.12) 
1 51305 
(17.21) 
1 
  Black 
1801 
(24.65) 
0.81*    
(0.69-0.96) 
2682 
(9.84) 
0.39*** 
(0.32-0.49) 
4004 
(25.20) 
0.93     
(0.81-1.07) 
5192 
(8.46) 
0.40*** 
(0.34-0.48) 
  
South 
Asian 
1168 
(18.56) 
0.61*** 
(0.46-0.80) 
1339 
(3.81) 
0.16*** 
(0.09-0.27) 
2871 
(17.49) 
0.61**  
(0.43-0.88) 
2582 
(3.14) 
0.15*** 
(0.09-0.26) 
  Mixed 
376 
(31.38) 
1.16     
(0.90-1.51) 
587 
(18.40) 
0.82     
(0.62-1.10) 
992 
(28.73) 
1.14*   
(1.01-1.29) 
1387 
(14.28) 
0.72*    
(0.54-0.97) 
  Other 
2658 
(25.40) 
0.91     
(0.80-1.04) 
4010 
(11.62) 
0.52*** 
(0.44-0.62) 
6980 
(22.39) 
0.88     
(0.75-1.02) 
9977 
(10.69) 
0.56*** 
(0.49-0.65) 
  
Not 
stated 
13993 
(26.18) 
0.97     
(0.85-1.11) 
17395 
(17.99) 
0.90     
(0.79-1.04) 
10324 
(23.53) 
0.93     
(0.81-1.08) 
11655 
(15.53) 
0.90     
(0.81-1.01) 
Deprivation   
level† Least 
11328 
(21.62) 
1 17108 
(15.86) 
1 19388 
(19.64) 
1 28722 
(13.64) 
1 
  Middle 
11643 
(26.32) 
1.32*** 
(1.16-1.49) 
16582 
(18.38) 
1.23*** 
(1.15-1.32) 
19825 
(23.25) 
1.26*** 
(1.14-1.39) 
26994 
(15.31) 
1.19*** 
(1.09-1.29) 
  Most 
11369 
(29.97) 
1.61*** 
(1.40-1.86) 
14865 
(19.00) 
1.37*** 
(1.26-1.48) 
20096 
(27.98) 
1.63*** 
(1.47-1.82) 
25232 
(16.71) 
1.40*** 
(1.31-1.50) 
Number (%) of smokers 
9138 
(25.82) 
 8811 
(17.55) 
 14229  
(23.65) 
 12424 
(15.13) 
 
Total N  35393  50,202  60160  82098  
N = denominator (number of patients with a smoking code); % = percentage of smokers; AOR = Adjusted Odds Ratio (adjusted 
for age group, ethnicity, IMD, practice clustering); CI = 95% Confidence Interval; $ = Reference group; † = missing IMD (2700 
pre-QOF+; 2001 post-QOF+); * = p<0.05; ** = p<0.01; *** = p<0.001 
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 Prior to QOF+, there was again little variation seen in the chance of smokers getting advice. 
Men and women with unstated ethnicity were statistically less likely to receive smoking 
cessation advice than White patients (for men, 26.6% vs 41.8%, AOR 0.49, CI 0.39 to 0.62, 
p<0.001; for women 29.7% vs 43.3%, AOR 0.55, CI 0.44 to 0.69, p<0.001). However, men 
and women in the most deprived areas were more likely to receive advice than those in the 
most affluent (for men, 58.7% vs 32.5%, AOR 1.38, CI 1.10 to 1.75, p<0.01; for women, 
42.0% vs 35.5%, AOR 1.34, CI 1.03 to 1.75, p<0.05).  
After the introduction of QOF+ smoking cessation advice to smokers was still provided 
relatively equitably. However men aged 50 to 69 years were now less likely to receive advice 
compared to those aged 30 to 49 years (52.1% vs 64.1%, CI 0.64 to 0.87, p<0.001) and 
women aged under-30 were more likely to receive advice (67.5% vs 54.8%, AOR 1.59, CI 
1.39 to 1.81, p<0.001). Patients with unstated ethnicity continued to be less likely to receive 
advice compared with White patients. The relative advantage patients from the most deprived 
areas had in receiving advice prior to the introduction of QOF+ had now gone, with patients 
from all deprivation groups receiving similar rates of advice. 
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Table 13: Patient characteristics associated with smokers in the Hammersmith & 
Fulham open cohort receiving cessation advice or referral pre/post QOF+ 
    Pre-QOF+ Post-QOF+ 
    Men Women Men Women 
    
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N          
(%) 
AOR       
(CI) 
N           
(%) 
AOR       
(CI) 
Age group <30 
2482 
(38.52) 
1.09     
(0.85-1.40) 
3413 
(42.46) 
1.25     
(0.97-1.61) 
3982 
(64.06) 
1.15     
(0.98-1.34) 
5007 
(67.45) 
1.59*** 
(1.39-1.81) 
  30 to 49 
4740 
(35.34) 
1 4054 
(35.57) 
1 7810 
(60.20) 
1 6051 
(54.80) 
1 
  50 to 69 
1773 
(34.97) 
1.05     
(0.87-1.27) 
1217 
(38.37) 
1.15     
(0.95-1.41) 
2241 
(52.12) 
0.75*** 
(0.64-0.87) 
1220 
(54.92) 
1.05     
(0.90-1.22) 
  70+ 
143 
(39.86) 
1.27     
(0.84-1.93) 
127 
(39.37) 
1.29     
(0.76-2.20) 
196 
(51.53) 
0.73     
(0.50-1.06) 
146 
(52.74) 
0.99     
(0.69-1.41) 
Ethnic 
group White 
4021 
(41.81) 
1 4792 
(43.28) 
1 8441 
(62.08) 
1 8829 
(62.02) 
1 
  Black 
444 
(45.05) 
1.07     
(0.80-1.42) 
264 
(47.35) 
1.16     
(0.88-1.52) 
1009 
(64.32) 
1.10     
(0.97-1.26) 
439 
(64.01) 
1.14     
(0.91-1.43) 
  
South 
Asian 
217 
(39.63) 
0.82     
(0.45-1.49) 
51   
(45.10) 
1.13     
(0.54-2.33) 
502 
(63.15) 
1.05     
(0.81-1.36) 
81   
(66.67) 
1.26     
(0.77-2.06) 
  Mixed 
118 
(55.93) 
1.67     
(0.97-2.86) 
108 
(55.56) 
1.66     
(1.00-2.75) 
285 
(69.82) 
1.46     
(0.91-2.34) 
198 
(68.18) 
1.31     
(0.88-1.96) 
  Other 
675 
(44.74) 
1.10     
(0.87-1.39) 
466 
(41.85) 
0.94     
(0.71-1.25) 
1563 
(63.98) 
1.05     
(0.91-1.22) 
1067 
(66.64) 
1.22     
(1.00-1.49) 
  Not stated 
3663 
(26.56) 
0.49*** 
(0.39-0.62) 
3130 
(29.74) 
0.55*** 
(0.44-0.69) 
2429 
(45.99) 
0.54*** 
(0.43-0.67) 
1810 
(43.26) 
0.51*** 
(0.41-0.63) 
Deprivation   
level† Least 
2449 
(32.46) 
1 2713 
(35.50) 
1 3808 
(59.98) 
1 3919 
(60.37) 
1 
  Middle 
3064 
(34.76) 
1.14     
(0.97-1.33) 
3048 
(38.22) 
1.15     
(0.98-1.35) 
4609 
(60.73) 
1.04     
(0.89-1.21) 
4132 
(60.96) 
1.03     
(0.87-1.22) 
  Most 
3407 
(39.65) 
1.38**  
(1.10-1.75) 
2825 
(42.02) 
1.34*    
(1.03-1.75) 
5622 
(59.57) 
0.97     
(0.78-1.21) 
4217 
(58.43) 
0.91     
(0.72-1.14) 
Number (%) of smokers 
3308 
(36.20) 
 3408 
(38.68) 
 8522 
(59.89) 
 7440 
(59.88) 
 
Total N   9138  8811  14229  12424  
N = denominator (smokers in the full cohort); % = percentage of smokers receiving advice or referral; AOR = Adjusted Odds 
Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence Interval; $ = Reference group; † = 
missing IMD (443 pre-QOF+; 346 post-QOF+); * = p<0.05; ** = p<0.01; ** = p<0.0001 
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4. Differential effect of QOF+ on individual groups of patients 
Table 14 shows the relative chance of benefitting from the introduction of QOF+ for men and 
women of different age groups, ethnic groups and deprivation levels, in each case adjusted 
for the other variables. As previously found with the complete case cohort, there were 
statistically significant improvements for almost all age groups and ethnic groups, and for all 
levels of deprivation, so exceptions are described in the paragraphs below.  
Smoking status 
Patients aged under-30 appeared to benefit the most from QOF+ for the recording of smoking 
status (AOR for men under-30 years 3.21, CI 3.06 to 3.36, p<0.001; AOR for women under-
30 years 3.82, CI 3.67 to 3.98, p<0.001), although all age groups saw large improvements. 
South Asian patients also saw the greatest improvements (AOR for South Asian men 2.16, CI 
1.83 to 2.56, p<0.001; AOR for South Asian women 2.33, CI 1.90 to 2.86, p<0.001). Men 
with Mixed ethnicity were the only group to be only as likely to be asked about smoking after 
QOF+ as before. 
Smoking prevalence 
Women aged 50 to 69 years saw the biggest reductions in smoking rates (AOR 0.78, CI 0.71 
to 0.85, p<0.001). Patients aged over-70 years were again the only group not to have reduced 
their smoking rates significantly after the introduction of QOF+. Black men, men with Mixed 
ethnicity, Other women, and South Asian patients had similar rates of smoking before and 
after the introduction of QOF+. 
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Smoking advice 
All groups benefitted from the introduction of QOF+ and were significantly more likely to 
receive advice compared with the pre-QOF+ period. The youngest patients saw the most 
improvement (AOR for men aged under-30 2.85, CI 2.57 to 3.16, p<0.001; AOR for women 
aged under-30 2.81, CI 2.57 to 3.07, p<0.001). South Asian men again benefitted most from 
QOF+ on smoking advice levels (AOR = 2.61, CI 1.88 to 3.62, p<0.001). Women with Other 
ethnicity saw the greatest improvements (AOR = 2.78, CI 2.22 to 3.47, p<0.001). The most 
affluent group was somewhat more likely to have seen an improvement in rates of smoking 
advice post-QOF+ (AOR 3.12, CI 2.80 to 3.47, p<0.001). 
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Table 14: Within-group analysis for the Hammersmith & Fulham open cohort: effect of QOF+ on smoking outcomes1 
    Smoking status ascertained post QOF+ Smokers post QOF+ Smoking advice to smokers post QOF+ 
    Men Women Men Women Men Women 
    AOR (CI) AOR CI AOR CI AOR CI AOR CI AOR CI 
Age group <30 2.21*** 2.10-2.33 2.60*** 2.49-2.72 0.93* 0.87-0.98 0.82*** 0.78-0.86 2.59*** 2.33-2.88 2.52*** 2.30-2.77 
  30 to 49 1.17*** 1.12-1.22 1.28*** 1.24-1.33 0.85*** 0.82-0.89 0.86*** 0.83-0.90 2.49*** 2.30-2.69 1.95*** 1.79-2.13 
  50 to 69 0.93* 0.87-0.99 1.17*** 1.09-1.26 0.88** 0.82-0.96 0.77*** 0.70-0.85 1.62*** 1.42-1.86 1.74*** 1.46-2.06 
  70+ 0.91 0.76-1.07 1.39*** 1.18-1.63 1.04 0.81-1.34 0.94 0.72-1.23 1.44 0.89-2.34 1.70* 1.01-2.86 
Ethnic group White 1.14*** 1.09-1.19 1.35*** 1.30-1.41 0.89*** 0.85-0.93 0.83*** 0.80-0.87 2.31*** 2.13-2.49 2.18*** 2.02-2.34 
  Black 1.51*** 1.33-1.71 2.53*** 2.24-2.87 1.01 0.88-1.15 0.86 0.73-1.01 2.21*** 1.75-2.78 1.95*** 1.42-2.67 
  
South 
Asian 
2.22*** 1.88-2.64 2.50*** 2.02-3.09 0.93 0.77-1.11 0.78 0.55-1.12 2.81 2.00-3.94 2.38* 1.13-5.00 
  Mixed 1.08 0.82-1.43 2.07*** 1.61-2.66 0.87 0.67-1.14 0.73* 0.56-0.95 1.86** 1.19-2.93 1.64 1.00-2.70 
  Other 1.26*** 1.13-1.40 1.64*** 1.49-1.81 0.84** 0.76-0.94 0.89 0.79-1.00 2.18*** 1.81-2.63 2.78*** 2.22-3.48 
  Not stated 1.50*** 1.44-1.56 1.92*** 1.84-2.00 0.85*** 0.80-0.90 0.82*** 0.77-0.87 2.43*** 2.17-2.71 1.90*** 1.68-2.15 
Deprivation level Least 1.24*** 1.18-1.30 1.63*** 1.55-1.70 0.88*** 0.83-0.94 0.85*** 0.80-0.90 2.74*** 2.45-3.05 2.51*** 2.26-2.79 
  Middle 1.37*** 1.30-1.44 1.63*** 1.56-1.71 0.86*** 0.81-0.90 0.81*** 0.77-0.86 2.56*** 2.33-2.83 2.28*** 2.06-2.52 
  Most 1.36*** 1.30-1.43 1.67*** 1.60-1.75 0.90*** 0.85-0.95 0.84*** 0.79-0.89 1.91*** 1.75-2.09 1.70*** 1.53-1.88 
1 = Adjusted odds ratios (AOR)(adjusted by age, ethnicity, IMD and practice clustering) for outcome for each group post-QOF+ compared with pre-QOF+  
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Key points 
The introduction of QOF+ was associated with large increases in the proportion of patients 
without smoking-related diseases having their smoking status recorded, a reduction in 
smoking prevalence and an increase in the proportion of smokers receiving smoking 
cessation advice. Advice appeared to have been provided largely equitably across the 
different demographic groups, with a few exceptions, summarised below. 
Overall, most groups saw improvements in the recording of smoking status but patients aged 
under-30 years were less likely to be asked about smoking, and patients over-70 years more 
likely to be asked, in the complete case cohort. These findings were reversed in the sensitivity 
analysis with the open cohort design, suggesting younger newly registered patients were 
more likely to be asked about smoking than older patients. South Asian men and women 
from all ethnic groups other than White were more likely to have their smoking status 
recorded before and after the introduction of QOF+. This result was the same in the 
sensitivity analysis. 
Men aged under-30 years and patients over-70 years were less likely to smoke than patients 
aged 30 to 49 years. South Asian and Other men were less likely to smoke than White men 
and Black, South Asian and Mixed ethnicity women were less likely to smoke than White 
women, and this held after the introduction of QOF+ in both cohorts. 
Patients in the middle and more deprived areas were more likely to smoke than those in the 
least deprived areas, and this was the case after the introduction of QOF+ despite reductions 
in smoking prevalence in all deprivation groups. Smoking advice increased after the 
introduction of QOF+ and all groups benefitted from the increase.  
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Within-group comparisons showed that most groups benefitted from QOF+ for the smoking 
outcomes studied, with the main exception being patients aged over-70 years for whom 
outcomes were similar before and after the introduction of QOF+, or only slightly improved 
compared with the other age groups, probably due to the very low prevalence of smoking in 
this age group. 
Strengths and weaknesses of the studies  
The studies used data from a large number of patients without smoking-related diseases 
registered at general practices in an ethnically diverse area of North West London. Findings 
from the studies may be generalisable to other health systems with universal coverage that 
provide financial incentives for primary prevention activities.  As with the Wandsworth 
study, all practices in the study used electronic medical records to record clinical information.  
Pre-QOF ethnicity coding was poor for these patients, possibly because national QOF did not 
attach much financial incentive to their recording, or because they attended the general 
practice infrequently. After the introduction of QOF+ ethnicity recording for this group 
improved considerably. 
As previously discussed in Chapter 6, I included patients without an ethnic group category 
into a group where ethnicity was ‘not stated’ in order to avoid bias of multiple imputation. 
but this group would have included people from all the other ethnic groups and may have 
introduced bias as well. A sensitivity analysis conducted after excluding the ‘not-stated’ 
group could also be used to address this problem.  
My results were based on outcomes recorded in the medical record over the 27 months prior 
to the introduction of QOF+ and the 33 months after the introduction of QOF+, the duration 
of funding for QOF+. Practices would have had an extra six months to achieve smoking 
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outcomes post-QOF+, but this was the period of time specified by QOF+ business rules, 
whereas 27 months was specified by national QOF business rules, so the comparison is valid. 
I found that smoking prevalence overall was similar to estimated national prevalence at 
baseline (20.0% vs 21.0%) but lower than estimated national prevalence over the follow up 
period (16.2% vs 20.0). APHO local prevalence data is modeled from data from health 
surveys but is not age-standardised and does not take into account local initiatives. In 
addition, as mentioned in the Wandsworth study, smoking status recorded in general practice 
is self-reported and not verified by CO reading or urinary cotinine, so subject to reporting 
bias. Most likely the majority of people who stop smoking access help through NHS stop 
smoking services provided through clinics and pharmacies, of which Hammersmith & 
Fulham has many, as detailed in the background section. It is not possible to disentangle the 
differential effects of GP stop smoking advice and NHS stop smoking services in the 
reduction of smoking prevalence seen in this study. 
My sample includes patients who would have been exception reported when calculating 
QOF+ payments. However, as for the Wandsworth study, this may provide a more complete 
picture of the delivery of cessation interventions in primary care.232 A few patients with 
chronic kidney disease (CKD) may have been included in the study sample, as diagnosis 
codes for this condition were not extracted. However, the majority of patients with CKD have 
other co-morbidities such as diabetes and hypertension, conditions excluded from the study 
sample, so the numbers of patients with CKD included would be small (around 100) and not 
impact on the studies’ findings. 
I was unable to determine the quality of advice given, as these data were not available. 
However, it is likely to vary considerably between those practitioners who provide minimal 
advice or sign-posting to NHS stop smoking services, to those who provide evidence-based 
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brief intervention, taking into account the situation of the patient at the time. Qualitative 
research may be useful in answering this question. Also, quit rates could not be determined in 
this study, as these are not specifically coded in primary care.  It is not possible to attribute 
changes in smoking outcomes to the financial incentive as this was an observational study. 
However, there were no major changes in national tobacco control policy at the time of the 
study, so QOF+ may have had an effect. 
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Chapter 8: Effect of financial incentives on ethnic 
disparities in smoking cessation interventions when 
pregnant women book for antenatal care in primary care: 
before-and-after open cohort study using data from 
Hammersmith & Fulham, London 
 
Hypothesis 
As stated in Chapter 4, the null hypothesis for this research is that financial incentives do not 
affect the provision of smoking cessation activities in primary care and therefore also do not 
affect smoking prevalence, regardless of demographic group. The alternative hypothesis is 
that financial incentives do affect these outcomes. 
Main research question 
What are the effects of financial incentives on smoking cessation activities undertaken in 
healthcare, and do they affect inequalities in the provision of smoking cessation activities in 
primary care? 
Aims 
In this study I plan to examine the effect of financial incentives on the provision of smoking 
cessation activities for women attending booking appointments for antenatal care. I also aim 
to examine inequalities in provision of smoking outcomes for pregnant women from different 
demographic groups based on age, gender, ethnicity and socio-economic status. 
Objectives 
To examine the effects of a local financial incentive scheme (QOF+) on smoking cessation 
activities, smoking prevalence, and inequalities in the provision of smoking cessation 
activities to different groups (defined by age, gender, ethnicity and socio-economic status) for 
pregnant women using data from general practices in Hammersmith & Fulham, London, UK. 
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Background 
Hammersmith & Fulham prioritised smoking cessation activity in primary care through a 
local version of the UK’s financial incentive scheme (the Quality and Outcomes Framework, 
QOF), named QOF+, as previously described. The scheme was introduced on 1 July 2008 
and was in place until 31 March 2011. In addition to extending financial incentives for 
smoking cessation work to include all patients for recording smoking status and providing 
smoking cessation advice or referral, QOF+ also introduced specific financial incentives for 
the recording of smoking status for pregnant women. For pregnant women it is important to 
identify smokers in order to help them stop smoking and avoid damage to their unborn 
children, so their status has to be ascertained at booking (preferably before the 12th week of 
pregnancy). I wanted to evaluate the effect of the financial incentive for smoking cessation 
among pregnant women. 
Methods 
 
Setting and patients 
As I described in Chapter 7, The London Borough of Hammersmith & Fulham is situated in 
North West London has a population of approximately 182,500. The population is younger 
than average for London as a whole and is ethnically diverse, with around 22% of the 
population from Black and Minority Ethnic groups (Greater London Authority 2008 Ethnic 
Group population predictions), compared with around 11% for the UK as a whole.220 The 
borough is rated as more deprived than England as a whole, with around 26.6% of it 
population living in the 20% most deprived areas in England, compared with an average for 
England of 19.8%.  
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Smoking levels in Hammersmith and Fulham are estimated to have stayed the same over the 
last two years according to the Association of Public Health Observatories. In 2008-9, the 
baseline year for this study, 6.3% of pregnant women in the borough smoked, better than the 
average for women smoking while pregnant in England (14.7%). In 2010-11 smoking rates 
had dropped still further in pregnant women (4.4% vs 13.7% of pregnant women in England 
as a whole).221 
NHS stop smoking services available in Hammersmith and Fulham in community settings 
include one-to-one support with trained advisors throughout the borough, based at seven 
drop-in community clinics and at around 28 pharmacies, and a free phone number for advice. 
Smokers can access planned programmes of six free weekly sessions of behavioural support 
and prescriptions for NRT or tobacco-dependence medication such as Bupropion 
(http://www.kick-it.org.uk/). 
Under QOF+ participating general practices were incentivised to record the smoking status of 
pregnant women at the time of their booking appointment for antenatal care, and to record 
that smoking cessation advice or referral had been provided at the booking appointment for 
those pregnant women who were smokers. For a list of the QOF+ smoking indicators for 
pregnant women see Figure 35.  
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Figure 35: QOF+ indicators for smoking in pregnancy   
 
Study design 
I carried out a before-and-after open cohort study using anonymised data extracted from 30 
general practices in Hammersmith and Fulham. All the general practices had electronic 
medical records (EMR).132 The data contained the medical records of adults (aged over 16 
years) registered between 1 July 2008 and 31 March 2011.  
Patients included in the study were all pregnant women, whether or not they had other 
chronic diseases. They were included in the study if they booked for antenatal care with 
participating general practices in Hammersmith & Fulham during the study period. For this 
study the baseline period was 33 months before the introduction of QOF+ on 1 July 2008, 
and the follow up period was for 33 months afterwards. I chose 33 months for the pre-QOF+ 
period in order to include similar numbers of pregnant women in both the baseline and the 
follow up.  
I undertook two study designs in order to compare ascertainment rates of the indicators on the 
day of booking with rates during the 27 months prior to booking. However, I have reported 
only the results for the date of the antenatal booking appointment in this thesis, as this was 
the main study question. Results for the recording of indicators within 27 months of booking 
are shown in Appendix B. 
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Study variables 
The following binary outcome measures were extracted from the data:  
• Percentage of pregnant women (> 15 years) with smoking status recorded at the 
booking appointment, before (33 months before 1 July 2008), and after the 
introduction of QOF+ (1 July 2008 to 31 March 2011, 33 months); 
• Percentage of those pregnant women whose smoking status was ascertained at the 
booking appointment who were smokers before and after the introduction of QOF+; 
• Percentage of pregnant women who were smokers given smoking cessation advice at 
their booking appointment. 
Hammersmith & Fulham Primary Care Trust staff assigned patients a deprivation score 
(Index of Multiple Deprivation, IMD238) based on their post-code before the data were 
anonymised and extracted to a research database held at the Department of Primary Care and 
Public Health, Imperial College London. London Queen Square Research Ethics Committee 
granted ethics approval for the use of the data for research.  
Statistical analysis 
I calculated the proportions of patients with the smoking outcomes at baseline and during the 
study period. I examined differences in these outcomes by age group, ethnic group, IMD, and 
practice size (both studies). 
Bivariate analyses for these outcomes by age group, ethnicity, IMD, and were all statistically 
significant (not reported) but practice size was not. I therefore included all the predictor 
variables except practice size in a multiple logistic regression model taking into account 
practice clustering at the general practice level. I also conducted a within-group analysis, 
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adjusted for the other main variables, to determine whether QOF+ had influenced outcomes 
for some groups more or less than for others. I analysed the data with STATA version 11. 
Results 
1. Smoking status ascertained 
At baseline there were 4,384 pregnant women, of whom 65.7% had smoking status recorded 
at the booking appointment during the 33 months up to the introduction of QOF+ on 1 July 
2008 to 31 March 2011. In the 33 months following the introduction of QOF+ there were 
6,592 pregnant women and these who had smoking status ascertained at booking had 
increased to 77.1% compared with the pre-QOF+ period, a significant increase (AOR 1.67, 
CI 1.43 to 1.96, p<0.001). When I looked at smoking status recorded at or within 27 months 
before booking the proportion with smoking status recorded was higher at 89.1% pre-QOF+ 
and 92.3% post-QOF+ (Appendix B, Table 1). The results for pregnant women having 
smoking status ascertained at booking before and after the introduction of QOF+, subdivided 
by ethnic group, are given in Table 15. 
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Table 15: Patient characteristics associated with having smoking status ascertained at 
booking before and after the introduction of QOF+ in Hammersmith & Fulham 
  Smoking status ascertained at 
booking (Pre-QOF+) 
Smoking status ascertained at booking 
(Post-QOF+) 
  N % AOR (CI) N % AOR (CI) 
Age group <21 197 20.30 0.10*** (0.06-0.16) 206 41.26 0.15*** (0.11-0.21) 
 21 to 30 1481 57.60 0.49*** (0.43-0.57) 2286 69.99 0.44** (0.38-0.52) 
 31 to 40 $ 2401 72.89 1 3654 83.36 1 
 40+ 305 72.43 1.12 (0.86-1.46) 446 79.37 0.78 (0.60-1.01) 
Ethnic group White $ 2130 66.15 1 3977 75.16 1 
 Black 444 69.59 1.56** (1.11-2.18) 779 82.93 2.10*** (1.67-2.64) 
 South 
Asian 
98 77.55 1.85** (1.20-2.85) 285 87.72 3.24*** (2.03-5.18) 
 Mixed 93 68.82 1.49 (0.94-2.37) 180 77.22 1.43** (1.10-1.86) 
 Other 433 73.67 1.67*** (1.32-2.11) 870 81.84 1.68*** (1.36-2.08) 
 Not stated 1186 58.43 0.82 (0.65-1.03) 501 69.66 0.90 (0.73-1.11) 
Deprivation† Least $ 1415 69.82 1 2026 80.26 1 
 Middle 1496 64.97 0.88 (0.72-1.08) 2284 77.58 0.91 (0.75-1.10) 
 Most 1373 61.18 0.80* (0.65-0.99) 2415 73.45 0.74** (0.61-0.90) 
Total N 
 
 4384 65.47  6592 77.14  
N = denominator (number of registered pregnant women); % = percentage of pregnant women with smoking status 
ascertained; AOR = Adjusted Odds Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence 
Interval; $ = Reference group;    † = missing IMD (100 pre-QOF+; 131 post-QOF+* = p<0.05; ** = p<0.01; *** = p<0.001 
 
Prior to QOF+ the younger two groups of pregnant women were less likely to be asked than 
those aged 31 to 40. Only 20.3% of women under-21 years were asked about smoking, and 
57.6% of those aged 21 to 30 years, compared with 72.9% of women aged 31 to 40 years 
(AOR 0.10, CI 0.06 to 0.16 for those under-21 years; AOR 0.49, CI 0.43 to 0.57 for those 
aged 21 to 30 years). Black, South Asian and Other women were more likely to be asked 
about smoking than White women. For example, 77.6% of South Asian women were asked 
compared with 66.2% of White women (AOR 1.85, CI 1.20 to 2.85). Women from the most 
deprived group were slightly less likely to have smoking status recorded at booking 
compared with those from the least deprived group (61.2% vs 69.8%, AOR 0.80, CI 0.65 to 
0.99). 
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After QOF+ younger women were still less likely to have smoking status recorded at 
booking, despite a large increase in recording overall, with 41.3% of those under-21 years 
being asked and 70.0% of those aged 21 to 30 years, compared with 83.4% of those aged 31 
to 40 years (AOR 0.15, CI 0.11 to 0.21 for those under-21 years; AOR 0.44, CI 0.38 to 0.52 
for those aged 21 to 30 years). Women from all ethnic groups except those without a stated 
ethnicity were now more likely to have smoking status recorded at booking compared with 
White women. For example, 87.7% of South Asian women had status recorded compared wit 
75.2% of White women (AOR 3.24, CI 2.03 to 5.18). After QOF+ 73.5% of women in the 
most deprived areas had their smoking status recorded compared with 80.3% of those from 
the most affluent areas (AOR 0.74, CI 0.61 to 0.90). 
2. Smoking prevalence  
Smoking prevalence among pregnant women at baseline was 2.7% and after the introduction 
of QOF+ smoking prevalence fell to 1.8%. Compared with the pre-QOF+ period the AOR for 
smoking prevalence was 0.63 (CI 0.43 to 0.92). When the smoking prevalence in the 27 
months prior to booking was examined for comparison the rates were 10.5% and 6.8% 
(Appendix B, Table 2) suggesting that many women had stopped smoking before their 
booking appointment. Smoking prevalence before and after the introduction of QOF+ is 
given in Table 16. 
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Table 16: Patient characteristics associated with having a smoking code of ‘current 
smoker’ at booking pre/post QOF+ in Hammersmith & Fulham 
  Smokers (Pre-QOF+) Smokers (Post-QOF+) 
  N % AOR (CI) N % AOR (CI) 
Age group <21 40 10.00 5.78** (1.70-19.70) 85 10.59 6.65*** (2.78-15.91) 
 21 to 30 852 4.69 2.56*** (1.82-3.60) 1600 2.31 1.70* (1.06-2.72) 
 31 to 40 $ 1748 1.77 1.00 3046 1.48 1.00 
 40+ 227 1.32 0.80 (0.25-2.57) 354 0.28 0.20 (0.03-1.48) 
Ethnic group White $ 1408 3.34 1 2989 1.81 1 
 Black 309 1.62 0.31** (0.16-0.61) 646 1.86 0.85 (0.40-1.79) 
 South Asian 76 1.32 0.34 (0.04-2.80) 250 0.40 0.20 (0.02-1.55) 
 Mixed 64 9.38 1.61 (0.50-5.18) 139 2.16 1.15 (0.42-3.18) 
 Other 319 1.25 0.30* (0.09-0.98) 712 1.26 0.58 (0.30-1.14) 
 Not stated 691 2.17 0.58 (0.28-1.21) 349 3.72 1.62 (0.85-3.09) 
Deprivation† Least $ 988 1.82 1 1626 1.11 1 
 Middle 972 2.26 1.20 (0.68-2.11) 1772 2.48 2.00* (1.08-3.73) 
 Most 840 4.29 2.25* (1.16-4.38) 1580 1.77 1.33 (0.67-2.64) 
Total  2867 2.72  5085 1.81  
N = number of pregnant women with smoking status ascertained; % = percentage of smokers; AOR = Adjusted Odds Ratio 
(adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence Interval; $ = Reference group; † = 
missing IMD (70 pre-QOF+; 107 post-QOF+* = p<0.05; ** = p<0.01; *** = p<0.001 
 
Pre-QOF+ smoking rates were higher among younger women, with 10.0% of women under-
21 years smoking, and 4.7% of women aged 21 to 30 years, compared with 1.8% of women 
aged 31 to 40 years (AOR 5.78, CI 1.70 to 19.70 for those under-21 years; AOR 2.56, CI 
1.82 to 3.60 for those aged 21 to 30 years). Black and Other women were less likely to smoke 
than White women (1.6% of Black women smoked compared with 3.3% of White women, 
AOR 0.31, CI 0.16 to 0.61; 1.25% of Other women, AOR 0.30, CI 0.09 to 0.98). Smoking 
rates were higher in the most deprived areas compared with those from the most affluent 
areas (4.3% vs 1.8%, AOR 2.25, CI 1.16 to 4.38). 
After QOF+, smoking rates remained higher in the younger groups of women, but disparities 
in rates of smoking across ethnic groups had attenuated, although for South Asian women 
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this may be due to small numbers of women who smoked, as the smoking prevalence was 
only 0.4% in this group compared with 1.8% in White women. Smoking rates were similar in 
the most and least deprived groups, but rates in the middle deprived group were now higher 
at 2.5% compared with 1.1% in the most affluent area (AOR 2.00, CI 1.08 to 3.73).  
3. Smoking advice 
Before the introduction of QOF+, 29.5% of pregnant smokers were given advice and after the 
introduction of QOF+ this proportion increased to 50.0%. The overall AOR for pregnant 
women who smoked being given advice after the introduction of QOF+ compared with the 
prior period was 2.33 (CI 1.35 to 4.02, p<0.001), showing that the financial incentive had a 
significant impact. These rates of advice are similar to those for women who were found to 
be smokers the 27-month period prior to booking (23.4% pre-QOF+ and 48.9% post-QOF, 
Appendix B, Table 3). The proportions of smokers receiving advice pre/post-QOF+ are given 
in Table 17. In the multiple logistic regression there were no significant results and many 
groups were dropped from the analysis due to small numbers, so the results of the analysis 
are not reported. 
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Table 17: Patient characteristics associated with smokers receiving cessation advice or 
referral at booking pre/post QOF+ in Hammersmith & Fulham 
  Smokers (Pre-QOF+) Smokers (Pre-QOF+) 
  N % N % 
Age group <21 4 25.00 9 55.56 
 21 to 30 40 25.00 37 51.35 
 31 to 40  31 32.26 45 46.67 
 40+ 3 66.67 1 100.00 
Ethnic group White  47 31.91 54 51.85 
 Black 5 40.00 12 50.00 
 South Asian 1 0.00 1 0.00 
 Mixed 6 33.33 3 33.33 
 Other 4 25.00 9 33.33 
 Not stated 15 20.00 13 64.54 
Deprivation† Least  18 38.89 18 55.56 
 Middle 22 31.82 44 47.73 
 Most 36 25.00 28 50.00 
Total  78 29.49 92 50.00 
N = Number of pregnant women who smoke; % = percentage of smokers receiving advice or referral;                 
† = missing IMD (2 pre-QOF+; 2 post-QOF+) 
 
 
Prior to QOF+, although there were large differences in rates of advice these did not reach 
significance in the multiple logistic regression analysis due to small numbers. For women in 
the different age groups rates varied from 25.0% in the youngest to 66.7% in the oldest. 
Similarly, difference in the rates of advice to smokers of differing ethnicity ranged from 
20.0% for those with unstated ethnicity to 40.0% for Black women. Rates varied from 25.0% 
in the most deprived group to 38.9% in the least deprived group.  
After the introduction of QOF+ advice rates for younger patients were higher than for those 
aged 31 to 40 years (55.6% vs 46.7%). Rates of advice to smokers of different ethnicity 
ranged from 33.3% for women of Mixed or Other ethnicity to 64.5% of women with unstated 
ethnicity. There were smaller differences with deprivation, with 55.6% of women in the least 
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deprived areas receiving advice, 47.7% in the middle group and 50.0% in the most deprived 
group.   
4. Differential effect of QOF+ on individual groups of patients 
Table 18: Within-group analysis pregnant women study: effect of QOF+ in 
Hammersmith & Fulham on smoking outcomes1‡ 
  Smoking status 
ascertained post QOF+ 
Smokers post QOF+ 
  AOR (CI) AOR CI 
Age group <21 2.98*** 1.85-4.80 1.37 0.34-5.54 
 21 to 30 1.55*** 1.34-1.79 0.52** 0.32-0.84 
 31 to 40 $ 1.77*** 1.55-2.02 0.82 0.50-1.33 
 40+ 1.14 0.78-1.67 0.11 0.01-1.24 
Ethnic group White 1.59*** 1.41-1.80 0.52** 0.35-0.78 
 Black 2.15*** 1.61-2.88 1.09 0.38-3.14 
 South 
Asian 
2.26* 1.20-4.26 0.54 0.03-9.04 
 Mixed 1.51 0.82-2.78 0.20* 0.04-0.96 
 Other 1.57** 1.18-2.10 0.93 0.27-3.20 
 Not stated 1.76*** 1.39-2.24 1.42 0.65-3.14 
Deprivation level Least 1.60*** 1.35-1.89 0.55 0.28-1.08 
 Middle 1.79*** 1.53-2.09 1.21 0.70-2.09 
 Most 1.63*** 1.40-1.91 0.41** 0.24-0.68 
1AOR for outcome for each group post-QOF+ compared with pre-QOF+ (adjusted for age 
group, ethnicity, IMD and practice clustering); ‡ = results from the multiple logistic regression 
analysis for smoking advice omitted due to small numbers 
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Table 18 shows the relative chance of benefitting from the introduction of QOF+ for pregnant 
women in different age groups, ethnic groups and deprivation levels, in each case adjusted 
for the other variables and for practice clustering. As previously found with the primary 
prevention study in Chapter 7, there were statistically significant improvements for almost all 
age groups and ethnic groups, and for all levels of deprivation, so exceptions are described in 
the paragraphs below.  
Smoking status 
Women aged under-21 years saw the greatest improvements in recording of smoking status 
(AOR 2.98, CI 1.85 to 4.80, p<0.001) of all the age groups. Women over 40 years had similar 
levels of ascertainment before and after the introduction of QOF+, as did women from the 
Mixed ethnic group. 
Smoking prevalence 
Only women aged 31 to 40 years had significantly reduced their smoking rates in the post-
QOF+ period compared to the pre-QOF+ period. Women from most ethnic groups were 
smoking at similar levels pre/post-QOF+ with the exception of White women and those with 
Mixed ethnicity (AOR for White women 0.52, CI 0.35 to 0.78, p<0.001; AOR for Mixed 
ethnicity 0.20, CI 0.04 to 0.96, p<0.05). Women in the most deprived areas had significantly 
reduced their smoking rates (AOR 0.41, 0.24 to 0.68, p<0.05). 
Smoking advice 
The within-groups multiple logistic regression analysis results have not been reported as 
many groups were dropped from the analysis due to small numbers.  
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Key points  
The introduction of QOF+ was associated with an increase in the proportion of pregnant 
women whose smoking status was ascertained at the booking appointment. However, the 
financial incentive did not affect existing disparities. For example, younger women and 
White patients were less likely to be asked about smoking both before and after its 
introduction. 
There were relatively low rates of ascertainment of smoking status and advice given to 
smokers on the booking date compared with rates of recording in the 27 months prior to the 
booking appointment (of up to 92% post-QOF+), which may be explained by recording error.  
Smoking prevalence among pregnant women fell after the introduction of QOF+, although 
younger women were still more likely to smoke than other age groups after the introduction 
of QOF+. The numbers of smokers were too small to pick up differences in rates of smoking 
between different ethnic groups, and women from more deprived areas were still more likely 
to smoke than those from more affluent areas. The proportion of those pregnant women who 
smoked given advice increased from 29.5% to 50.0% and advice was provided largely 
equitably.  
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Strengths and weaknesses of the study  
This study has similar general strengths and weaknesses as those discussed in Chapter 7, with 
a few specific points. Results were based on outcomes recorded in the medical record over 
the 33 months prior to the introduction of QOF+ and the 33 months after the introduction of 
QOF+, the duration of funding for QOF+, so practices would have had the same amount of 
time to achieve smoking outcomes before and after the introduction of QOF. 
The numbers of patients were much smaller than in the main studies, particularly the numbers 
of smokers. Therefore, the multiple logistic regressions for smoking cessation advice were 
underpowered with many groups being dropped from the analyses. 
Rates of recording of smoking status and advice to smokers were lower than in the main 
QOF+ studies. Some of this can be explained by the more exacting requirement under QOF+ 
business rules for these outcomes to be recorded on the day of booking. However, I also 
found that smoking prevalence for both baseline and follow up periods was lower than 
expected from APHO estimates using modeled data.  
These findings may have been due to recording error. Some of the booking appointments 
would likely be undertaken by community midwives who were not so familiar with the 
templates on the EMR, or may have been using the patients’ hand-held notes which is the 
usual practice for antenatal care, with the findings on smoking added to the EMR at a later 
date. It is also possible that clinicians may not have inputted smoking status on the day of 
booking if it had not changed from an earlier time. Finally as previously discussed, smoking 
status recorded in general practice is self-reported and not verified by CO reading or urinary 
cotinine, so subject to reporting bias, especially as some pregnant women who smoke may 
have felt uncomfortable admitting this to midwives or other clinicians. 
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My sample includes patients who would have been exception reported when calculating 
QOF+ payments. However, as for the Wandsworth study, this may provide a more complete 
picture of the delivery of cessation interventions in primary care.232  
It is not possible to attribute changes in smoking outcomes to the financial incentive as this 
was an observational study, as previously described. However, this is the first time healthcare 
workers have been financially incentivised for providing smoking cessation advice to 
pregnant women in the UK, and as there was no change in tobacco policy during this time, so 
QOF+ may have had an effect. 
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Chapter 9: Discussion  
 
Key findings 
In my systematic review of financial incentives for smoking cessation activities in primary 
care I found that most studies examined process measures such as recording of patients’ 
smoking status and recording whether smoking cessation advice had been given to smokers, 
or that smokers had been referred to smoking cessation services, or prescribed stop-smoking 
medication. For these measures, almost all of the studies showed statistically significant 
improvements following the introduction of financial incentives.  Only three experimental 
studies examined the impact of financial incentives on quit rates, and these showed mixed 
results, showing no effect of the financial incentive alone, but improved quit rates when 
combined with practitioner training and cost-free nicotine-replacement medication. Although 
QOF studies showed reductions in prevalence following the introduction of the financial 
incentive scheme, the designs of the studies meant it was not possible to attribute the 
reduction to QOF.  
 
Only three studies examined the effect of financial incentives on inequalities in smoking 
cessation activities in primary care and they were all QOF studies. McGovern et al in their 
study of patients with CHD found that patients over the age of 75 years were less likely to be 
offered advice compared with younger patients after the introduction of QOF, as were 
women compared with men.196 Millett et al in their study of patients with diabetes found that 
women were more likely to have their smoking status recorded after QOF and less likely to 
smoke than men were but the reduction in smoking prevalence after QOF was brought in was 
less for women than men. McGovern et al found that women were more likely to be offered 
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advice than men. In another study, of patients with CHD, Millett et al found that patients 
from Black and Asian groups benefitted more from the improvement in smoking outcomes 
associated with QOF compared with white British patients.177 However, there was no 
significant difference in the changes in smoking rates between most and least deprived 
groups, whereas McGovern et al found more deprived groups were more likely to be asked 
about smoking than more affluent groups. Given this gap in the literature, I aimed to examine 
the effect of financial incentives on inequalities in smoking cessation in my studies of 
smoking outcomes in Wandsworth, and Hammersmith & Fulham.  
 
In the Wandsworth study I found that a large percentage of patients with CVD had their 
smoking status ascertained and, if smokers, received smoking cessation advice after the 
introduction of QOF. Although patients with respiratory disease were less likely to have their 
smoking status ascertained than those with CVD, smokers in both these disease groups 
received similar levels of advice. The rates of ascertainment and advice were considerably 
lower among patients in the depression group and the group without smoking-related 
diseases, which suggests that practices may have been concentrating their smoking cessation 
efforts on the chronic diseases associated with larger financial rewards within QOF in 2007 
(as described in Chapter 3) and where the absolute benefits of smoking cessation might be 
seen as greatest. This variation may also be because patients with cardiovascular conditions, 
respiratory diseases, chronic kidney disease or diabetes are regularly reviewed in primary 
care and so staff may have more opportunity to discuss smoking. Other factors which may 
impact on the provision of smoking cessation more generally include lack of time to discuss 
preventive healthcare during the appointment (typically 10 minutes in UK primary care) and 
concerns amongst general practitioners that discussing issues such as smoking when patients 
present with an unrelated problems may be seen as intrusive or as ‘nagging’.239  
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There was encouragingly little variation between ethnic groups in the provision of smoking 
cessation advice or referral, with the notable exception of black Caribbean men with 
depression, who were much less likely to receive such advice than white British men.  
Patients with CVD had lower smoking prevalence than patients in the other groups, and were 
more likely to receive smoking cessation advice than the other groups, with the exception of 
those with respiratory disease who received similar levels of advice. The differences in 
smoking outcomes were most marked for the group without the smoking-related long-term 
conditions for which smoking cessation is maximally rewarded by QOF, reflecting QOF’s 
focus on secondary prevention.  
Patients with respiratory diseases had a higher smoking prevalence than those with CVD 
despite the equal emphasis by QOF and despite receiving similar levels of cessation 
interventions. Smoking rates among patients with depression were extremely high and they 
were much less likely to receive a cessation intervention. This is concerning given that 
smoking habits are particularly difficult for depressed patients to break even with support.240 
My findings confirm those of other authors who have found higher rates of smoking among 
individuals with mental health problems.85 224  
Following on from the Wandsworth study, I wanted to focus on the effect of financial 
incentives on smoking cessation activities for primary prevention in primary care. I was able 
to do this using general practice data from Hammersmith & Fulham which allowed me to 
look at the impact of enhanced financial incentives through QOF+ on the delivery of smoking 
cessation interventions and possible effects on inequalities.  
In the first QOF+ study, looking at a complete case cohort of patients without smoking-
related conditions previously incentivised through national QOF, I found that the introduction 
of an enhanced financial incentive was associated with large increases in the proportion of 
 216 
 
patients who had their smoking status ascertained (increasing from 62.3% to 75.8% in the 
complete case cohort). As the baseline figures for ascertainment are similar to those for 
patients without smoking-related diseases in the Wandsworth study of around 59%, the 
improvement after the introduction of QOF+ is strongly suggestive of an effect of the 
enhanced financial incentive. 
 There was some increase in the differences seen in smoking ascertainment between age 
groups before QOF+. For example, women under-30 years were less likely to be asked about 
smoking status after the introduction of QOF+ in the complete case cohort, but more likely to 
be asked in the open cohort sensitivity analysis. The open cohort included patients newly 
registering and it may be that women in this age group were more mobile, and more likely to 
be asked when registering at a general practice. Disparities in rates of ascertainment with 
ethnic group, with White patients being less likely to be asked than those from other ethnic 
groups, particularly for women, remained after the introduction of QOF+. Whereas 
ascertainment was equitable between different deprivation groups prior to the introduction of 
QOF+, the more deprived groups were somewhat less likely to have smoking status recorded 
after its introduction. 
Smoking rates were lower after the introduction of QOF+ compared with the pre-QOF+ 
period (reducing from 20.0% to 16.2%). However, existing differences in smoking 
prevalence with respect to age, ethnicity and deprivation remained after the introduction of 
QOF+, and results were similar in the sensitivity analysis. The design of this study means it is 
not possible to attribute reduction in smoking prevalence directly to QOF+. There had not 
been any radical change in tobacco policy over the study period (the ban on smoking in 
public places had been introduced earlier, in 2007), although in 2008 NICE published 
guidance to local authorities in providing smoking cessation services with a focus on manual 
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workers, pregnant women and ‘hard to reach’ groups.241 It is possible that the focus on asking 
patients about smoking who would not normally have been targeted by National QOF may 
have had an effect.  
Rates of recorded smoking advice to smokers increased hugely after the introduction of 
QOF+ (increasing from 35.4% to 54.0%). Advice appeared to have been provided largely 
equitably across the different demographic groups. Women under-30 years were more likely 
to be given advice then those aged 30 to 49 years.  
Looking at the within-groups comparisons in the main study, most groups benefitted from the 
introduction of QOF+ across all outcomes. Exceptions included men aged over-70 years for 
recording of smoking status, and both men and women over-70 years for whom outcomes 
were similar before and after the introduction of QOF+ for smoking prevalence and advice to 
smokers. The youngest patients and South Asian patients had the greatest increase in the 
chance of being asked about smoking after the introduction of QOF+. White patients, those 
with unstated ethnicity and women with Mixed or Other ethnicity saw the greatest reductions 
in smoking prevalence after the introduction of QOF+, although overall were more likely to 
smoke than other ethnic groups. South Asian and Mixed patients, and Black women had 
similar levels of advice before and after the introduction of QOF+ whereas all other groups 
had much improved rates of advice after its introduction. 
In the second QOF+ study, looking at the effect of the financial incentive on smoking 
indicators for pregnant women booking for antenatal care in primary care, I found that the 
introduction of a financial incentive was associated with an increase in the proportion of 
pregnant women whose smoking status was ascertained at the booking appointment 
(increasing from 65.5% to 77.1%). Higher rates of ascertainment were found both before and 
after the introduction of QOF+ if the time period 27 months prior to booking is examined (up 
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to 92% post-QOF, Appendix B). This may reflect recording error, either because midwives 
were not used to the EMR, or they used paper records and the data were transferred to the 
EMR at a later date, or other clinicians did not update the record on the booking date when 
they saw that smoking status had previously been recorded, if it had not changed. The 
financial incentive did not appear to affect existing disparities. For example, younger women 
and White patients were less likely to be asked about smoking both before and after its 
introduction. 
Smoking prevalence among pregnant women were also lower following the introduction of 
QOF+ compared with the pre-QOF+ period (smoking rates dropped from 2.7% to 1.8% 
among those whose smoking status was ascertained at booking). These figures are lower than 
expected from APHO estimates and may reflect under-recording as previously discussed. 
However, when smoking codes during the 27 months prior to booking were examined this 
gave a prevalence of 10.5% pre-QOF+ and 6.8% post-QOF+ and these are likely to be over-
estimates as women are more likely stop smoking when they find out they are pregnant, 
although this varies with socio-economic status, with the most deprived women being less 
likely to stop than the most affluent.242 Younger pregnant women were still more likely to 
smoke than other age groups before and after the introduction of QOF+. The numbers of 
pregnant smokers were too small to pick up statistically significant differences in rates of 
smoking between different ethnic groups following QOF+ despite rates varying from 0.4% in 
South Asian women to 3.7% in women with unstated ethnicity. Women from more deprived 
areas were more likely to smoke than those from more affluent areas at both time points.  
The proportion of pregnant women who smoked who were given advice also increased 
following the introduction of QOF+, from 29.5% to 50.0% and advice was provided largely 
equitably between groups. Although, it is not possible to attribute these positive changes 
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directly to QOF+, as previously described, this is the first time healthcare workers have been 
financially incentivised for providing smoking cessation advice to pregnant women in the 
UK. However, the reduction in smoking prevalence likely reflects the existing downward 
trend as prevalence was calculated on the date of booking for antenatal care.  
For the within-groups comparison in the pregnant women study, most groups benefitted from 
the introduction of QOF+ in their chance of being asked about smoking, with the exception 
of women aged over-40 years and those with Mixed ethnicity. Pregnant women aged 21 to 30 
years saw the greatest reduction in smoking prevalence, as did White women and those with 
Mixed ethnicity, and those from the most deprived areas. Smoking advice rates improved the 
most for women aged 21 to 30 years and women with unstated ethnicity, and the least for 
women in the most deprived areas, but as the numbers of smoking pregnant women were 
small several groups were dropped from the analysis. 
Previous research 
The findings from my systematic review confirm with those from other systematic reviews 
showing that financial incentives tend to improve the recording of process measures in 
smoking cessation,138 184 190 but my study identified a larger number of studies in addition to 
those identified by previous authors as the review was more recent and because as I included 
observational studies in the review. In my studies using primary care data from Wandsworth, 
I found that the recording of smoking status for patients with cardiovascular disease was 
89%, 72% for respiratory disease and 60% for depression and other conditions. Other QOF 
studies have shown similarly high levels of recording for smoking-related conditions after the 
introduction of QOF. For those that looked at all registered patients recording levels were 
lower (39% in 2005 in the paper by Coleman et al160, 79.5% in 2010 in Simpson et al’s 
paper181) probably because of the lower incentives provided for primary prevention in 
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patients without smoking-related chronic diseases, or because patients in this group were less 
likely to attend the general practice for routine appointments.  
In the Hammersmith & Fulham studies where I was able to compare outcomes before and 
after the introduction of QOF+, I found improvement in the percentage of patients asked 
about smoking of 13.5% in the main study (from 62.3% to 75.5%) and 18.6% in the study 
with pregnant women (from 65.7% to 77.1%). These improvements seen in the H&F studies 
are at the lower end of improvements in recording seen in the before-and-after QOF studies 
identified in the systematic review, which ranged from 19%194 to 52%.198 However, I studied 
only patients without smoking-related illnesses who might not attend their GP surgery for 
other reasons when smoking could be discussed, whereas other studies included either only 
patients with smoking-related diseases, or all patients, including those with smoking-related 
conditions.  
Smoking prevalence reduced by 3.8% in the Hammersmith & Fulham main study (from 
20.0% to 16.2%). These are similar to reductions seen by other QOF studies. For example, 
Millett et al found a 3.8% reduction in smoking prevalence in their study of patients with 
diabetes (from 20.0% in 2003 to 16.8% in 2005).180 Simpson et al found a reduction of 6% in 
their study of all registered patients (from 28.4% in 2001/2 to 22.4% in 2006/7).181 Although 
the 0.9% reduction in prevalence among pregnant women (from 2.7% to 1.8%) was smaller 
than for QOF studies looking at either all patients or groups with chronic diseases, the 
prevalence among pregnant women was small to start with and there were no studies 
identified in the systematic review looking at the effect of financial incentives on pregnant 
women with which to compare the change in prevalence. 
Rates of advice recorded in the Wandsworth study were between 80% (for patients with 
depression) and 93% for those with cardiovascular conditions). Similar rates of advice were 
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seen in the QOF studies identified in the systematic reviews, but lower rates for the trials and 
before-and-after studies in other setting. For example, Chang et al found rates increased by 
5.6% to 26.8% after the change in financial incentive in Taiwan.201 Rates of advice increased 
by 18.6% in the Hammersmith & Fulham main study (from 35.4% to 54.0%). This is 
somewhat higher than improvements in recorded smoking advice in other QOF studies, 
which varied between 12.2% in the study of patients with diabetes by Tahrani et al (from 
83.8% in 2004 to 95.0% in 2006)198 to 16.4% in the study by Campbell et al looking at 
patients with CHD, asthma and diabetes (from 80.6% in 2003 to 97.0% in 2005),168, both 
published in 2007. 
I found differences between different demographic groups for smoking outcomes. Patients 
from ethnic minority groups were more likely to be asked and advised about smoking on the 
whole than White patients, and were less likely to smoke, but received relatively equitable 
rates of stop smoking advice. The main exception to this was that Black Caribbean men with 
depression had higher rates of smoking and were less likely to receive smoking cessation 
advice.  
 
The Wandsworth study examined differences in smoking outcomes by disease group and 
ethnicity, stratified by gender and adjusted by age group, deprivation and practice size so did 
not specifically examine differences between patients in different age group or deprivation 
levels. The Hammersmith & Fulham studies, although also stratified by gender, did look at 
differences with age and deprivation as well as ethnicity. Similar outcomes were found for 
ethnicity in these studies as for Wandsworth but I found additional differences with the other 
variables. For instance, in the complete case cohort, patients over-70 years were more likely 
to be asked about smoking and those under-30 years were less likely, but patients in both the 
age groups were less likely to smoke than those aged 30 to 49 years and that did not change 
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with QOF+, whereas pregnant women under-21 years were much more likely to smoke than 
those aged 31 to 40 years. Patients from more deprived areas were also more likely to smoke 
than those from the least deprived areas before and after the financial incentive.  
Other researchers have found similar differences after the introduction of national QOF on 
inequalities. For example, Millett et al examined differences with ethnicity in the likelihood 
of patients with CHD being asked about smoking pre/post-QOF and found a greater 
improvement for South Asian patients compared with white British patients.177 In another 
study of patients with diabetes, Millett et al found variations in outcomes with respect to 
gender, age and ethnicity after the introduction of QOF.180 Improvements in the recording of 
smoking status were greater for women compared to men and for ethnic groups (except 
Bangladeshi) compared with white British patients. McGovern et al in their QOF study of 
patients with CHD found that older patients were less likely to be asked about smoking pre-
QOF but after the introduction of QOF this difference was attenuated.196 They found that 
people from more deprived areas benefitted more than those from the least deprived. They 
also found that female smokers were more likely to be offered advice compared with males. 
However, smokers over the age of 75 years were less likely to be offered advice compared 
with younger smokers. 
 
My findings regarding inequalities in smoking prevalence and advice across ethnic groups 
have confirmed those of Lyratzopoulos et al243 who studied UK primary care patients 
attending for cardiovascular risk screening and found that South Asian patients were 
significantly less likely to smoke than people of other ethnicities. However, these findings, 
and those in my study, may mask differences in risk factors within the South Asian group. 
For instance smoking rates being higher among Bangladeshi and Pakistani men compared 
with Indian men, as shown in the Wandsworth study and also in research by Bhopal et al.244 
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245 In addition, the results of my studies are similar to those from a recent study that 
examined ethnic group differences in smoking prevalence using data from the Health Survey 
for England. 228 This found higher smoking rates among Bangladeshi and black Caribbean 
men and I found this to be the case for black Caribbean men with depression and black 
Caribbean and Bangladeshi men in the group without these chronic diseases. The authors also 
found that white British and black Caribbean women are more likely to smoke than women 
from other ethnic groups and my findings in both studies confirmed this. A recent US survey 
found non-Hispanic white people were more likely to smoke than those from other ethnic 
groups but there was little variation between ethnic groups in the chance of being offered 
smoking cessation advice.246-248 My results confirm research looking at process measures of 
care, which found provision of smoking cessation advice to be fairly equitable by ethnic 
group.177 178 249 
Several researchers have documented the trend of reduced prevalence of smoking in 
pregnancy250-253 and my findings confirm this. There has been very little research looking at 
variation in smoking prevalence by ethnic group in pregnancy. One report produced by the 
US Centers for Disease Control and Prevention in 2001254 noted declines in all ethnic groups 
but that smoking rates were highest for American Indians and non-Hispanic Whites, and 
among pregnant teenagers. Similar finding were also reported by Salihu et al.255 There has 
been more research on differences with socio-economic group. For instance, Penn found 
higher rates of smoking among less educated pregnant women and those in unskilled manual 
or unemployed groups.252 Mohsin et al in their study in New South Wales, Australia, found 
greater reductions in smoking among more affluent pregnant women from more compared 
with those from more disadvantaged backgrounds.251 I did not find any papers examining the 
effects of financial incentives on smoking cessation work with pregnant women. 
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Strengths and limitations  
I utilized a broad search strategy for the systematic review and hence was able to identify a 
large number of studies to include. Most of these were evaluations of the UK QOF and 
showed improvement in the recording of smoking status and advice given to smokers. 
However, only a few studies examined quit rates, and these showed more of an effect when 
financial incentives were provided along with practitioner training and free or subsidized 
smoking-cessation medication. The QOF studies showed a drop in smoking prevalence, but 
could not take into account changes resulting from tobacco control policy occurring over the 
study period. I was not able to determine an optimum quantity for the financial incentive due 
to the variation in amount over all the studies. There was only one cost-effectiveness study 
identified but this showed that the addition of a financial incentive was beneficial as long as it 
was accompanied with GP training and subsidized stop-smoking medication. 
In the Wandsworth and Hammersmith & Fulham studies, I was able to analyse data from a 
large number of patients registered at general practices in two ethnically diverse areas of 
London with relatively complete ethnicity coding. The findings may be generalisable to other 
health systems with universal coverage that provide financial incentives for prevention 
activities.  All practices in the study used electronic medical records to record clinical 
information.  
The data on recording of advice given to smokers in the Wandsworth study may have been 
subject to recording bias in that patients with conditions not incentivised by the version of 
QOF in 2007 might have received smoking cessation advice but this advice may not have 
been coded. I was also unable to determine the quality of advice given, as these data were not 
available.  
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Similarly, there may have been a recording bias in the Hammersmith & Fulham study of 
pregnant women. Rates of recording of smoking status and advice to smokers were lower 
than in the main QOF+ studies. Some of this can be explained by the more exacting 
requirement under QOF+ business rules for these outcomes to be recorded on the day of 
booking. However, smoking prevalence for both baseline and follow up periods was lower 
than expected from APHO estimates. Some of the booking appointments would have been 
undertaken by community midwives who might not be familiar with the templates on the 
EMR, or may have recorded outcomes in the patients hand-held notes with the results added 
to the EMR at a later date. General practice clinicians may not have inputted smoking status 
on the day of booking if it had not changed from an earlier time. 
My samples for all the studies included patients who would have been exception reported 
when calculating QOF or QOF+ payments. Although the number increased following the 
introduction of the financial incentive the numbers were small and in any case may provide a 
more complete picture of the delivery of cessation interventions in primary care.232  
I was not able to judge the quality of advice given in both the Wandsworth and the 
Hammersmith & Fulham studies, as these data were not available in either dataset. I was also 
unable to determine quit rates, as these are not specifically coded on patients’ EMRs. 
However, the drop in prevalence is suggestive of an effect. Smoke-free legislation was 
introduced into England from 1 July 2007, and this may have impacted on the results 
observed in the Wandsworth study. However, there was no change in national tobacco 
control policy during the Hammersmith & Fulham study, although guidance to local 
authorities on smoking cessation was published in 2008.  
The numbers of patients in the second Hammersmith & Fulham study of pregnant women 
were much smaller than in the main studies, particularly the numbers of smokers. Therefore, 
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the multiple logistic regressions for smoking cessation advice were underpowered and 
differences in advice rates between groups were not statistically significant. 
I found that smoking prevalence overall was different in both areas than that expected from 
modeled estimates by the Association of Public Health Observatories. However, as discussed 
in the individual studies, such modeled data do not take into account local initiatives for 
smoking cessation. Estimates are based on the social and demographic characteristics of an 
area and are not age-standardised. Prevalence estimates based on general practice data may 
be more relevant at the local level but may be out of date for patients who attend 
infrequently. In addition, smoking status is self-reported and not verified by CO reading or 
urinary cotinine.  
It is not possible to attribute changes in smoking outcomes to the financial incentives in any 
of the studies as they were observational studies. More robust methods to evaluate the impact 
of QOF such as randomised controlled trials were not possible as QOF was brought in 
nationally. I had hoped to compare data from Hammersmith & Fulham with national data 
from the GP Research Database (GPRD) but did not have access to GPRD data within the 
time available for the PhD. However, previous research suggests marked improvement in 
smoking and other outcome measures were associated with the introduction of QOF,233 234 
and that this may also have affected ethnic groups differently.235 Also, for the pregnant 
women study, this is the first time healthcare workers have been financially incentivised for 
providing smoking cessation advice to pregnant women in the UK, and there was no change 
in tobacco policy during this time, so QOF+ may have had an effect. 
Financial incentive schemes can have unintended outcomes as described in Chapter 3, 
including gaming,215 adverse patient selection,216 and relative neglect of unrewarded 
activities.217 I did not examine these outcomes in my studies.  
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Implications for policy and practice 
My research has shown that enhanced financial incentives in primary care for smoking 
cessation are associated with increased recording of smoking status and advice to smokers. 
However, whether this reflects more people being asked and advised or just better recording 
made possible through investment in computer systems and data entry is unclear.173 Financial 
incentives appear to be associated with reductions in smoking prevalence and this happens 
even for people without smoking-related diseases. There is also some effect on reducing 
inequalities in smoking cessation. Reducing smoking prevalence in all groups will have a 
large population impact on health outcomes, but from the Marmot review and Whitehall 
studies we know that efforts need to continue to reduce prevalence among disadvantaged 
groups in order to reduce health inequalities.46 This provides a compelling reason for 
extending these incentives for smoking cessation for primary prevention within national QOF 
indicators and making additional incentives available for targeted smoking cessation work for 
hard to reach groups, such as with people severe mental health problems. Now that Public 
Health England is due to oversee the public health domain of QOF then further incentives for 
prevention work should be considered, and within this, a focus on smoking cessation work 
for high prevalence groups to reduce inequalities. As smoking is the most important cause of 
premature mortality and inequalities in health it is important that this indicator is not 
considered for removal from national QOF in the future, even if maximal levels of 
achievement are reached (as shown for cardiovascular disease in my Wandsworth study) as 
there tends to be a fall-off in achievement when indicators are removed.256  
Policy makers should be aware that few cost-effectiveness studies on financial incentives 
have been undertaken in the UK and that such incentives need to be continued long-term to 
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avoid the drop off effect described in the literature. We also need to see what the effect is of 
rewarding relative improvements or reducing inequalities rather than solely rewarding 
absolute achievement as is currently the case. Although I found low rates of exception 
reporting in my studies, QOF targets may become more exacting in future, as recently 
announced by the Department of Health,257 so we also should regularly review exception 
reporting to ensure that patients who are harder to reach continue to receive smoking 
cessation advice and referral.173 
Although population level tobacco control interventions have been shown to have a bigger 
impact on quit rates than individual level smoking cessation treatment,183 NHS smoking 
cessation services have been shown to be effective107 108 and to reduce health inequalities by 
improving the proportion of smokers from more deprived areas who quit, even though people 
from this group find it more difficult to quit than those from more affluent areas.6 As around 
80% of the population is estimated to visit their GP each year, even asking about smoking 
can improve quit rates.116 Encouraging smoking cessation work in primary care through 
financial incentives should improve rates further and translate to a large public health impact.  
There has been little research into the impact smoking cessation advice in primary care can 
make on inequalities. My research shows that specific groups such as young people, people 
with severe mental health problems, and people from more deprived areas seem to benefit 
less from financial incentives for smoking cessation. These groups may require case-finding 
and more tailored interventions.59 However, my study only included people registered with 
GPs so it is possible that health inequalities will widen for those living at the margins (such 
as migrants not entitled to routine primary care and the homeless). A concern is that financial 
incentives can exacerbate socio-economic inequalities as more affluent patients tend to access 
and benefit from public health interventions more readily than more deprived patients, the so-
called ‘Inverse Equity Hypothesis,’ postulated by Victora et al.258 This hypothesis 
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distinguishes between short term possible increases in disparities and longer term reductions 
as interventions diffuse into poorer groups 
The systematic review showed evidence for the effectiveness of financial incentives on quit 
rates was mixed and I was not able to examine this, as quit rates are not recorded in primary 
care. Better data linkage with NHS smoking cessation services could improve monitoring of 
quit rates and then general practice data could contribute more usefully to national smoking 
cessation statistics.  
This research has also shown that local versions of QOF may be effective in meeting the 
needs of the local population. However, they are vulnerable to the current financial climate 
and shown by the discontinuation of QOF+ when efficiency savings were needed in 
Hammersmith & Fulham.  
There may be implications for workload if financial incentives for smoking cessation are 
extended to primary prevention. Ascertainment of smoking status could be made by 
telephone and internet brief intervention may suit some patients better than face-to-face 
advice.259 Personalised text messaging support is an effective and cost-effective means of 
delivering smoking cessation advice.  Free et al have examined the effect of an automated 
text-messaging cessation programme called ‘txt2stop’ in an large RCT, with six-month 
follow up and found significantly improved quit rates in the intervention group compared 
with the control group (10.7% intervention group vs 4.9% control group, relative risk 2.20 
(CI 1.80 to 2.68), p<0.0001).260 
My research shows an additional effect of financial incentives, with their associated 
improvements in computer records and templates, on improved ethnicity coding. This should 
allow local authorities to focus on ethnic groups with high smoking prevalence, such as 
Bangladeshi and Pakistani men, for tailored smoking cessation advice. It may also help 
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improve other services for ethnic groups by contributing to joint strategic needs assessments. 
Ongoing follow-up evaluation of QOF needs to continue to see if inequalities improve long-
term.  
Future research 
The systematic review should be repeated regularly to pick up new studies examining the 
effect of financial incentives on smoking cessation work in healthcare. It will also be useful 
to determine whether smoking outcomes change if incentives are changed or discontinued, as 
Lester et al have found that performance falls off when this occurs.256  
 
I would suggest conducting further research using time trend analysis for follow up of 
smokers to see the impact of financial incentives on smoking outcomes overall and among 
different demographic groups to examine the inverse equity hypothesis. I would also like to 
compare Hammersmith & Fulham data with GPRD data, or other boroughs similar to 
Hammersmith & Fulham, over the same time period to look for the difference the local 
smoking cessation incentives have made as a comparison group is lacking in the studies 
carried out so far. Linking QOF and QOF+ data with HES data and incorporating statistical 
modeling would be helpful to examine the impacts of financial incentives for smoking on 
longer-term outcomes such as myocardial infarction, stroke and TIA.  
 
My systematic review and those of other authors have identified a lack of cost-effectiveness 
studies for financial incentives for smoking cessation work. These should be carried out as a 
priority.  
 
Qualitative research on health practitioners’ views of the of QOF, or any pay for performance 
scheme, on its impact on the nurse-patient or doctor-patient relationship (both on attention to 
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the patient given the reliance on the computer and recording of information, on concerns 
about potentially hijacking the patient’s agenda in the consultation in order to gain QOF 
points), would be interesting areas of investigation. Qualitative research with practitioners, 
patients and extracting text portions of the EMR associated with the recording of smoking 
status and advice for smokers may help determine the quality of advice given in primary care, 
which I was unable to examine in my studies. 
Conclusions  
Financial incentives are associated with large improvements in the ascertainment of smoking 
status and recording of advice to smokers. This is most evident among patients with smoking-
related diseases when no comparable incentive is provided for achieving smoking indicators 
for patients without these diseases. However, when specific incentives are provided for 
primary prevention a similar improvement in smoking outcomes is seen. For pregnant women 
this improvement also holds, although the numbers of pregnant women who smoke are small 
and the impact of a financial incentive may have been made prior to the women attending for 
their booking appointments. 
Disparities with respect to age and ethnicity persisted after the introduction of financial 
incentives for smoking cessation. These disparities are most obvious for the youngest and the 
oldest patients, for White patients, and for those ethnic groups with particular conditions, 
most notably black Caribbean men with depression. 
Financial incentives for smoking cessation work in primary care have a part to play in the 
prevention of smoking related diseases. They may improve outcomes when combined with 
NHS smoking cessation services and subsidised access to nicotine-addiction treatments such 
as NRT, Bupropion and Verenicline. However, tobacco control policies may have a bigger 
impact overall. Increasing the price and availability of tobacco products has been shown to 
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dissuade young people from taking up smoking in the first place. The same measures can 
contribute to reducing the health gap between rich and poor by prompting cessation in people 
from more deprived areas where health outcomes are worst. 
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Appendix A: Downs and Black checklist for measuring 
study quality  
 
Reproduced with permission from the Journal of Epidemiology & Community Health 1998, 
page 382. 
Score 1 for 'yes', 0 for 'no' or 'unable to determine', except item 5 (see below)  
Reporting 
1. Is the hypothesis/aim/objective of the study clearly described? 
2. Are the main outcomes to be measured clearly described in the Introduction or 
Methods section? 
3. Are the characteristics of the patients included in the study clearly described? 
4. Are the interventions of interest clearly described? 
5. Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? (Yes = 2, Partially = 1, No = 0) 
6. Are the main findings of the study clearly described? 
7. Does the study provide estimates of the random variability in the data for the 
main outcomes? 
8. Have all important adverse events that may be a consequence of the 
intervention been reported? 
9. Have the characteristics of patients lost to follow up been described? 
10. Have actual probability values been reported? 
External validity 
11. Were the subjects asked to participate in the study representative of the 
entire population from which they were recruited? 
12. Were those subjects who were prepared to participate representative of the 
entire population from which they were recruited? 
13. Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? 
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Internal validity - bias 
14. Was an attempt made to blind study subjects to the intervention they have 
received? 
15. Was an attempt made to blind those measuring the main outcomes of the 
intervention? 
16. If any of the results of the study were based on 'data dredging', was this 
made clear? 
17. In trials and cohort studies, do the analyses adjust for different lengths of 
follow-up of patients, or in case-control studies, is the time period between the 
intervention and outcome the same for cases and controls? 
18. Were the statistical tests used to assess the main outcomes appropriate? 
19. Was compliance with the intervention/s reliable? 
20. Were the main outcome measures used accurate (valid and reliable)? 
Internal validity - confounding (selection bias) 
21. Were the patients in different intervention groups (trial and cohort studies) or 
were the cases and controls (case-control studies) recruited from the same 
population? 
22. Were the patients in different intervention groups (trial and cohort studies) or 
were the cases and controls (case-control studies) recruited over the same 
period of time? 
23. Were study subjects randomised to intervention groups? 
24. Was the randomised intervention assignment concealed from both patients 
and health care staff until recruitment was complete and irrevocable? 
25. Was there adequate adjustment for confounding in the analyses from which 
the main findings were drawn? 
26. Were losses to follow-up taken into account? 
Power 
27. Did the study have sufficient power to detect a clinically important effect 
whwere the probability value for a difference being due to chance is less than 
5%? (Modified from original paper to 1 if a sample size calculation had been 
reported and 0 if it had not) 
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Appendix B: Alternative analysis for smoking in pregnancy 
study 
 
Table 1: Patient characteristics associated with having smoking status ascertained at or 
within 27 months of booking before and after the introduction of QOF+ 
  Smoking status ascertained at or <27 months 
of booking 
(Pre-QOF+) 
 
Smoking status ascertained at or <27 
months of booking 
(Post-QOF+) 
  N % AOR (CI) N % AOR (CI) 
 
Age group <21 197 80.20 0.58*** (0.40-0.83) 206 85.44 0.52** (0.32-0.86) 
 21 to 30 1481 88.25 0.79** (0.66-0.94) 2286 91.60 0.75** (0.63-0.90) 
 31 to 40 $ 2401 90.34 1 3654 93.32 1 
 40+ 305 88.85 1.00 (0.72-1.40) 446 90.36 0.71 (0.49-1.03) 
Ethnic 
group 
White $ 2130 92.16 1 3977 91.78 1 
 Black 444 93.02 1.3 (0.83-2.03) 779 95.38 2.15*** (1.47-3.15) 
 South Asian 98 96.94 2.63 (0.87-7.93) 285 96.49 2.84* (1.19-6.79) 
 Mixed 93 89.25 0.8 (0.37-1.72) 180 92.22 1.18 (0.72-1.92) 
 Other 433 96.54 2.88** (1.54-5.39) 870 96.09 2.49** (1.49-4.20) 
 Not stated 1186 78.67 0.34*** (0.25-0.46) 501 82.44 0.45*** (0.36-0.58) 
Deprivation
† 
Least $ 1415 90.46 1 2026 92.89 1 
 Middle 1496 89.04 0.99 (0.70-1.41) 2284 92.73 0.96 (0.74-1.24) 
 Most 1373 88.13 0.89 (0.63-1.25) 2151 91.17 0.72* (0.56-0.93) 
Total N 
 
 4384 
 
89.07  6592 
 
92.28  
 
N = denominator (number of registered pregnant women); % = percentage of pregnant women with smoking status 
ascertained; AOR = Adjusted Odds Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence 
Interval; $ = Reference group;    † = missing IMD (100 pre-QOF+; 131 post-QOF+; * = p<0.05; ** = p<0.01; *** = p<0.001 
 
Effect of QOF+ on the recording of smoking status: AOR 1.07, CI 0.87 to 1.29, p=0.65 
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Table 2: Patient characteristics associated with having a smoking code of ‘current 
smoker’ at or within 27 months of booking pre/post QOF+ 
  Smoker at or <27 months of booking 
(Pre-QOF+) 
 
Smoker at or <27 months of booking 
(Post-QOF+) 
  N % AOR (CI) N % AOR (CI) 
 
Age group <21 158 25.32 3.90*** (2.42-6.28) 176 18.75 5.23*** (3.08-8.88) 
 21 to 30 1,306 15.01 2.16*** (1.68-2.77) 2,094 10.70 3.05*** (2.39-3.90) 
 31 to 40 $ 2,167 7.20 1 3,410 3.90 1 
 40+ 127 7.01 1.01 (0.65-1.55) 403 5.21 1.43 (0.86-2.36) 
Ethnic group White $ 1,962 11.82 1 3,650 7.62 1 
 Black 413 5.57 0.29*** (0.18-0.45) 743 5.38 0.49* (0.28-0.86) 
 South 
Asian 
95 5.26 0.40* (0.16-0.96) 275 1.14 0.10** (0.20-0.47) 
 Mixed 83 20.48 1.23 (0.76-2.02) 166 8.43 0.87 (0.49-1.54) 
 Other 418 6.22 0.40*** (0.25-0.65) 836 4.67 0.49*** (0.36-0.65) 
 Not stated 931 11.60 0.84 (0.64-1.09) 413 8.72 0.94 (0.59-1.50) 
Deprivation† Least $ 1,280 6.72 1 1,882 4.73 1 
 Middle 1,332 11.71 1.71*** (1.37-2.14) 2,118 7.27 1.38* (1.04-1.83) 
 Most 1,210 13.72 1.97*** (1.41-2.75) 1,961 8.31 1.48** (1.16-1.89) 
Total N 
 
 3,902 10.53  6,083 6.76  
 
N = denominator (number of registered pregnant women); % = percentage of pregnant women with smoking status 
ascertained; AOR = Adjusted Odds Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence 
Interval; $ = Reference group;    † = missing IMD     (83 pre-QOF+; 121 post-QOF+; * = p<0.05; ** = p<0.01; *** = p<0.001 
 
Effect of QOF+ on smoking prevalence: AOR 0.62, CI 0.52 to 0.74, p<0.001 
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Table 3: Patient characteristics associated with smokers receiving cessation advice or 
referral at or within 27 months of booking pre/post QOF+ 
  Smoking status ascertained at or <27 
months of booking 
(Pre-QOF+) 
Smoking status ascertained at or <27 
months of booking 
(Post-QOF+) 
 
  N % AOR (CI) N % AOR (CI) 
 
Age group <21 40 27.50 1.57 (0.90-2.76) 33 57.58 1.59 (0.67-3.78) 
 21 to 30 196 21.43 0.95 (0.75-1.35) 224 46.88 1.03 (0.70-1.51) 
 31 to 40 $ 156 23.72 1 133 46.62 1 
 40+ 19 31.58 0.97 (0.51-1.85) 21 71.43 2.90 (1.00-2.30) 
Ethnic 
group 
White $ 232 20.26 1 278 48.56 1 
 Black 23 39.13 1.04 (0.68-1.59) 40 50.00 1.12 (0.54-2.30) 
 South 
Asian 
5 0.00 0.54 (0.19-1.49) 4 25.00 ‡ 
 Mixed 17 35.29 2.54*** (1.53-4.22) 14 45.86 0.72 (0.26-2.05) 
 Other 26 30.77 0.85 (0.50-1.45) 39 41.03 0.79 (0.39-1.60) 
 Not stated 108 24.07 0.78 (0.51-1.18) 36 63.89 1.79* (1.02-3.13) 
Deprivatio
n† 
Least $ 86 26.74 1 89 49.44 1 
 Middle 156 21.15 1.11 (0.78-1.59) 154 46.75 0.94 (0.53-1.69) 
 Most 166 23.49 2.65*** (1.76-4.00) 163 50.92 1.04 (0.58-1.84) 
Total N 
 
 411 23.36  411 48.90  
 
N = denominator (number of registered pregnant women); % = percentage of pregnant women with smoking status 
ascertained; AOR = Adjusted Odds Ratio (adjusted for age group, ethnicity, IMD and practice clustering); CI = 95% Confidence 
Interval; $ = Reference group;    † = missing IMD; (3 pre-QOF+; 5 post-QOF+; ‡ = dropped due to small numbers; * = p<0.05; 
** = p<0.01; *** = p<0.001 
 
Effect of QOF+ on advice to smokers: AOR 3.35, CI 2.15 to 5.22, p<0.001 
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Appendix C: Publications arising from this work  
 
Publications arising directly from this work 
Hamilton FL, Greaves F, Majeed A, Millett C. Effectiveness of providing financial incentives 
to healthcare professionals for smoking cessation activities: systematic review. 
Tobacco control 2013;22(1):3-8. 
Hamilton FL, Laverty AA, Vamos EP, Majeed A, Millett C. Effect of financial incentives on 
ethnic disparities in smoking cessation interventions in primary care: cross-sectional 
study. J Public Health (Oxf) 2013;35(1):75-84. 
 
These papers are reproduced on the following pages. 
 
Publications related to this work 
Hamilton FL, Bottle A, Vamos EP, Curcin V, Anthea, Molokhia M, et al. Impact of a pay-
for-performance incentive scheme on age, sex, and socioeconomic disparities in 
diabetes management in UK primary care. The Journal of ambulatory care 
management 2010;33(4):336-49. 
Vamos EP, Pape UJ, Bottle A, Hamilton FL, Curcin V, Ng A, et al. Association of practice 
size and pay-for-performance incentives with the quality of diabetes management in 
primary care. CMAJ : Canadian Medical Association journal = journal de 
l'Association medicale canadienne 2011;183(12):E809-16. 
doi: 10.1136/tobaccocontrol-2011-050048
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Effectiveness of providing financial incentives to
healthcare professionals for smoking cessation
activities: systematic review
F L Hamilton, F Greaves, A Majeed, C Millett
ABSTRACT
Objective Financial incentives are seen as one
approach to encourage more systematic use of smoking
cessation interventions by healthcare professionals.
A systematic review was conducted to examine the
evidence for this.
Methods Medline, Embase, PsychINFO, Cochrane
Library, ISI Web of Science and sources of grey literature
were used as data sources. Studies were included if they
reported the effects of any financial incentive provided to
healthcare professionals to undertake smoking
cessation-related activities. Data extraction and quality
assessment for each study were conducted by one
reviewer and checked by a second. A total of 18 studies
were identified, consisting of 3 randomised controlled
trials and 15 observational studies. All scored in the mid
range for quality. In all, 8 studies examined smoking
cessation activities alone and 10 studied the UK’s Quality
and Outcomes Framework targeting quality measures for
chronic disease management including smoking
recording or cessation activities. Five non-Quality and
Outcomes Framework studies examined the effects of
financial incentives on individual doctors and three
examined effects on groups of healthcare professionals
based in clinics and general practices. Most studies
showed improvements in recording smoking status and
smoking cessation advice. Five studies examined the
impact of financial incentives on quit rates and longer-
term abstinence and these showed mixed results.
Conclusions Financial incentives appear to improve
recording of smoking status, and increase the provision
of cessation advice and referrals to stop smoking
services. Currently there is not sufficient evidence to
show that financial incentives lead to reductions in
smoking rates.
INTRODUCTION
Preventing smoking-related diseases is a key inter-
national public health objective.1 2 Article 14 of the
WHO Framework Convention of Tobacco Control
(FCTC) recommends that countries implement
‘demand reduction measures concerning tobacco
dependence and cessation’ alongside population
level strategies such as the introduction of smoke-
free workplaces, restricting advertising and raising
taxation on tobacco. Individual-level smoking
cessation interventions by healthcare professionals
are highly cost effective when compared to
other medical interventions and, if delivered equi-
tably, can reduce health inequalities related to
tobacco use.3e5
Despite their cost effectiveness, smoking
cessation interventions have historically been
underprovided in healthcare.6 Reasons for this may
include practitioners’ negative attitudes towards
discussing smoking cessation with their patients,
doubts about the effectiveness of providing
smoking cessation advice, concern about compro-
mising the doctor-patient relationship, perceived
lack of expertise, lack of time in the consultation
and competing priorities.7 Healthcare workers who
smoke are more likely to have a negative view of
their personal effectiveness in giving smoking
cessation advice to patients8 9 and a belief that such
advice is ineffective.8 Despite these views, practi-
tioners generally consider disease prevention activ-
ities to be important and worth spending time on
during the consultation.10
Pay for performance schemes are becoming
more widespread in healthcare, particularly in the
USA11 12 and the UK.13e15 They aim to improve
the quality of healthcare by providing ﬁnancial
incentives to practitioners for achieving perfor-
mance targets. Financial incentives are seen as one
approach to encourage more systematic use of
smoking cessation interventions and have been
incorporated into many ﬁnancial incentive
programmes. For example, the Quality and
Outcomes Framework (QOF), introduced in the
UK in 2004, rewards smoking cessation activities
mainly as a part of secondary prevention manage-
ment of long term conditions such as coronary
heart disease, diabetes and chronic obstructive
pulmonary disease.16
We conducted a systematic review to examine
evidence for the effectiveness of providing ﬁnancial
incentives to healthcare professionals on the
provision and impact of smoking cessation
interventions.
METHODS
Search strategy for identification and selection of
studies
We identiﬁed studies by searching the electronic
databases Medline, Embase, PsychINFO, the
Cochrane Database of Systematic Reviews, ISI Web
of Science and sources of grey literature. The search
terms are described in full in online only appendix
A on the Tobacco Control website. We included
papers in languages other than English in the
search. The titles and abstracts of those studies
identiﬁed by the initial searches were scanned,
and for those that appeared relevant the full paper
was obtained and reviewed. Further papers were
identiﬁed by looking at the citations and reference
lists of review papers and papers identiﬁed in the
initial search.
< Additional materials are
published online only. To view
these files please visit the
journal online (http://
tobaccocontrol.bmj.com).
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Methods of review
Inclusion criteria for studies to review:
1. Types of studies: randomised controlled trials (RCTs),
controlled trials and observational studies with a before and
after design reporting quantitative results.
2. Participants: participants aged 15 and over, with and without
chronic disease, registered with any healthcare provider.
3. Types of ﬁnancial incentives: studies that examined the
effects of ﬁnancial incentives (pay for performance) for
individual and groups of healthcare providers (doctors, nurses
or other members of healthcare teams) to provide smoking
cessation advice, referral and/or prescription of medication to
help with smoking cessation.
Exclusion criteria:
1. Studies that examined ﬁnancial or other rewards to patients,
patient competitions, or provision of reduced cost or free
medication to help with smoking cessation (unless this was
associated with a provider ﬁnancial incentive).
2. Papers that reported results as a composite quality score
including other measures of chronic disease management if it
was not possible to isolate impacts on smoking-related
activities.
Assessment of methodological quality, data extraction and data
synthesis
Two researchers (FLH and FG) scored each paper for methodo-
logical quality using a modiﬁed version of the Downs and Black
guidelines17 for assessing the quality of randomised and non-
randomised studies of healthcare interventions. The scoring
system ranged from 1 (poor) to 4 (excellent). Any differences of
opinion were resolved by discussion with CM. FLH and FG
extracted the numerical results from the identiﬁed papers for
the results section of the review. FLH used the data to estimate
the effect size (OR) for each outcome for each study if not
reported.
RESULTS
Search results
The ﬂow chart of our search strategy for included studies is
summarised in ﬁgure 1. We identiﬁed 18 studies for inclusion in
the review.
Included studies
There were two sets of duplicate papers, reporting results
using the same data. For the ﬁrst set, Twardella and Brenner
200718 and Salize et al 2009,19 we included the later paper as
it also reported cost data. For the second set, Coleman et al
200720 and Coleman et al 2010,21 we included the earlier paper
as the numerator and denominator variables were reported in
full, whereas the later paper only showed graphs. The ﬁnal
set of studies included 10 observational before and after
studies examining the effect of QOF in the UK and 8
studies looking at speciﬁc ﬁnancial incentives for smoking
cessation. Tables containing full details of each included study
including setting, design, intervention and outcomes are
available on the Tobacco Control website (see online only tables 1
and 2).16 20 22e36
Intervention, setting and study design
A total of 10 papers looked at the effects of QOF in the UK. The
ﬁnancial rewards available through QOF for smoking cessation
activities are paid to general practices rather than individual
clinicians and depend on the achievement of points for quality
targets in chronic disease management rather than improve-
ments from baseline. There are a maximum of 1000 points
available per practice for achieving quality targets, of which 79
are for smoking indicators, payable on a sliding scale (see online
only appendix B on the Tobacco Control website). Practices are
paid on average £130.50 per point in 2011/12, representing
a potential maximum income for smoking cessation work of
£10 309.50 (US$16 325 at the exchange rate on 15 September
Figure 1 Flow diagram of literature
search and study identification.
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2011). The ﬁnancial rewards are paid to general practices rather
than individual clinicians.
We report these papers separately as several looked at smoking
cessation in patients with particular chronic diseases such as
coronary heart disease, asthma, diabetes and stroke while others
looked at smoking cessation for all registered patients, and we
wanted to see if there would be any difference between these
two approaches. In addition, the papers used data from different
regions of the UK, apart from two that used data from repre-
sentative general practices from all over the UK. Only two of the
QOF studies were designed to take account of secular changes in
smoking prevalence, resulting from new guidelines for smoking
cessation, recent ﬁscal policy or legislation, either by comparing
actual outcomes against predicted outcomes,24 or by using
interrupted time series analysis.25
Other studies we identiﬁed examined the effect of fee for
service or bonus-type payments on smoking cessation activities
alone in the UK, Germany, Taiwan and the USA. They included
two randomised controlled trials,19 30 one cluster randomised
controlled trial,36 two serial cross-sectional studies comparing
health maintenance organisations (HMO)s with and without
ﬁnancial incentives for smoking cessation activities,33 34 and
three before and after designs.31 32 35 The designs of the before
and after studies did not take account of secular changes in
smoking prevalence.
Four studies examined the effect of ﬁnancial incentives on
individual doctors.19 30 31 35 In one study it was unclear whether
the incentive payment was to individual doctors or to groups of
doctors in the organisation.34 The remainder looked at the
effects on providing incentives to groups of healthcare profes-
sionals such as clinics or general practices.
Incentives included large, bonus-type payments such as for
An et al30 in which US$5000 was provided to participating
clinics for achieving 50 referrals to a stop smoking telephone
advice service, then US$25 per patient after the ﬁrst 50. For
Roski et al36 the incentive was US$5000eUS$10 000 if $75% of
patients at participating clinics had their smoking status
recorded and if $65% of smokers had been given smoking
cessation advice. For the studies by Chang et al31 35 the bonus
was paid per smoker advised and was of the order of US$24. In
two of the papers the payment was paid per smoker who
stopped smoking, varying from US$2432 to US$152.19 For the
cross-sectional studies of HMO funding33 34 the amount of the
incentive was not reported and direct communication from the
authors conﬁrmed they had not collected this information for
the studies.
Outcome measures examined
Most of the studies examined process measures such as
recording of smoking status, smoking cessation advice and/or
referral to smoking cessation services. For these measures, most
of the studies showed an improvement after ﬁnancial incentives
were introduced. Three studies examined the impact of ﬁnancial
incentives on quit rates. There was too great a degree of
statistical heterogeneity for the studies to be combinable for
meta-analysis even when undertaken separately for QOF and
non-QOF studies (I2 >90%, p<0.001 using RevMan37).
Smoking status
For QOF studies the improvements in recording smoking status
ranged from 19%22 (72.4% in 2003, 91.4% in 2005, OR 3.12, 95%
CI 2.80 to 3.48), to 52%27 (44% in 2004 to 96% in 2005, OR
24.19, 95% CI 22.42 to 26.11). The improvement in the RCT by
Roski et al36 was 7.3% (54% for incentives clinics, 46.7% for
control clinics, OR 1.34, 95% CI 1.17 to 1.54) and 1.7% for
incentive plus registry clinics (48.4% for incentive plus registry
clinics, OR 1.07, 95% CI 0.92 to 1.25).
Smoking advice or referral
For QOF studies recorded smoking advice increased by between
12.2% (from 83.8% in 2004 to 96% in 2006, OR 4.64, 95% CI
5.23 to 5.34)27 to 16.4% (80.6% in 2003, 97.0% in 2005, OR
7.87, 95% CI 5.68 to 10.90).24 The other studies’ ﬁndings on
smoking advice were less consistent. Roski et al36 and Coleman
et al32 found no difference between control and ﬁnancial inter-
vention groups. Otherwise the improvement ranged from an
increase of 2.25% in Chang et al’s patient database study (0.50%
in 2004, 2.75% in 2005, OR 5.05, 95% CI 4.98 to 5.12)35 to 5.7%
in the study by Chang et al using the Taiwan Tobacco survey
(21.1% in 2004, 26.8% in 2005, adjusted OR 1.26, 95% CI 1.11
to 1.42).31
Prescriptions for nicotine replacement therapy (NRT)/buproprion
Two studies found ﬁnancial incentives were associated with an
increase in the proportion of smokers receiving prescriptions. For
Coleman et al32 comparing pre/post-QOF, the OR was 6.32,
(95% CI 5.85 to 6.83). For McMenamin et al33 comparing HMOs
with ﬁnancial incentives to those without, the OR was 2.75
(95% CI 1.33 to 5.65).
Quit rates
Three non-QOF studies examined quit rates and longer-term
abstinence but produced mixed ﬁndings. Chang et al (2008)35
found no improvement in quit rates over the previous 6 months
when funding for smoking cessation activities in Taiwan
increased between 2004 in 2005 (25.2% in 2004 vs 21.3% in
2005, OR 0.96, 95% CI 0.87 to 1.06). Roski et al36 found no
difference in 7-day quit rates in their RCT (22.4% vs 19.2%, OR
1.21, 95% CI 0.98 to 1.49 for incentive clinics compared with
control clinics; 21.7% vs 19.2%, OR 1.16, 95% CI 0.91 to 1.48 for
registry clinics compared with control clinics). Salize et al19 also
found no difference in effect in their cluster RCT, for the
ﬁnancial incentive group (TI) compared with the usual care
group (TAU). However, they did ﬁnd an improved quit rate in
the group with general practitioner (GP) training plus patient-
reimbursed medications (TM) of 12.1% compared with 2.7% for
TAU, OR 4.98 (95% CI 1.22 to 22.16) and also in the group with
GP training, patient reimbursement plus GP incentives (TI/TM),
of 14.6%, OR 6.16 (95% CI 1.44 to 26.37), the large CIs reﬂecting
the relatively small sample size of the study. However, the TI/
TM group did not signiﬁcantly outperform the TM group,
suggesting that the cost-free medication may have accounted for
the effect observed.
Changes in smoking prevalence
Three QOF studies looked at smoking prevalence. They were
not able to examine quit rates as such as these are not speciﬁ-
cally recorded on GP electronic medical records. Cupples et al28
found no difference between recorded smoking prevalence
between patients with coronary heart disease (CHD) in the
Ireland where there was no ﬁnancial incentive scheme compared
with Northern Ireland (QOF). Millett et al16 found a reduction
in smoking prevalence in patients with diabetes following the
introduction of QOF (from 20.0% to 16.2%, OR 0.73, 95% CI
0.69 to 0.86). Simpson et al29 found a reduction in smoking
prevalence in UK from 28.4% in 2001/2 to 22.4% in 2006/7, OR
0.73 (95% CI 0.72 to 0.73). However, it was not clear whether
this reduction was due to smokers quitting through GP
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management or whether it can be explained by secular trends in
the UK.
Chang et al (2010)31 also noted a reduction in smoking prev-
alence between 2004 and 2007 (23.9%, 22.2%, 21.4% and 21.1%
for each year respectively) and an increase in the proportion
of ex-smokers in Taiwan (6.4%, 5.7%, 7.4% and 7.4% respec-
tively) associated with the increase in funding for smoking
cessation activities, but the authors acknowledge they could
not distinguish whether this was due to the funding change or
more widespread information about smoking through media
campaigns and hospital-based smoker identiﬁcation
programmes.
DISCUSSION
Principal findings
We identiﬁed 18 studies examining the effects of ﬁnancial
incentives for healthcare providers on smoking cessation activi-
ties and outcomes. The studies scored in the mid range for
quality with a validated scoring guideline, so there were no
methodologically poor studies, but there were also no excellent
studies. We expected the RCTs to score higher than observa-
tional studies but this was not the case. This may be because
those observational studies examining system-wide pay for
performance schemes scored highly for having large sample sizes
and very representative samples.
Most of the studies examined process measures such as
recording of smoking status, recording that smoking cessation
advice had been given and/or that patients were referred to
smoking cessation services. For these measures, almost all
studies showed improvements when ﬁnancial incentives were
introduced. In the study by Coleman et al (2001)32 where the
ﬁnancial incentive did not result in more patients recalling
receiving smoking cessation advice, the authors considered that
the smoking cessation training given to practice staff before the
control period may have diluted the effect of the ﬁnancial
incentive. For the study by Roski et al,36 the authors suggested
that management directives to improve productivity and reduce
costs may have affected outcomes negatively.
The two studies examining the effect of ﬁnancial incentives
on rates of prescribing nicotine replacement therapy (NRT)/
bupropion found an increase in prescribing rates,32 33 but in the
study by Coleman et al32 the increase in the proportion of
smokers receiving prescriptions (from 1% in 2000 to 6% in 2004)
was far less than the increase in the proportion of smokers given
advice (from 7% to 37%) and the authors suggest that this might
be because prescribing was not incentivised. Another explana-
tion might be that patients were prompted to attend commu-
nity stop smoking clinics where these medications are available
or to buy NRT over the counter.
Studies that examined quit rates had mixed results. Those
examining system-level incentive schemes found a reduction in
smoking prevalence, but limitations in study design meant it was
not possible to determine whether this was due to smokers
quitting through doctor management, or an effect of merely
being asked about smoking by a clinician, or due to secular
changes in smoking behaviour, or a combination of all three. QOF
papers were not able to look at quitting smoking as an outcome
as this is not recorded consistently by GPs, possibly because
currently practices are not incentivised to do so. Also, a large
proportion of smoking cessation activity takes place outside
primary care, in community pharmacies and stop-smoking
clinics, and information about quitters is often not relayed to GPs.
The results from Salize et al’s cluster RCT19 suggested that
ﬁnancial incentives might inﬂuence quitting behaviour if
combined with no cost NRTand/or buproprion prescriptions in
addition to GP training, but a similar level of impact was seen
with just the free medication group. This result is pertinent to
the USA and the UK. In the USA, the Affordable Care Act38
mandates Medicaid coverage of tobacco-dependence treatments
for pregnant women from October 2010. Coverage for all
Medicaid enrolees will be increased by January 2014, whereby
tobacco-dependence cessation drugs will no longer be excluded
from covered beneﬁts. In the UK, people can access nicotine
replacement treatment, bupropion or varenicline without charge
from UK National Health Service (NHS) smoking cessation
services or from GPs for the price of a prescription (currently
£7.20, equivalent to US US$11.83), or without cost if exempt
from prescription charges.
Strengths and weaknesses of the review
We employed a comprehensive search strategy to identify rele-
vant papers and included those with observational designs as
well as RCTs. This meant that a larger number of papers were
included in our study compared to previous systematic reviews.
Petersen et al,39 looking at the effects of pay for performance
schemes on improving healthcare quality, identiﬁed nine studies
that looked at prevention activities, of which two were for
smoking cessation. This review was conducted in 2005 before
pay for performance schemes became more common, which
might explain the paucity of relevant studies. In a recent
systematic review of strategies to increase the delivery of
smoking cessation activities in primary care settings, Papadakis
et al6 identiﬁed only three papers examining the effect of
ﬁnancial incentives. The authors excluded trials that were not
indexed within Medline as randomised controlled trials,
controlled clinical trials, or evaluation studies, whereas we did
not limit our search in this way. Observational studies are
inherently less robust methodologically compared with cohort
or randomised controlled trials and we acknowledge this.
However, as interventions for smoking cessation are necessarily
complex, we felt it was important to include these studies
to attempt a comprehensive view of the literature currently
available.
Most studies focused on process measures (recording smoking
status and advice given) rather than quit rates as outcomes, so
improvements may be due to improved recording rather than
increased delivery of smoking cessation interventions. Of the
non-QOF studies, follow-up times for quit rates were reasonable
at between 6 and 12 months, with the exception of the 7 day
quit rates reported by Roski et al36 As previously mentioned,
most of the observational studies we identiﬁed did not take
account of secular changes in smoking during the intervention
period.
Out of the 18 included studies, 10 examined the impact of the
UK’s QOF. Their ﬁndings may not be generalisable to other
countries as the size of the incentive is large and is supported by
prompts from the electronic medical records (EMRs)40 41 and
a comprehensive specialist smoking cessation service. The non-
QOF studies identiﬁed in our review examined ﬁnancial
incentives that were mainly aimed at doctors. Therefore, the
generalisability of most of these studies to clinicians other than
doctors may be limited. However, those examining QOF would
include work performed by practice nurses.
The ﬁnancial incentives tested differed in amount and in this
review, we were not able to identify an optimal amount. If
health practitioners were offered very large amounts for each
smoker who stopped then the intervention would likely to be
successful but would not be ﬁnancially practical. In addition, the
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results from Salize et al19 suggest that subsidised smoking
cessation medication may have more of an effect that a ﬁnancial
incentive. Only one study examined the cost effectiveness of
ﬁnancial incentives19 and found that GP training and remuner-
ation per abstinent patient was not effective compared to usual
treatment. However, GP training plus cost-free smoking cessa-
tion medication and a combination of GP training, free medi-
cation and remuneration were both more cost effective
interventions compared with usual treatment.
Our ﬁndings ﬁt with those from other systematic
reviews42e44 that have found multicomponent interventions
more effective than single-component interventions in helping
primary care doctors to deliver prevention services, including
smoking cessation.45 Therefore, ﬁnancial incentives may have
more impact when combined with other interventions, such
as clinician education and subsidised smoking cessation
prescriptions.
Financial incentive schemes can have unintended outcomes,
such as gaming,46 adverse patient selection,47 poor performance
for unrewarded activities48 and taking away doctors’ internal
motivation49 and the studies did not examine these. Also, unless
quit rates are rewarded, such schemes may become tickbox
exercises in recording process measures. For example, recording
that smoking cessation advice has been given is no indication of
the quality of advice given, and having someone stop smoking is
obviously more valuable than simply recording smoking status.
Suggestions for further research
Most of the studies we identiﬁed used a before and after design,
only two of which took into account secular changes in smoking
prevalence. Further RCTs or cohort studies would be required to
determine the effectiveness of ﬁnancial incentives. Further cost
effectiveness studies, including calculation of price elasticity and
possible optimum incentive levels, are also necessary.
CONCLUSIONS
Financial incentives can be effective in improving the recording
of smoking status, recording of smoking cessation advice and
referral to smoking cessation services. Given the effectiveness of
doctor advice to smokers in reducing smoking rates4 any inter-
vention to increase such advice is important. However, only ﬁve
studies evaluated smoking rates and for these there were mixed
results. Overall, these results are encouraging but the area does
require more comparative studies. As several areas of the UK are
currently developing local versions of the QOF50 in which
prevention activities such as smoking cessation are more
strongly incentivised, this gives a further opportunity to
examine the effectiveness of ﬁnancial incentives for smoking
cessation by comparing the effects in these areas with
other similar areas where these activities are not additionally
incentivised.
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Effect of financial incentives on ethnic disparities in smoking
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ABSTRACT
Background Smoking cessation interventions are underprovided in primary care. Financial incentives may help address this. However, few
studies in the UK have examined their impact on disparities in the delivery of smoking cessation interventions.
Methods Cross-sectional study using 2007 data from 29 general practices in Wandsworth, London, UK. We used logistic regression to
examine associations between disease group [cardiovascular disease (CVD), respiratory disease, depression or none of these diseases], ethnicity
and smoking outcomes following the introduction of the Quality and Outcomes Framework in 2004.
Results Significantly, more CVD patients had smoking status ascertained compared with those with respiratory disease (89 versus 72%), but
both groups received similar levels of cessation advice (93 and 89%). Patients with depression or none of the diseases were less likely to have
smoking status ascertained (60% for both groups) or to receive advice (80 and 75%). Smoking prevalence was high, especially for patients
with depression (44%). White British patients had higher rates of smoking than most ethnic groups, but black Caribbean men with depression
had the highest smoking prevalence (62%).
Conclusions Smoking rates remain high, particularly for white British and black Caribbean patients. Extending financial incentives to include
recording of ethnicity and rewarding quit rates may further improve smoking cessation outcomes in primary care.
Keywords disparities, financial incentives, inequalities, prevention, smoking cessation
Introduction
Smoking cessation interventions by health-care professionals
are highly effective and cost-effective in reducing tobacco
use,1–4 but these interventions are often under-provided in
primary care.5 Reasons for this include time pressures and
competing priorities.6 However, medical professionals
believe that preventative care is important and worthwhile.7
Financial incentives are increasingly being used to encour-
age smoking cessation activities. Although a recent systemat-
ic review8 suggests that such schemes may improve
recording of smoking status, advice and referral, the evi-
dence for their effects on quit rates is mixed. The Quality
and Outcomes Framework (QOF), introduced in 2004,
incentivizes the delivery of smoking cessation activities in
UK primary care mostly for patients with cardiovascular
and respiratory conditions.9 The National Institute for
Health and Clinical Excellence (NICE) has recommended
that QOF be developed to reduce variations in health out-
comes and smoking cessation is one area where inequalities
could be tackled.
There is little research in the UK examining disparities in
smoking prevalence and the provision of smoking cessation
interventions between people of different ethnicities.10
Studies from the USA have shown higher smoking preva-
lence among Whites and African-Americans,11,12 and for
non-White smokers to be less likely to receive smoking ces-
sation advice.13,14 This is an important area of research,
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given the higher risk of smoking-related diseases among
south Asian and African-Caribbean populations.10 This
study examines disparities in smoking prevalence and the
delivery of smoking cessation interventions between ethnic
groups following the introduction of QOF.
Methods
Setting and patients
We conducted a cross-sectional study using an anonymized
extract of data from 29 of the 34 general practices in
Wandsworth containing the medical records of all adult
patients (16years) registered on 31 December 2007. We
excluded those patients who registered in the last 3 months
of 2007, or registered at a practice for ,3 months, as prac-
tices might not have had the opportunity to record smoking
status for newly registered patients.15 All general practices in
Wandsworth were using electronic medical records, reﬂect-
ing the high use of electronic medical records in UK
primary care.16 Missing data for the study variables were
minimal.
We divided the patients into four disease categories de-
pending on the presence of relevant Read diagnosis codes17
dated prior to or during the study year:
† cardiovascular disease (CVD), or having a long-term con-
dition predisposing to CVD (coronary heart disease,
hypertension, heart failure, atrial ﬁbrillation, stroke, transi-
ent ischaemic attack, diabetes, chronic renal failure);
† respiratory disease (asthma, chronic obstructive pulmon-
ary disease);
† depression;
† none (having none of the above speciﬁed conditions).
We chose the ﬁrst two disease groups because smoking ces-
sation activity for these conditions is rewarded by QOF (see
Supplementary data, Appendix). The depression group was
chosen due to the known association between depression
and smoking,18 and these patients would most likely attend
regularly, giving extended opportunities for smoking cessa-
tion advice. To avoid double counting, we categorized
patients in the following hierarchical order: (1) CVD, (2) re-
spiratory disease excluding those with CVD, (3) depression
excluding those with CVD or respiratory disease, and (4)
none—those not included in 1, 2 or 3.
Study variables
Binary variables for patients in each of the disease categories
were used to generate the following outcome measures:
† proportion of patients with smoking status ascertained;
† proportion of patients coded as smokers;
† proportion of smokers offered cessation advice or refer-
ral to smoking cessation services.
We used the business rules for QOF to determine whether
smoking status was ascertained. These allow practice to per-
manently record as ‘non-smokers’ any ex-smokers with
three consecutive non-smoker codes and all never-smokers
over 25 years.
Ethnicity was derived from the 2001 Census Ethnic
Categories, collapsed to give nine categories including ‘not-
stated’. We included patients with missing ethnicity in the
‘not stated’ group as other methods of dealing with these
data (considered missing not at random) were inappropri-
ate19,20 and excluding these patients from the analysis may
have introduced bias. Age was recorded as a continuous
variable. Patients were assigned a deprivation score based on
individual general practice post-code using the Index of
Multiple Deprivation, IMD,21 a validated proxy measure.22
Statistical analysis
Data analysis was conducted separately for men and women
due to the known differences in smoking prevalence by
gender within ethnic minority groups in the UK.10 We com-
puted percentages of patients with smoking status ascer-
tained, whether they were current smokers and whether they
had been offered cessation advice.
We then undertook individual bivariate analyses for these
outcomes by age, ethnicity, IMD, and practice size. Tests for
interactions (between gender and disease, and disease and
ethnicity) suggested that a stratiﬁed analysis would be appro-
priate. All results were statistically signiﬁcant, so we included
all as predictor variables in the multivariate logistic model,
while taking into account practice clustering (29 clusters) to
allow for the fact that patients from some ethnic groups
may be more likely to be registered in certain practices than
others). We analysed the data with STATA version 11.
Results
In 2007, 172 685 adult patients were registered at participat-
ing general practices in Wandsworth. There were 21 826
patients with CVD (10 517 men and 11 309 women); 12 798
with respiratory disease (6129 men and 6669 women); 12
312 with depression (4420 men and 7892 women) and 125
749 with none of the diseases of interest (66 297 men and
59 452 women). Ethnicity coding was present in 92%
patients with CVD, 82% with respiratory conditions, 80%
with depression and 74% in the group without these
chronic diseases. The numbers of patients in the different
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disease groups subdivided by ethnic group and gender are
given in Table 1.
Smoking outcomes for patients in the different disease
groups, subdivided by ethnicity and gender, are given in
Tables 2–4. Key results from the Tables are reported below
and also results of analyses by disease group, stratiﬁed by
gender and adjusted for ethnicity, age, deprivation and prac-
tice clustering.
Smoking status ascertained
Overall, 89% of patients in the CVD group had their
smoking status ascertained in 2007, while patients in the
other three disease groups were less likely to have their
smoking status ascertained compared with those in the
CVD group [72% of patients with respiratory disease,
adjusted odds ratio (AOR) 0.53, 95% conﬁdence intervals
(CI) 0.42–0.67; 60% of patients with depression, AOR
0.25, CI 0.19–0.33; 60% of patients with none of these
conditions, AOR 0.30, CI 0.22–0.41].
For CVD, white British patients were less likely to be
asked about smoking than patients from all ethnic minority
groups except white Other (Table 2). For respiratory
disease, there was less variation, the main exception being
that black Caribbean patients were less likely to be asked
about smoking than white British patients (54 versus 67%
for men; 73 versus 79% for women).
For depression, black African patients were more likely to
be asked about smoking compared with white British patients
(62 versus 50% for men; 78 versus 63% for women), as were
Pakistani patients (74% for men and 77% for women).
Indian women were also more likely to be asked about
smoking than white British women (80 versus 63%).
For patients with none of the diseases of interest, black
African patients were more likely to be asked about smoking
than white British patients (59 versus 52% for men; 73
versus 68% for women) as were Indian women, compared
with white British women (79 versus 68%). However, black
Caribbean men were less likely to be asked than white
British men (44 versus 52%).
Smoking prevalence
The overall smoking prevalence was 31% for men and 22%
for women. Compared with patients with CVD, patients
from the other disease groups were more likely to smoke,
and this was most striking for people with depression (42%
of depressed patients smoked compared with 21% of
patients with CVD, AOR 2.58, CI 2.26–2.93).
We found that 28% of white British men with CVD were
smokers and 23% of white British women (Table 3).
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Table 2 Proportion of patients with smoking status ascertained in 2007, by disease group, ethnicity and gender
CVD Respiratory disease Depression Nonea
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
White British 85.74 (—) 88.45 (—) 67.16 (—) 78.91 (—) 49.75 (—) 63.25 (—) 52.37 (—) 67.61 (—)
White Other 86.45, 1.07
(0.91–1.28)
88.09, 0.98
(0.78–1.25)
70.37, 1.17
(0.86–1.57)
75.22, 0.84
(0.66–1.06)
46.34, 0.91
(0.62–1.32)
65.52, 1.12
(0.88–1.43)
49.64, 1.01
(0.86–1.18)
61.62**, 0.82
(0.73–0.92)
Black African 92.10**, 2.31
(1.48–3.61)
98.16**, 8.57
(5.62–13.05)
70.30, 1.26
(0.78–2.02)
79.17, 1.04
(0.66–1.65)
62.26**, 1.92
(1.23–3.00)
77.69**, 2.09
(1.27–3.45)
59.37**, 1.38
(1.13–1.68)
73.21**, 1.32
(1.06–1.65)
Black Caribbean 88.79, 1.27
(0.96–1.68)
94.63**, 2.48
(1.55–3.96)
53.50**, 0.59
(0.44–0.79)
73.36*, 0.75
(0.57–0.99)
39.13, 0.69
(0.43–1.10)
67.82, 1.22
(0.92–1.63)
44.14**, 0.69
(0.54–0.88)
66.74, 0.92
(0.79–1.06)
Indian 94.08**, 2.93
(1.53–5.60)
99.03**, 15.98
(5.49–46.51)
64.00, 0.74
(0.44–1.25)
92.41**, 2.72
(1.36–5.46)
58.82, 1.44
(0.57–3.64)
80.00**, 2.35
(1.35–4.11)
55.18, 1.09
(0.79–1.49)
78.59**, 1.72
(1.30–2.28)
Pakistani 93.66**, 2.84
(1.93–4.16)
97.50**, 9.14
(2.52–33.14)
69.09, 1.08
(0.57–2.05)
91.80, 2.78
(0.98–7.86)
73.53*, 2.77
(1.27–6.02)
77.08*, 2.06
(1.10–3.89)
51.84, 1.08
(0.75–1.57)
73.42, 1.39
(0.95–2.02)
Bangladeshi 93.94*, 2.87
(1.06–7.82)
97.30, 6.57
(0.83–54.67)
90.91, 5.68
(0.90–35.90)
100† 33.33, 0.73
(0.06–8.53)
80.00, 2.43
(0.94–6.31)
50.70, 1.02
(0.63–1.65)
69.23, 1.09
(0.55–2.15)
Chinese 97.22, 5.47
(0.72–41.61)
97.4, 5.82
(0.79–42.71)
62.50, 0.71
(0.25–2.03)
69.23, 0.69
(0.33–1.44)
100† 84.62, 3.28
(0.47–22.80)
56.20, 1.29
(0.90–1.84)
75.42, 1.48
(0.95–2.31)
Mixed ethnicity 89.07*, 1.52
(1.06–2.17)
94.85**, 2.79
(1.56–5.00)
61.03, 0.84
(0.45–0.92)
73.50, 0.74
(0.54–1.01)
52.03, 1.12
(0.82–1.53)
64.29, 1.06
(0.75–1.51)
52.05, 1.04
(0.80–1.34)
68.67, 1.07
(0.89–1.28)
Ethnicity not stated 75.78**, 0.57
(0.43–0.75)
85.20, 0.79
(0.49–1.28)
56.83*, 0.64
(0.45–0.92)
72.76, 0.71
(0.48–1.06)
42.38, 0.72
(0.43–1.18)
57.11, 0.77
(0.58–1.03)
49.00, 0.81
(0.50–1.32)
61.52**, 0.72
(0.59–0.87)
All 87.46 91.38 64.87 77.53 49.12 64.29 51.35 66.27
aNot diagnosed with CVD, respiratory disease or depression. AOR, adjusted odds ratio; CI, 95% confidence intervals.
Significance in multivariate analysis adjusting for age, IMD and practice clustering, with white British as reference group: *P, 0.05; **P  0.01; †not included in the analysis due to small numbers.
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Table 3 Smoking prevalence in 2007, by disease group, ethnicity and gendera
CVD Respiratory disease Depression Noneb
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
White British 28.29 (—) 23.07 (—) 30.44 (—) 26.62 (—) 48.13 (—) 40.30 (—) 30.70 (—) 21.08 (—)
White Other 23.58**, 0.75
(0.63–0.90)
18.40**, 0.73
(0.59–0.89)
28.11, 0.91
(0.70–1.18)
20.13**, 0.67
(0.51–0.87)
49.03, 1.04
(0.75–1.45)
31.57**, 0.67
(0.55–0.82)
33.58, 1.03
(0.94–1.13)
23.37, 1.02
(0.89–1.16)
Black African 11.43**, 0.28
(0.19–0.41)
2.44**, 0.06
(0.03–0.10)
17.98**, 0.49
(0.31–0.78)
10.57**, 0.31
(0.18–0.51)
41.30, 0.72
(0.44–1.20)
22.55**, 0.40
(0.23–0.69)
20.27**, 0.51
(0.38–0.67)
6.42**, 0.21
(0.15–0.29)
Black Caribbean 25.69, 0.90
(0.73–1.10)
12.03**, 0.38
(0.31–0.48)
37.14, 1.31
(0.95–1.82)
25.20, 0.85
(0.63–1.16)
61.97*, 1.69
(1.12–2.54)
35.94, 0.78
(0.51–1.18)
48.09**, 1.50
(1.29–1.74)
26.43, 0.89
(0.78–1.02)
Indian 17.05**, 0.54
(0.39–0.75)
1.51**, 0.05
(0.02–0.12)
18.33, 0.54
(0.26–1.13)
10.39**, 0.38
(0.19–0.74)
42.86, 0.86
(0.35–2.11)
13.16**, 0.23
(0.10–0.52)
25.05**, 0.64
(0.52–0.78)
6.21**, 0.21
(0.15–0.30)
Pakistani 14.16**, 0.38
(0.28–0.53)
0.92**, 0.03
(0.01–0.11)
27.12, 0.88
(0.47–1.66)
4.76**, 0.14
(0.05–0.40)
47.06, 0.98
(0.49–1.97)
3.03**, 0.05
(0.01–0.36)
33.27, 0.91
(0.78–1.07)
4.80**, 0.15
(0.10–0.23)
Bangladeshi 13.64**, 0.36
(0.21–0.63)
7.89**, 0.21
(0.07–0.64)
25.00, 0.73
(0.16–3.39)
0.00† 50.00, 1.18
(0.21–6.63)
8.33, 0.13
(0.02–1.01)
36.00, 0.86
(0.62–1.19)
4.92**, 0.19
(0.08–0.44)
Chinese 18.18, 0.60
(0.27–1.34)
5.41**, 0.15
(0.04–0.52)
9.09, 0.23
(0.02–2.17)
11.54, 0.35
(0.11–1.10)
0.00† 45.45, 1.11
(0.13–2.85)
20.18**, 0.54
(0.37–0.77)
9.90**, 0.33
(0.23–0.49)
Mixed ethnicity 23.95**, 0.74
(0.60–0.90)
10.58**, 0.32
(0.24–0.43)
27.78, 0.87
(0.61–1.23)
22.6, 0.78
(0.58–1.07)
51.24, 1.06
(0.72–1.55)
42.20, 1.06
(0.83–1.35)
36.80, 1.10
(0.97–1.24)
21.04*, 0.84
(0.72–0.98)
Ethnicity not stated 30.70, 1.05
(0.80–1.38)
21.48, (0.79
(0.55–1.13)
32.24, 1.07
(0.80–1.44)
22.45, 1.01
(0.76–1.33)
54.42, 1.32
(0.91–1.92)
45.81*, 1.28
(1.02–1.60)
40.35, 1.07
(0.76–1.49)
26.82, 1.13
(0.93–1.37)
All 24.43 16.20 29.53 24.01 49.63 38.25 33.21 20.98
aOf patients with a smoking code, the proportion recorded as smokers (for denominators, see Table 1). AOR, adjusted odds ratio; CI, 95% confidence intervals.
bNot diagnosed with CVD, respiratory disease or depression.
Significance in multivariate analysis adjusting for age, IMD and practice clustering, with white British as reference group: *P, 0.05; **P  0.01; †not included in the analysis due to small numbers.
E
F
F
E
C
T
O
F
F
IN
A
N
C
IA
L
IN
C
E
N
T
IV
E
S
O
N
E
T
H
N
IC
D
IS
P
A
R
IT
IE
S
5
 at Imperial College London Library on October 2, 2012 http://jpubhealth.oxfordjournals.org/ Downloaded from 
Table 4 Smokers offered smoking cessation advice or referral in 2007, by disease group, ethnicity and gender
CVD Respiratory disease Depression Nonea
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
Men, %,
AOR (CI)
Women, %,
AOR (CI)
White British 92.37 (—) 94.80 (—) 89.00 (—) 89.82 (—) 81.45 (—) 80.11 (—) 74.26 (—) 76.93 (—)
White Other 90.26, 0.79
(0.42–1.49)
90.48**, 0.50
(0.31–0.81)
94.28, 2.04
(0.75–5.50)
91.58, 1.22
(0.57–2.65)
73.68, 0.64
(0.30–1.36)
75.78, 0.80
(0.52–1.23)
73.21, 0.88
(0.75–1.02)
76.61, 1.05
(0.83–1.33)
Black African 88.89, 0.76
(0.30–1.90)
92.86, 0.77
(0.12–5.00)
93.75, 2.07
(0.27–15.69)
84.62, 0.70
(0.12–4.22)
78.95, 0.93
(0.28–3.15)
65.22, 0.50
(0.18–1.40)
76.24, 1.16
(0.78–1.73)
79.17, 0.82
(0.58–1.16)
Black Caribbean 94.32, 1.41
(0.78–2.56)
95.20, 1.09
(0.34–3.54)
92.31, 1.36
(0.42–4.45)
90.48, 1.11
(0.49–2.55)
59.09**, 0.34
(0.18–0.66)
78.21, 0.95
(0.60–1.51)
71.02, 1.00
(0.73–1.36)
75.77, 1.01
(0.78–1.30)
Indian 90.67, 0.87
(0.43–1.76)
100† 100† 75.00, 0.38
(0.07–1.85)
83.33, 1.06
(0.11–9.61)
80.00, 1.08
(0.10–11.13)
81.58*, 1.24
(0.84–1.82)
67.74, 0.88
(0.45–1.70)
Pakistani 89.36, 0.69
(0.29–1.63)
100† 100† 100† 87.50, 1.65
(0.43–6.34)
100† 79.77, 1.15
(0.64–2.08)
66.67, 0.83
(0.37–1.86)
Bangladeshi 100† 100† 66.7, 0.13
(0.01–1.11)
100† 50.00, 0.28
(0.01–5.57)
100† 77.78, 1.67
(0.94–2.96)
100†
Chinese 87.50, 0.45
(0.08–2.62)
100† 100† 100† V† 80.00, 1.19
(0.08–17.88)
81.82, 1.52
(0.68–3.40)
63.16, 0.77
(0.38–1.57)
Mixed ethnicity 93.96, 1.30
(0.59–2.85)
92.54, 0.68
(0.35–1.35)
83.64, 0.69
(0.34–1.08)
89.39, 1.01
(0.44–2.28)
88.71, 1.85
(0.69–5.00)
76.47, 0.92
(0.56–1.52)
73.58, 1.06
(0.88–1.27)
73.74, 0.91
(0.75–1.10)
Ethnicity not stated 96.33, 2.41
(0.66–8.84)
90.80, 0.57
(0.16–2.07)
82.65, 0.62
(0.35–1.08)
86.27, 0.70
(0.39–1.27)
82.05, 1.05
(0.52–2.21)
89.78**, 2.14
(1.37–3.35)
68.49, 0.76
(0.43–1.37)
76.78, 1.02
(0.68–1.52)
All 92.45 93.92 88.86 89.49 80.03 80.28 73.21 76.40
aNot diagnosed with CVD, respiratory disease or depression. AOR, adjusted odds ratio; CI, 95% confidence intervals; V, no observations.
Significance in multivariate analysis adjusting for age, IMD and practice clustering, with white British as reference group: *P, 0.05; **P  0.01; †not included in the analysis due to small numbers.
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Patients with CVD in most ethnic groups were less likely to
smoke than white British patients (smoking prevalence
ranged from 0.92% for Pakistani women to 26% for black
Caribbean men).
For respiratory disease, 30% of white British men and
26% of white British women were smokers. There was
much less variation with ethnicity than with CVD for men,
with black African men being the only group less likely than
white British men to smoke (18 versus 30%). Women from
white Other, black African, Indian and Pakistani ethnic
groups were less likely to smoke than white British females
(20, 11, 10 and 5%, respectively, compared with 27% of
white British women).
The prevalence of smoking in patients with depression
was very high at 48% for white British men and 40% for
white British women. Men in all ethnic groups had high
smoking rates (over 40%), but black Caribbean men were
more likely to smoke compared with white British men (62
versus 48%). For women with depression, only those with
unstated ethnicity had higher smoking rates than white
British women (46 versus 40%).
In the group of patients without CVD, respiratory disease
or depression, smoking prevalence was 31% for white
British men and 21% for white British women. There was a
considerable variation with ethnicity in this group, but most
notably, black Caribbean men were more likely to smoke
than white British men (48 versus 31%).
Smoking cessation advice or referral
Smokers with depression or none of the conditions of inter-
est were less likely to receive smoking cessation advice than
those with CVD or respiratory diseases (80% of patients
with depression compared with 93% of patients with CVD
and 89% with respiratory disease, AOR 0.34, CI 0.22–0.51;
and 75% of patients with none of the conditions had
smoking advice, AOR 0.27, CI 0.17–0.40.
There was very little variation with ethnicity for smoking
cessation advice or referral (Table 4), with most groups
beneﬁtting equally. The exceptions were white Other women
with CVD, who were less likely to receive advice compared
with white British women (90 versus 95%). Black Caribbean
men with depression were also much less likely to receive
such advice compared with white British men (59 versus
81%). However, women with depression whose ethnicity
was unstated were more likely to receive advice compared
with white British women (90 versus 80%), and Indian men
from the group with none of the diseases of interest were
more likely to receive advice than white British men (82
versus 74%).
Discussion
Main finding of this study
We found that a large percentage of patients with CVD had
their smoking status ascertained and, if smokers, received
smoking cessation advice. Patients with respiratory disease
were less likely to have their smoking status ascertained than
those with CVD, but smokers in both groups received
similar levels of advice. The rates of ascertainment and
advice were considerably lower among patients in the other
two disease groups. This suggests that practices may be fo-
cusing their smoking cessation efforts on secondary preven-
tion for the chronic diseases incentivized within QOF (see
Supplementary data, Appendix). Alternatively, this may be
because patients with chronic diseases attend more regularly,
so staff may have more opportunity to provide smoking-
cessation advice. Other factors which may impact on
smoking cessation efforts more generally include a lack of
time within a typical primary care consultation and concerns
that discussing issues such as smoking when patients
present with an unrelated problems may be seen as intrusive
or as ‘nagging’.23
Smoking prevalence overall was higher than the national
average (24% for men, 21% for women, Health Survey for
England, 2007), partly reﬂecting the younger population in
Wandsworth. There were particularly high rates of smoking
seen in patients with depression (especially black Caribbean
men, white British patients and those with unrecorded eth-
nicity) plus patients in the group with none of the diseases
of interest.
There was encouragingly little variation in the provision
of smoking cessation advice or referral, with the exception
of black Caribbean men with depression. Our ﬁndings
conﬁrm those of other authors which have found higher
smoking rates in individuals with mental health pro-
blems.18,24 This is concerning, given that smoking habits are
particularly difﬁcult for depressed patients to break even
with support.25 These results highlight the need to intensify
smoking cessation interventions in primary care as both a
primary and secondary prevention intervention.
What is already known on this topic
There has been little research in the UK examining ethnic
group differences in smoking prevalence and in access to
cessation interventions. More research on this topic has
been conducted in the USA as previously discussed. This
may be due to historically poor ethnicity coding in UK
primary care, although this is improving and has recently
been incentivized under QOF. Other researchers have
found that ﬁnancial incentives increase the delivery of
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smoking cessation interventions.8,9,26–29 Our ﬁndings do
not support concerns raised in the USA that pay for per-
formance schemes may increase disparities in healthcare
through ‘cherry-picking,’ whereby ‘physicians or health plans
have an incentive to avoid or disenroll minority patients who
may be more challenging to provide quality care for’.30
Our ﬁndings conﬁrm those of Lyratzopoulos et al.31 who
studied UK primary care patients attending for cardiovascular
risk screening and found that South-Asian patients were sig-
niﬁcantly less likely to smoke than people of other ethnicities.
Our results are also similar to those from a recent study
examining ethnic group differences in smoking prevalence
using data from the Health Survey for England10 which
found higher smoking rates among Bangladeshi and black
Caribbean men. The authors also found that white British
and black Caribbean women were more likely to smoke than
women from other ethnic groups and our ﬁndings conﬁrmed
this. A recent US survey found that non-Hispanic white
people were more likely to smoke than those from other
ethnic groups, but there was little variation between ethnic
groups in the chance of being offered smoking cessation
advice.32 Our results conﬁrm research looking at process
measures of care, which found provision of smoking cessa-
tion advice to be fairly equitable by ethnic group.33–35
What this study adds
We found evidence of high and equitable delivery of
smoking cessation interventions in disease areas incentivized
by QOF. However, the relatively low use of cessation inter-
ventions among patients without those diseases and the
high prevalence of smoking in all patient groups highlight a
need to strengthen delivery, both as a primary and second-
ary prevention.36 This may be achieved by directly rewarding
quit rates, as is currently the case for the locally enhanced
smoking cessation services provided by pharmacies in many
areas in the UK, or through the development of local ver-
sions of QOF.37 This should include efforts to address per-
sisting disparities (e.g. black Caribbean men with
depression). Our ﬁndings highlight the importance of im-
proving coding of ethnicity in primary care systems in order
to facilitate timely dissemination of information on ethnic
group differences in smoking prevalence and access to
smoking cessation interventions.
Limitations of this study
All practices in the study used electronic medical records to
record clinical information. While this permitted us to
examine the delivery the cessation interventions in an
extended number of ethnic categories using the data collected
by primary care teams, the numbers of patients were too
small in a few groups to produce meaningful results.
Our outcome measures were based on recordings made in
the medical record over the past 12 months rather than in the
past 15 months as suggested by QOF. This is because we had
incomplete data on the date that ascertainment occurred.
However, in practice, most patients with chronic diseases are
reviewed at least annually in primary care, and asking about
smoking status for smokers and recent ex-smokers is
prompted by electronic review templates. Our ﬁndings are
similar to previous research looking at the proportion of
patients with smoking status ascertained every 15 months.9
Although smoking cessation advice was one of our
outcome measures, we were unable to determine the quality
of advice given. The data may also have been subject to
recording bias in that patients with conditions not incenti-
vized by QOF might have received smoking cessation
advice, but this may not have been coded.
The group of patients without the diseases of interest
contained patients with conditions such as schizophrenia or
other psychoses for whom the recording of smoking status
and advice were due to be rewarded by QOF after 2007.
Practices may have started recording smoking outcomes for
these patients in anticipation, but this is unlikely to have a
major bearing on our ﬁndings, given that the number of
patients involved would have been small.
Our observational study does not permit attribution of
the high levels of cessation interventions found to QOF
payments. However, previous research suggests marked im-
provement in smoking and other outcome measures after
the introduction of QOF.9,38 Our ﬁndings may be generaliz-
able only to health systems with universal coverage which
incorporate ﬁnancial incentives into prevention activities.
Unlike national QOF data, our sample includes patients
who would have been exception reported when calculating
QOF payments. However, this may provide a more complete
picture of the delivery of cessation interventions in primary
care.39 We were also unable to examine quit rates in our
study, as these are not speciﬁcally coded in primary care.
Smoke-free legislation was introduced into England from
1 July 2007, and this may have impacted on the results we
observed and may also have affected ethnic groups differ-
ently.40 For example, those groups for whom drinking
alcohol is prohibited would be inﬂuenced less by the
smoking ban in public bars.
Conclusions
Three years after the introduction of QOF, a large propor-
tion of patients with CVD in Wandsworth had smoking
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status recorded compared with patients from other disease
groups. Most smokers with CVD or respiratory disease were
offered smoking cessation advice, and there was little vari-
ation with ethnicity. However, patients with depression or
other conditions were less likely to receive such advice, par-
ticularly black Caribbean men. We found that patients from
ethnic groups associated with increased risk of CVD were
more likely to be asked about smoking, for example, south
Asian patients. Despite the introduction of QOF, there
remain high rates of smoking among patients with CVD,
respiratory disease and depression, suggesting that there is
still considerable scope for improving health status through
encouraging smoking cessation in these groups.
Supplementary data
Supplementary data are available at PUBMED online.
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32 West Grove 
Walton-on-Thames 
Surrey KT12 5NX 
f.hamilton@imperial.ac.uk 
6 March 2013 
Dear London Health Observatory 
 
I am completing my PhD thesis at Imperial College London entitled ‘Evaluating the impact 
of financial incentives on inequalities in smoking cessation in primary care.’ 
I seek your permission to reprint, in my thesis, an extract from the local tobacco profiles 
statistics on the website: Local tobacco control profile for Hammersmith & Fulham and Local 
tobacco control profile for Wandsworth.  
I would like to include the figure in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's electronic repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then 
sign. 
Yours sincerely, 
 
 
Dr Fiona Hamilton 
 
 Permission granted for the use requested above: 
I confirm that I am the copyright holder of the paper above and hereby give permission to 
include it in the print and electronic version of your thesis. I understand that the electronic 
version of the thesis will be made available, via the internet, for non-commercial purposes 
under the terms of the user licence. 
[please edit the text above if you wish to grant more specific permission]  
Signed: 
Name: 
Organisation: 
Job title: 
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